temozolomide has been researched along with Disease Exacerbation in 286 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "In this phase II study, we investigate clinical outcomes and tolerability of hypofractionated radiotherapy (HRT) combined with temozolomide (TMZ) to treat elderly patients with glioblastoma (GBM)." | 9.27 | Interim Results of a Phase II Study of Hypofractionated Radiotherapy with Concurrent Temozolomide Followed by Adjuvant Temozolomide in Patients over 70 Years Old with Newly Diagnosed Glioblastoma. ( Amsbaugh, M; Boakye, M; Burton, E; Hattab, EM; Nelson, M; Ugiliweneza, B; Williams, B; Woo, S; Yusuf, M, 2018) |
| "We report a longitudinal assessment of health-related quality of life (HRQOL) in patients with glioblastoma (GBM) treated on a prospective dose escalation trial of 5-fraction stereotactic radiosurgery (25-40 Gy in 5 fractions) with concurrent and adjuvant temozolomide." | 9.24 | Phase 1/2 Trial of 5-Fraction Stereotactic Radiosurgery With 5-mm Margins With Concurrent and Adjuvant Temozolomide in Newly Diagnosed Supratentorial Glioblastoma: Health-Related Quality of Life Results. ( Adler, JR; Azoulay, M; Chang, SD; Choi, CYH; Fujimoto, D; Gibbs, IC; Hancock, SL; Harraher, C; Harsh, GR; Jacobs, LR; Li, G; Modlin, LA; Nagpal, S; Pollom, EL; Recht, LD; Seiger, K; Soltys, SG; Thomas, RP; Tupper, L; von Eyben, R; Wynne, J, 2017) |
| "Bevacizumab plus bi-weekly temozolomide was well tolerated and may be a salvage regimen to be considered in a subset of patients with recurrent glioblastoma." | 9.24 | Phase II study of bi-weekly temozolomide plus bevacizumab for adult patients with recurrent glioblastoma. ( Ahmadi, MM; Badruddoja, MA; Kuzma, K; Mahadevan, D; Norton, T; Pazzi, M; Sanan, A; Schroeder, K; Scully, T, 2017) |
| "While our study failed to meet the primary endpoint for objective radiographic response, patients with high-risk low-grade glioma receiving adjuvant temozolomide demonstrated a high rate of radiographic stability and favorable survival outcomes while meaningfully delaying radiotherapy." | 9.24 | Chemotherapy for adult low-grade gliomas: clinical outcomes by molecular subtype in a phase II study of adjuvant temozolomide. ( Berger, MS; Butowski, N; Chang, SM; Clarke, JL; Costello, JF; Dayal, M; Haas-Kogan, DA; Lin, Y; Molinaro, AM; Nelson, S; Perry, A; Phillips, JJ; Prados, M; Wahl, M, 2017) |
| "In glioblastoma multiforme (GBM), both temozolomide (TMZ) and cisplatin are very active at various toxic levels." | 9.24 | Continuous dose-intense temozolomide and cisplatin in recurrent glioblastoma patients. ( Guo, Y; Kong, X; Ma, W; Wang, R; Wang, Y, 2017) |
| "In elderly patients with glioblastoma, the addition of temozolomide to short-course radiotherapy resulted in longer survival than short-course radiotherapy alone." | 9.24 | Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma. ( Back, M; Baumert, BG; Brandes, AA; Cairncross, JG; Chinot, O; Ding, K; Fariselli, L; Fay, M; Feuvret, L; Franceschi, E; Golfinopoulos, V; Hirte, H; Laigle-Donadey, F; Laperriere, N; Mason, WP; Menten, J; Nishikawa, R; O'Callaghan, CJ; Osoba, D; Perry, JR; Phillips, C; Roa, W; Rossiter, JP; Sahgal, A; Tills, M; Wick, A; Wick, W; Winch, C, 2017) |
| "The proposed use of bevacizumab with radiotherapy/temozolomide for newly diagnosed glioblastoma raised potential safety concerns." | 9.22 | Bevacizumab, temozolomide, and radiotherapy for newly diagnosed glioblastoma: comprehensive safety results during and after first-line therapy. ( Chinot, OL; Cloughesy, T; Dhar, S; Garcia, J; Henriksson, R; Mason, W; Nishikawa, R; Pozzi, E; Saran, F; Wick, W, 2016) |
| "To investigate the safety of combined Wilms tumor 1 peptide vaccination and temozolomide treatment of glioblastoma, a phase I clinical trial was designed." | 9.20 | Wilms tumor 1 peptide vaccination combined with temozolomide against newly diagnosed glioblastoma: safety and impact on immunological response. ( Arita, N; Chiba, Y; Hashimoto, N; Hosen, N; Izumoto, S; Kagawa, N; Kijima, N; Kinoshita, M; Morimoto, S; Morita, S; Nakajima, H; Nishida, S; Oji, Y; Oka, Y; Sakamoto, J; Sugiyama, H; Tsuboi, A; Yoshimine, T, 2015) |
| "Valproic acid (VPA) is an antiepileptic agent with histone deacetylase inhibitor (HDACi) activity shown to sensitize glioblastoma (GBM) cells to radiation in preclinical models." | 9.20 | A Phase 2 Study of Concurrent Radiation Therapy, Temozolomide, and the Histone Deacetylase Inhibitor Valproic Acid for Patients With Glioblastoma. ( Camphausen, K; Chang, MG; Fine, HA; Holdford, DJ; Krauze, AV; Myrehaug, SD; Shih, J; Smith, S; Tofilon, PJ, 2015) |
| "To evaluate the efficacy and safety of TTFields used in combination with temozolomide maintenance treatment after chemoradiation therapy for patients with glioblastoma." | 9.20 | Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. ( Barnett, GH; Caroli, M; Chen, TC; Desai, R; Engelhard, HH; Fink, KL; Hegi, ME; Henson, JW; Honnorat, J; Hottinger, AF; Idbaih, A; Kanner, AA; Kesari, S; Kew, Y; Kirson, ED; Landolfi, J; Lieberman, F; Palti, Y; Ram, Z; Silvani, A; Sroubek, J; Steinberg, DM; Stupp, R; Taillibert, S; Taylor, LP; Toms, SA; Tran, DD; Tran, ND; Weinberg, U; Zhu, JJ, 2015) |
| "To evaluate the efficacy of limited margins intensity-modulated radiotherapy (IMRT) with temozolomide chemotherapy in patients with malignant glioma, and explore the prognostic factors of malignant glioma." | 9.20 | [Randomized controlled study of limited margins IMRT and temozolomide chemotherapy in patients with malignant glioma]. ( Cao, Y; Sun, J; Yang, X; Zhang, W, 2015) |
| " We sought to determine whether the addition of a vascular endothelial growth factor (VEGF) signaling inhibitor (cediranib) to conventional CRT had an impact on the frequency of PsP, by comparing two groups of patients with newly diagnosed glioblastoma before, during, and after CRT." | 9.19 | Low incidence of pseudoprogression by imaging in newly diagnosed glioblastoma patients treated with cediranib in combination with chemoradiation. ( Batchelor, TT; Emblem, KE; Gerstner, ER; Jain, RK; Jennings, D; Kalpathy-Cramer, J; Pinho, MC; Polaskova, P; Rosen, BR; Sorensen, AG; Wen, PY, 2014) |
| "The integrin antagonist cilengitide has been explored as an adjunct with anti-angiogenic properties to standard of care temozolomide chemoradiotherapy (TMZ/RT → TMZ) in newly diagnosed glioblastoma." | 9.19 | Cilengitide treatment of newly diagnosed glioblastoma patients does not alter patterns of progression. ( Clément, PM; Eisele, AC; Eisele, G; Krex, D; Neyns, B; Nikkhah, G; Ochsenbein, A; Picard, M; Schlegel, U; Simon, M; Stupp, R; Tabatabai, G; Tonn, J; Weller, M; Wick, A; Wick, W, 2014) |
| "To describe the quality of life (QOL) in elderly patients with glioblastoma (GBM) treated with an abbreviated course of radiation therapy (RT; 40 Gy in 15 fractions) plus concomitant and adjuvant temozolomide (TMZ)." | 9.17 | Health-related quality of life in elderly patients with newly diagnosed glioblastoma treated with short-course radiation therapy plus concomitant and adjuvant temozolomide. ( Baldoni, A; De Sanctis, V; Enrici, RM; Esposito, V; Lanzetta, G; Minniti, G; Scaringi, C, 2013) |
| "The current standard-of-care for glioblastoma (GBM) is represented by concomitant radiotherapy (RT) and temozolomide (TMZ), according to Stupp's protocol." | 9.17 | Continuous tamoxifen and dose-dense temozolomide in recurrent glioblastoma. ( Caroli, M; Carrabba, G; DI Cristofori, A; Lanfranchi, G; Menghetti, C; Rampini, P, 2013) |
| "To determine whether the pattern of progressive disease (PD) for glioblastoma multiforme (GBM) patients has changed with the introduction of the current standard of care protocol - postoperative conformal radiotherapy to a dose of 60 Gray in 30 fractions with concurrent low-dose (75-100 mg/m(2) ) temozolomide, followed by six cycles of adjuvant high-dose (150-200 mg/m(2) ) temozolomide - as compared with radiotherapy alone." | 9.16 | The addition of temozolomide does not change the pattern of progression of glioblastoma multiforme post-radiotherapy. ( Bressel, M; Gunjur, A; Ryan, G, 2012) |
| "A prospective randomized controlled multicenter phase III trial was conducted to evaluate the effects of neoadjuvant chemotherapy with nimustine (ACNU)-cisplatin (CDDP) when used in conjunction with radiotherapy plus adjuvant temozolomide in patients with newly diagnosed glioblastoma." | 9.15 | Radiotherapy followed by adjuvant temozolomide with or without neoadjuvant ACNU-CDDP chemotherapy in newly diagnosed glioblastomas: a prospective randomized controlled multicenter phase III trial. ( Han, JH; Heo, DS; Jung, HW; Kim, CY; Kim, DG; Kim, DW; Kim, IA; Kim, IH; Kim, JE; Kim, JH; Kim, TM; Kim, YJ; Lee, SH; Nam, DH; Paek, SH; Park, BJ; Park, CK; Rhee, CH, 2011) |
| "To determine whether increased uptake on 11C-methionine-PET (MET-PET) imaging obtained before radiation therapy and temozolomide is associated with the site of subsequent failure in newly diagnosed glioblastoma multiforme (GBM)." | 9.14 | Association of 11C-methionine PET uptake with site of failure after concurrent temozolomide and radiation for primary glioblastoma multiforme. ( Cao, Y; Gomez-Hassan, D; Hayman, J; Junck, L; Lawrence, TS; Lee, IH; Piert, M; Rogers, L; Ten Haken, RK; Tsien, C, 2009) |
| "In 2004, a randomised phase III trial by the European Organisation for Research and Treatment of Cancer (EORTC) and National Cancer Institute of Canada Clinical Trials Group (NCIC) reported improved median and 2-year survival for patients with glioblastoma treated with concomitant and adjuvant temozolomide and radiotherapy." | 9.14 | Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. ( Allgeier, A; Belanger, K; Brandes, AA; Cairncross, JG; Eisenhauer, E; Fisher, B; Gijtenbeek, J; Gorlia, T; Hau, P; Hegi, ME; Janzer, RC; Lacombe, D; Ludwin, SK; Marosi, C; Mason, WP; Mirimanoff, RO; Mokhtari, K; Stupp, R; Taphoorn, MJ; van den Bent, MJ; Vecht, CJ; Villa, S; Weller, M; Wesseling, P, 2009) |
| "We evaluated the pharmacodynamic effects of the O(6)-methylguanine-DNA methyltransferase (MGMT) inactivator lomeguatrib (LM) on patients with melanoma in two clinical trials." | 9.14 | O(6)-methylguanine-DNA methyltransferase depletion and DNA damage in patients with melanoma treated with temozolomide alone or with lomeguatrib. ( Beith, J; Davis, ID; Haydon, A; Hayward, O; Hersey, P; Kefford, R; Lorigan, P; Margison, GP; McArthur, G; McGown, G; Middleton, MR; Mortimer, P; Ranson, M; Sabharwal, A; Thomson, D; Thorncroft, M; Watson, AJ, 2009) |
| "Alternative dosing schedules of temozolomide may improve survival in patients with newly diagnosed glioblastoma (GBM) by increasing the therapeutic index, overcoming common mechanisms of temozolomide resistance, or both." | 9.14 | Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma. ( Abrey, LE; Clarke, JL; DeAngelis, LM; Gavrilovic, I; Hormigo, A; Iwamoto, FM; Karimi, S; Lassman, AB; Nolan, CP; Panageas, K; Sul, J, 2009) |
| "To present outcome data in a prospective study of radiotherapy (RT) with concurrent and adjuvant temozolomide (TMZ) in children with diffuse intrinsic pontine gliomas (DIPGs)." | 9.14 | Prospective evaluation of radiotherapy with concurrent and adjuvant temozolomide in children with newly diagnosed diffuse intrinsic pontine glioma. ( Arora, B; Dutta, D; Gupta, T; Jalali, R; Kurkure, P; Munshi, A; Raut, N; Sarin, R, 2010) |
| "To determine the maximum tolerated dose of ABT-510, a thrombospondin-1 mimetic drug with antiangiogenic properties, when used concurrently with temozolomide and radiotherapy in patients with newly diagnosed glioblastoma." | 9.14 | A phase 1 trial of ABT-510 concurrent with standard chemoradiation for patients with newly diagnosed glioblastoma. ( Fathallah-Shaykh, HM; Fiveash, JB; Gillespie, GY; Gladson, CL; Huang, Z; Johnson, MJ; Kekan, MS; Kuo, H; Markert, JM; Meleth, S; Nabors, LB, 2010) |
| "PURPOSE Concomitant temozolomide (TMZ)/radiotherapy followed by adjuvant TMZ has increased survival in patients with glioblastoma multiforme (GBM)." | 9.14 | Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study. ( Bélanger, K; Easaw, J; Eisenstat, DD; Forsyth, P; Fulton, D; Kavan, P; Kirby, S; Macdonald, DR; Mason, WP; Perry, JR; Pouliot, JF; Shields, C; Thiessen, B, 2010) |
| "Temozolomide (TMZ) a recent, oral, second generation alkylating agent is a chemotherapeutic with demonstrated efficacy for the treatment of high-grade gliomas." | 9.12 | Surgery, radiotherapy and temozolomide in treating high-grade gliomas. ( Barbarisi, M; Moraci, A; Moraci, M; Parlato, C, 2006) |
| "Based on our findings in two paediatric patients, temozolomide may be a useful agent in the management of progressive recurrent low grade spinal cord astrocytomas." | 9.12 | Role of temozolomide in spinal cord low grade astrocytomas: results in two paediatric patients. ( Abboud, MR; Al Kutoubi, AO; Alaraj, AM; Chamoun, RB; Haddad, GF, 2006) |
| "Temozolomide is an oral alkylating agent that crosses the blood-brain barrier, and has preclinical activity in breast cancer." | 9.12 | Temozolomide in metastatic breast cancer (MBC): a phase II trial of the National Cancer Institute of Canada - Clinical Trials Group (NCIC-CTG). ( Bordeleau, L; Charpentier, D; Crump, M; Eisenhauer, E; Matthews, S; Trudeau, ME; Yelle, L, 2006) |
| "The implementation of combined radiochemotherapy (RCHT) with temozolomide (TMZ) has lead to a significant increase in overall survival times in patients with Glioblastoma multiforme (GBM), however, outcome still remains unsatisfactory." | 9.12 | Treatment of primary glioblastoma multiforme with cetuximab, radiotherapy and temozolomide (GERT)--phase I/II trial: study protocol. ( Combs, SE; Debus, J; Edler, L; Haselmann, R; Heeger, S; Schulz-Ertner, D, 2006) |
| "Based on the promising results of a Phase I study with a combination of gemcitabine and DTIC performed in advanced soft tissue sarcoma (ASTS) patients, and due to the limited efficacy of second or third line therapies in those patients, we designed a Phase II study to determine the activity of this new regimen." | 9.12 | Phase II study with the combination of gemcitabine and DTIC in patients with advanced soft tissue sarcomas. ( Buesa, JM; Del Muro, JG; Escudero, P; Esteban, E; Fra, J; Gión, M; Goitia, A; López-Pousa, A; Losa, R; Maurel, J; Nadal, R; Sierra, M; Uña, E, 2007) |
| "To assess the efficacy and tolerability of extended dose temozolomide and continuous thalidomide in patients with advanced metastatic cutaneous melanoma." | 9.12 | A phase II study of extended dose temozolomide and thalidomide in previously treated patients with metastatic melanoma. ( Arce-Lara, C; Kloecker, GH; Laber, DA; McMasters, KM; Miller, DM; Okeke, RI; Schonard, CL; Taft, BS, 2006) |
| "The methylation status of the O6-methylguanine-methyltransferase promoter (MGMTP) was evaluated in 68 low-grade gliomas treated by neoadjuvant temozolomide." | 9.12 | MGMT methylation: a marker of response to temozolomide in low-grade gliomas. ( Benouaich-Amiel, A; Crinière, E; Delattre, JY; Everhard, S; Hoang-Xuan, K; Kaloshi, G; Kujas, M; Lejeune, J; Marie, Y; Mokhtari, K; Sanson, M; Thillet, J, 2006) |
| "To evaluate tumor response, pharmacodynamic effects, and safety of a combination of lomeguatrib (LM), an O6-methylguanine DNA-methyltransferase (MGMT) inactivator, and temozolomide (TMZ), TMZ alone, and LM/TMZ after disease progression on TMZ alone in patients with advanced melanoma." | 9.12 | Randomized trial of the combination of lomeguatrib and temozolomide compared with temozolomide alone in chemotherapy naive patients with metastatic cutaneous melanoma. ( Baka, S; Beith, J; Davis, ID; Harris, PA; Haydon, A; Hersey, P; Kefford, RF; Margison, GP; McArthur, GA; Middleton, MR; Mortimer, P; Ranson, M; Sabharwal, A; Seebaran, A; Thompson, D; Watson, AJ, 2007) |
| "Evaluation of toxicity and efficacy of an alternating weekly regimen of temozolomide administered 1 week on and 1 week off in patients with recurrent glioma." | 9.12 | Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma. ( Blaschke, B; Felsberg, J; Herrlinger, U; Meyermann, R; Platten, M; Reifenberger, G; Steinbach, JP; Weller, M; Wick, A; Wick, W, 2007) |
| "We report a phase II trial of cisplatinum and temozolomide (TMZ) combination in recurrent malignant glioma patients." | 9.11 | Phase II trial of cisplatin plus temozolomide, in recurrent and progressive malignant glioma patients. ( Boiardi, A; Broggi, G; Eoli, M; Lamperti, E; Maccagnano, E; Salmaggi, A; Silvani, A, 2004) |
| "Temozolomide (TMZ) and 1, 3-bis (2-chloroethyl)-1-nitrosourea (BCNU) are reported to be active agents in anaplastic glioma (AG)." | 9.11 | Phase II study of neoadjuvant 1, 3-bis (2-chloroethyl)-1-nitrosourea and temozolomide for newly diagnosed anaplastic glioma: a North American Brain Tumor Consortium Trial. ( Chang, SM; Fine, H; Fink, KL; Greenberg, H; Hess, K; Jaeckle, KA; Junck, L; Kuhn, J; Mehta, M; Prados, MD; Robins, HI; Schold, C; Yung, WK, 2004) |
| "A prospective Phase II study of temozolomide (TMZ) was conducted in 16 patients with refractory meningioma." | 9.11 | Temozolomide for treatment-resistant recurrent meningioma. ( Chamberlain, MC; Groshen, S; Tsao-Wei, DD, 2004) |
| "Twenty-one patients with recurrent or progressive glioblastoma were enrolled in a prospective phase II trial to determine the safety and efficacy of a 1-week on/1-week off regimen of temozolomide administered at 150 mg/m2 on days 1 to 7 and days 15 to 21 of 28-day treatment cycles." | 9.11 | One week on/one week off: a novel active regimen of temozolomide for recurrent glioblastoma. ( Bamberg, M; Dichgans, J; Küker, WM; Steinbach, JP; Weller, M; Wick, W, 2004) |
| "This report describes a single-centre study with temozolomide (TMZ) (200 mg m(-2) day(-1) x 5 per cycle of 28 days) in children with (recurrent) high-grade glioma." | 9.11 | Temozolomide in paediatric high-grade glioma: a key for combination therapy? ( Couanet, D; Grill, J; Kalifa, C; Lelouch-Tubiana, A; Vassal, G; Verschuur, AC, 2004) |
| "Seventy-five consecutive patients with recurrent malignant astrocytomas and glioblastomas had been treated at our institute with per os temozolomide for five days every month." | 9.11 | Temozolomide chemotherapy of patients with recurrent anaplastic astrocytomas and glioblastomas. ( Afra, D; Sipos, L; Vitanovics, D, 2004) |
| "Patients with newly diagnosed, histologically confirmed glioblastoma were randomly assigned to receive radiotherapy alone (fractionated focal irradiation in daily fractions of 2 Gy given 5 days per week for 6 weeks, for a total of 60 Gy) or radiotherapy plus continuous daily temozolomide (75 mg per square meter of body-surface area per day, 7 days per week from the first to the last day of radiotherapy), followed by six cycles of adjuvant temozolomide (150 to 200 mg per square meter for 5 days during each 28-day cycle)." | 9.11 | Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. ( Allgeier, A; Belanger, K; Bogdahn, U; Brandes, AA; Cairncross, JG; Curschmann, J; Eisenhauer, E; Fisher, B; Gorlia, T; Janzer, RC; Lacombe, D; Ludwin, SK; Marosi, C; Mason, WP; Mirimanoff, RO; Stupp, R; Taphoorn, MJ; van den Bent, MJ; Weller, M, 2005) |
| " Food and Drug Administration approved temozolomide (Temodar capsules, Schering-Plough Research Institute) for the treatment of adult patients with newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and then as maintenance treatment." | 9.11 | Food and Drug Administration Drug approval summary: temozolomide plus radiation therapy for the treatment of newly diagnosed glioblastoma multiforme. ( Cohen, MH; Johnson, JR; Pazdur, R, 2005) |
| "Temozolomide (TMZ) and 13-cis-retinoic acid (cRA) have shown activity in prior single-agent trials of recurrent malignant gliomas (MG)." | 9.10 | Phase II evaluation of temozolomide and 13-cis-retinoic acid for the treatment of recurrent and progressive malignant glioma: a North American Brain Tumor Consortium study. ( Chang, S; Cloughesy, T; Fine, H; Fink, K; Greenberg, H; Hess, KR; Jaeckle, KA; Kuhn, J; Mehta, M; Nicholas, MK; Pollack, IF; Prados, M; Schiff, D; Yung, WK, 2003) |
| "Temozolomide is an imidazotetrazine with a mechanism of action similar to dacarbazine and equivalent activity in melanoma." | 9.10 | Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma. ( Arance, A; Ashcroft, L; Clamp, A; Danson, S; Hodgetts, J; Lomax, L; Lorigan, P; Middleton, MR; Ranson, M; Thatcher, N, 2003) |
| "The aim of this study was to assess the efficacy of temozolomide in patients with World Health Organisation (WHO) grade II gliomas treated with surgery alone using imaging and clinical criteria." | 9.10 | Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas. ( Abson, C; Ashley, S; Brada, M; Britton, J; Gonsalves, A; Hines, F; Sardell, S; Traish, D; Viviers, L; Westbury, C; Wilkins, P, 2003) |
| "Forty-three patients affected with LGG (29 astrocytoma, four oligodendroglioma and 10 mixed oligo-astrocytoma) were treated with temozolomide (TMZ) at the time of documented clinical and radiological progression." | 9.10 | Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and radiological response. ( Canalini, P; Carapella, CM; Carosi, M; Cianciulli, AM; Galiè, E; Giannarelli, D; Jandolo, B; Pace, A; Telera, S; Vidiri, A, 2003) |
| "To determine whether chemotherapy with temozolomide (TMZ) versus procarbazine (PCB) for recurrent glioblastoma multiforme (GBM) was associated with improvement in health-related quality of life (HRQOL)." | 9.09 | Health-related quality of life in patients treated with temozolomide versus procarbazine for recurrent glioblastoma multiforme. ( Brada, M; Osoba, D; Prados, M; Yung, WK, 2000) |
| "One of the objectives of this phase II study was to determine whether temozolomide (TMZ) improved the health-related quality of life (HRQL) of patients with recurrent anaplastic astrocytoma (AA)." | 9.09 | Health-related quality of life in patients with anaplastic astrocytoma during treatment with temozolomide. ( Brada, M; Osoba, D; Prados, MD; Yung, WK, 2000) |
| "Forty-one patients with high-grade glioma, at second recurrence or progression, of which twenty-two (54%) had glioblastoma multiforme, ten (24%) anaplastic astrocytoma, and nine (22%) anaplastic oligodendroglioma were administered temozolomide, 150 mg/m2/daily for five days every four weeks." | 9.09 | Temozolomide as a second-line systemic regimen in recurrent high-grade glioma: a phase II study. ( Amistà, P; Basso, U; Berti, F; Brandes, AA; Ermani, M; Gardiman, M; Monfardini, S; Pinna, G; Rotilio, A; Scienza, R, 2001) |
| "To assess the effectiveness and safety of procarbazine, lomustine, and vincristine (PCV) chemotherapy with other interventions in adults with recurrent high-grade glioma." | 8.95 | Procarbazine, lomustine and vincristine for recurrent high-grade glioma. ( Guo, J; Parasramka, S; Rosenfeld, M; Talari, G; Villano, JL, 2017) |
| " Two chemotherapeutic regimens are commonly used for the palliative treatment of malignant melanoma: intravenous administration of single-agent dacarbazine or oral administration of temozolomide." | 8.89 | Efficacy and side effects of dacarbazine in comparison with temozolomide in the treatment of malignant melanoma: a meta-analysis consisting of 1314 patients. ( Abdollahi, M; Nikfar, S; Teimouri, F, 2013) |
| " In this paper we address different clinical outcomes measures separately and we illustrate the value of multiple outcome measures using the results of a recent clinical trial comparing temozolomide with procarbazine in the treatment of Glioblastoma Multiforme." | 8.82 | Benefit of temozolomide compared to procarbazine in treatment of glioblastoma multiforme at first relapse: effect on neurological functioning, performance status, and health related quality of life. ( Kiebert, G; Macdonald, DR; Olson, J; Prados, M; Yung, A, 2005) |
| "The aim of this study was to clarify whether PET with 11C-methyl-l-methionine (11C-met PET) can predict consequential outcomes at the time of discontinuing temozolomide (TMZ)-adjuvant chemotherapy in patients with residual isocitrate dehydrogenase gene (IDH)-mutant lower-grade glioma." | 8.12 | PET With 11C-Methyl-l-Methionine as a Predictor of Consequential Outcomes at the Time of Discontinuing Temozolomide-Adjuvant Chemotherapy in Patients With Residual IDH-Mutant Lower-Grade Glioma. ( Beppu, T; Fujiwara, S; Iwaya, T; Nomura, JI; Ogasawara, K; Sasaki, T; Sato, Y; Sugai, T; Terasaki, K; Yamada, N, 2022) |
| "We included 41 patients with isocitrate dehydrogenase 1/2-wildtype glioblastoma, who received 12 or more cycles of temozolomide therapy between June 2006 and December 2019." | 8.12 | Continuing maintenance temozolomide therapy beyond 12 cycles confers no clinical benefit over discontinuation at 12 cycles in patients with IDH1/2-wildtype glioblastoma. ( Miyakita, Y; Narita, Y; Ohno, M; Takahashi, M; Tamura, Y; Yanagisawa, S, 2022) |
| "Drug resistance strikingly limits the therapeutic effect of temozolomide (TMZ) (a common drug for glioma)." | 8.02 | A positive feedback loop of lncRNA-RMRP/ZNRF3 axis and Wnt/β-catenin signaling regulates the progression and temozolomide resistance in glioma. ( Han, B; Hu, J; Jia, W; Liu, T; Tan, S; Xin, Y, 2021) |
| "Irinotecan and temozolomide (IT) is a widely used regimen for relapsed Ewing sarcoma (ES), although studies are largely limited to paediatric populations." | 8.02 | Irinotecan and temozolomide chemotherapy in paediatric and adult populations with relapsed Ewing Sarcoma. ( Abuhijla, F; Abuhijlih, R; Alnsour, A; Halalsheh, H; Ismail, T; Khozouz, O; Lewin, J; Salah, S; Shahin, O; Sultan, I; To, YH; Yaser, S, 2021) |
| "Improving the chemotherapy resistance of temozolomide (TMZ) is of great significance in the treatment of glioblastoma multiforme (GBM)." | 8.02 | Long noncoding RNA just proximal to X-inactive specific transcript facilitates aerobic glycolysis and temozolomide chemoresistance by promoting stability of PDK1 mRNA in an m6A-dependent manner in glioblastoma multiforme cells. ( Jiang, XB; Li, XD; Wang, MJ; Wang, X; Wu, YH; Zheng, JL, 2021) |
| "A generally used chemotherapeutic drug for glioma, a frequently diagnosed brain tumour, is temozolomide (TMZ)." | 7.96 | miR-152-5p suppresses glioma progression and tumorigenesis and potentiates temozolomide sensitivity by targeting FBXL7. ( Cao, Y; Fang, Y; He, R; Kong, S; Wang, B; Zhao, Z, 2020) |
| "Despite the clinical success of temozolomide (TMZ), its sensitivity remains a major challenge in glioblastoma (GBM)." | 7.91 | PLK4 is a determinant of temozolomide sensitivity through phosphorylation of IKBKE in glioblastoma. ( Han, L; Huang, K; Liang, H; Liu, Y; Wang, G; Wang, Q; Wang, Z; Wei, C; Zhang, A; Zhang, W; Zhang, Z; Zhen, Y; Zhou, J, 2019) |
| "Glioma is a frequently diagnosed brain tumors and Temozolomide (TMZ) is a common chemotherapeutic drug for glioma." | 7.91 | MicroRNA-34a-5p suppresses tumorigenesis and progression of glioma and potentiates Temozolomide-induced cytotoxicity for glioma cells by targeting HMGA2. ( Fu, T; Gao, M; Ma, S; Zhao, S, 2019) |
| "Our study tested the diagnostic accuracy of increased signal intensity (SI) within FLAIR MR images of resection cavities in differentiating early progressive disease (ePD) from pseudoprogression (PsP) in patients with glioblastoma treated with radiotherapy with concomitant temozolomide therapy." | 7.88 | Increased signal intensity within glioblastoma resection cavities on fluid-attenuated inversion recovery imaging to detect early progressive disease in patients receiving radiotherapy with concomitant temozolomide therapy. ( Agrawal, JP; Erickson, BJ; Korfiatis, P; Perry, LA, 2018) |
| "Although upfront temozolomide (TMZ) has been widely-used to treat 1p/19q-codeleted diffuse low-grade gliomas (LGG), its long-term impact on the growth kinetics of these tumors has not been determined." | 7.88 | Long-term impact of temozolomide on 1p/19q-codeleted low-grade glioma growth kinetics. ( Alentorn, A; Barritault, M; Bruna, J; Delattre, JY; Ducray, F; Honnorat, J; Idbaih, A; Izquierdo, C; Kaloshi, G; Meyronet, D; Ricard, D; Simó, M, 2018) |
| "Temozolomide (TMZ) is an alkylating agent frequently used in well-differentiated metastatic pancreatic neuroendocrine tumors (PNETs) with very variable responses." | 7.85 | Short article: Evaluation of O6-methylguanine-DNA methyltransferase as a predicting factor of response to temozolomide-based chemotherapy in well-differentiated metastatic pancreatic neuroendocrine tumors. ( Caroli-Bosc, FX; Cauchin, E; Dumars, C; Foubert, F; Girot, P; Matysiak-Budnik, T; Mosnier, JF; Muzellec, L; Regenet, N; Senellart, H; Touchefeu, Y, 2017) |
| "Radiation with concurrent and adjuvant (6 cycles) temozolomide (TMZ) is the established standard of postsurgical care for newly diagnosed glioblastoma (GBM)." | 7.85 | Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma: a secondary analysis of EORTC and NRG Oncology/RTOG. ( Baumert, BG; Blumenthal, DT; Brown, PD; Burt Nabors, L; Corn, BW; Erridge, SC; Gilbert, MR; Golfinopoulos, V; Gorlia, T; Hegi, ME; Hyun Nam, D; Kim, MM; Mason, WP; Mehta, MP; Mirimanoff, RO; Perry, JR; Reardon, DA; Stupp, R; van den Bent, MJ; Weller, M; Zhang, P, 2017) |
| "We retrospectively analyzed the data of 5 adult patients treated with temozolomide between 2008 and 2015 for a grade II intramedullary astrocytoma with progression after surgery." | 7.85 | [Contribution of temozolomide chemotherapy for intramedullary grade II spinal cord astrocytomas in adults: Our experience]. ( Chaskis, E; De Witte, O; Devriendt, D; Goldman, S; Lefranc, F; Luce, S; Minichini, V; Sadeghi, N, 2017) |
| "We performed a retrospective case series to evaluate the feasibility of adding temozolomide to pazopanib in advanced sarcoma patients following single-agent pazopanib failure." | 7.85 | Temozolomide post pazopanib treatment failure in patients with advanced sarcoma: A case series. ( Bupathi, M; Chen, JL; Hays, JL, 2017) |
| " When treated with temozolomide (TMZ), an oral alkylating chemotherapy drug, most low-grade gliomas (LGG) show an initial volume decrease but this effect is rarely long lasting." | 7.85 | Analysis of temozolomide resistance in low-grade gliomas using a mechanistic mathematical model. ( Alentorn, A; Delattre, JY; Ducray, F; Grenier, E; Honnorat, J; Idbaih, A; Kaloshi, G; Mazzocco, P; Ollier, E; Psimaras, D; Ricard, D; Samson, A, 2017) |
| "To explore the role of dynamic contrast material-enhanced magnetic resonance (MR) imaging in the differentiation of true progression from pseudoprogression in patients with glioblastoma on the basis of findings in entirely newly developed or enlarged enhancing lesions after concurrent radiation therapy and chemotherapy with temozolomide and to evaluate the diagnostic performance of the quantitative pharmacokinetic parameters obtained at dynamic contrast-enhanced MR imaging, such as the volume transfer constant (K(trans)), the extravascular extracellular space per unit volume of tissue(ve), and the blood plasma volume per unit volume of tissue(vp)." | 7.81 | Glioblastoma treated with concurrent radiation therapy and temozolomide chemotherapy: differentiation of true progression from pseudoprogression with quantitative dynamic contrast-enhanced MR imaging. ( Choi, SH; Kim, IH; Kim, JH; Kim, TM; Lee, SH; Park, CK; Park, SH; Sohn, CH; Yun, TJ, 2015) |
| "The purpose of this study was to assess the efficacy and toxicity of radiotherapy (RT) with concurrent temozolomide (TMZ) chemotherapy followed by adjuvant TMZ in children with diffuse intrinsic pontine glioma (DIPG)." | 7.81 | Temozolomide in the treatment of newly diagnosed diffuse brainstem glioma in children: a broken promise? ( Attinà, G; Balducci, M; Caldarelli, M; Colosimo, C; Lazzareschi, I; Mastrangelo, S; Maurizi, P; Riccardi, R; Ridola, V; Rizzo, D; Ruggiero, A; Scalzone, M, 2015) |
| "Temozolomide (TMZ) increases the overall survival of patients with glioblastoma (GBM), but its role in the clinical management of diffuse low-grade gliomas (LGG) is still being defined." | 7.81 | Evolution of DNA repair defects during malignant progression of low-grade gliomas after temozolomide treatment. ( Aburatani, H; Aihara, K; Berger, MS; Chang, SM; Costello, JF; Fouse, SD; Hallbeck, M; Heimans, JJ; Hong, C; Johnson, BE; Kloezeman, JJ; Lamfers, ML; Malmström, A; Mazor, T; Molinaro, AM; Mukasa, A; Reijneveld, JC; Saito, N; Söderkvist, P; Stenmark-Askmalm, M; Taylor, BS; van Thuijl, HF; Wesseling, P; Ylstra, B, 2015) |
| "A total of nine patients with malignant glioma, postoperatively presenting with a Karnofsky performance score (KPS) below 70, were treated with standalone metronomic low-dose chemotherapy with temozolomide and celecoxib (cyclo-oxygenase-2 inhibitor)." | 7.81 | Dual Anti-angiogenic Chemotherapy with Temozolomide and Celecoxib in Selected Patients with Malignant Glioma Not Eligible for Standard Treatment. ( Brawanski, KR; Freyschlag, CF; Grams, AE; Kerschbaumer, J; Nowosielski, M; Petr, O; Pinggera, D; Schmidt, FA; Seiz, M; Thomé, C; Tuettenberg, J, 2015) |
| " Our aim was to determine whether the subependymal enhancement pattern and ADC can differentiate true progression from pseudoprogression in patients with glioblastoma multiforme treated with concurrent chemoradiotherapy by using temozolomide." | 7.81 | Independent Poor Prognostic Factors for True Progression after Radiation Therapy and Concomitant Temozolomide in Patients with Glioblastoma: Subependymal Enhancement and Low ADC Value. ( Choi, SH; Kim, IH; Kim, JH; Kim, TM; Lee, SH; Park, CK; Park, SH; Sohn, CH; Yoo, RE; Yun, TJ, 2015) |
| " Interestingly, our findings showed an association of metformin therapy and prolonged progression-free survival in glioblastoma patients with diabetes and therefore serve as a foundation for further preclinical and clinical investigations." | 7.81 | Metformin influences progression in diabetic glioblastoma patients. ( Adeberg, S; Ben Harrabi, S; Bernhardt, D; Bostel, T; Debus, J; Diehl, C; Koelsche, C; Mohr, A; Rieken, S, 2015) |
| "To explore the role of histogram analysis of apparent diffusion coefficient (ADC) maps obtained at standard- and high-b-value (1000 and 3000 sec/mm(2), respectively) diffusion-weighted (DW) imaging in the differentiation of true progression from pseudoprogression in glioblastoma treated with radiation therapy and concomitant temozolomide." | 7.79 | Differentiation of true progression from pseudoprogression in glioblastoma treated with radiation therapy and concomitant temozolomide: comparison study of standard and high-b-value diffusion-weighted imaging. ( Choi, SH; Chu, HH; Jung, SC; Kim, IH; Kim, JH; Kim, SC; Kim, TM; Lee, AL; Lee, SH; Park, CK; Park, SH; Ryoo, I; Shin, H; Sohn, CH; Yeom, JA; Yoon, TJ, 2013) |
| " We retrospectively surveyed 32 patients with GBM or GBM with oligodendroglioma component (GBMO) who underwent biopsy or maximal tumor resection followed by concurrent radiotherapy and temozolomide (TMZ)." | 7.79 | IDH1 mutation as a potential novel biomarker for distinguishing pseudoprogression from true progression in patients with glioblastoma treated with temozolomide and radiotherapy. ( Houkin, K; Kamoshima, Y; Kobayashi, H; Motegi, H; Murata, J; Tanino, M; Terasaka, S; Yamaguchi, S, 2013) |
| "Combined temozolomide (TMZ) and radiation therapy (RT) is often used as initial treatment for anaplastic glioma." | 7.79 | Combined temozolomide and radiation as an initial treatment for anaplastic glioma. ( Chong, DQ; Chua, ET; Lim, KH; Ng, WH; See, SJ; Tan, SH; Tham, CK; Thomas, J, 2013) |
| "We report retrospective data on the feasibility and efficacy of prolonging adjuvant temozolomide (TMZ) more than 6 months after chemoradiotherapy completion in patients with glioblastoma (GBM)." | 7.78 | Prolonged temozolomide for treatment of glioblastoma: preliminary clinical results and prognostic value of p53 overexpression. ( Auberdiac, P; Cartier, L; Chargari, C; Forest, F; Fotso, MJ; Magné, N; Malkoun, N; Nuti, C; Pacaut, C; Peoc'h, M; Schmitt, T; Thorin, J, 2012) |
| "Two glioblastoma multiforme patients underwent (18)F-FMISO (fluoromisonidazole) positron emission tomography study to access the tumor oxygenation status before and immediately after fractionated radiotherapy concomitant with temozolomide chemotherapy." | 7.78 | Reoxygenation of glioblastoma multiforme treated with fractionated radiotherapy concomitant with temozolomide: changes defined by 18F-fluoromisonidazole positron emission tomography: two case reports. ( Aoyama, H; Hirata, K; Houkin, K; Kobayashi, H; Murata, J; Narita, T; Onodera, S; Shiga, T; Tanaka, S; Terasaka, S, 2012) |
| "The standard of care for newly diagnosed glioblastoma multiforme (GBM) is temozolomide (TMZ) chemotherapy given concurrently with radiation for 6 weeks followed by 6 months of adjuvant TMZ." | 7.78 | Extended adjuvant temozolomide for treatment of newly diagnosed glioblastoma multiforme. ( Easaw, JC; Roldán Urgoiti, GB; Singh, AD, 2012) |
| "We analyzed 62 consecutive patients with newly diagnosed glioblastoma treated between 2006 and 2008 with standard fractionation to a total dose of 60 Gy with concurrent temozolomide (97%) or arsenic trioxide (3%)." | 7.77 | Pattern of failure after limited margin radiotherapy and temozolomide for glioblastoma. ( Crocker, IR; Curran, WJ; McDonald, MW; Shu, HK, 2011) |
| "We investigated pseudoprogression (psPD) in patients with malignant gliomas treated with radiotherapy (RT) and maintenance temozolomide (TMZ) in terms of incidence, outcomes, and predictive and prognostic factors." | 7.77 | Pseudoprogression in patients with malignant gliomas treated with concurrent temozolomide and radiotherapy: potential role of p53. ( Choe, GY; Han, JH; Kang, HC; Kim, CY; Kim, IA; Kim, JH, 2011) |
| "To evaluate the safety and efficacy of hypofractionated radiotherapy (RT) with a standard temozolomide (TMZ) regimen for adults with newly diagnosed glioblastoma multiforme (GBM), twenty-six consecutive adults (range 39-79 years) who met our enrollment criteria received short courses of hypofractionated RT (45 Gy in 15 fractions over three weeks) with concomitant TMZ at 75 mg/m(2)/d." | 7.77 | A pilot study of hypofractionated radiation therapy with temozolomide for adults with glioblastoma multiforme. ( Eto, T; Nakashima, S; Ogo, E; Okada, Y; Shigemori, M; Sugita, Y; Terasaki, M; Tokutomi, T, 2011) |
| "Prolonged administration of temozolomide is widely used in patients with glioblastoma; whereas the treatment of anaplastic glioma differs between neurooncological centres." | 7.77 | Prolonged administration of temozolomide in adult patients with anaplastic glioma. ( Freyschlag, CF; Janzen, E; Lohr, F; Schmieder, K; Seiz, M; Smolczyk, DR; Thomé, C; Tuettenberg, J; Weiss, C; Wenz, F, 2011) |
| "Our objective was to retrospectively review temozolomide in advanced and recurrent uterine leiomyosarcoma and to determine if tumor O-methylguanine DNA methyltransferase (MGMT) expression correlated with clinical response." | 7.76 | Temozolomide in advanced and recurrent uterine leiomyosarcoma and correlation with o6-methylguanine DNA methyltransferase expression: a case series. ( Atkins, KA; Ferriss, JS; Jazaeri, AA; Lachance, JA; Modesitt, SC, 2010) |
| "One hundred and fourteen patients with glioblastoma multiforme received a median of 6 cycles of adjuvant first-line temozolomide (range 1-57)." | 7.76 | Long-term adjuvant administration of temozolomide in patients with glioblastoma multiforme: experience of a single institution. ( Freyschlag, CF; Krafft, U; Lohr, F; Schmieder, K; Seiz, M; Thomé, C; Tuettenberg, J; Weiss, C; Wenz, F, 2010) |
| "We report a case of prolonged survival in a patient with cervical intramedullary glioblastoma multiforme (GBM) treated with total resection, radiotherapy, and temozolomide." | 7.76 | Prolonged survival of a patient with cervical intramedullary glioblastoma multiforme treated with total resection, radiation therapy, and temozolomide. ( Huang, CY; Kuo, LT; Lien, HC; Liu, KL; Liu, MT; Tseng, HM, 2010) |
| "Concurrent temozolomide (TMZ) and radiotherapy became the new standard of care for patients diagnosed with glioblastoma multiforme (GBM)." | 7.76 | Pseudoprogression following concurrent temozolomide and radiotherapy in a patient with glioblastoma: findings on functional imaging techniques. ( Abe, K; Amano, T; Hiwatashi, A; Honda, H; Kamano, H; Nakamizo, A; Shioyama, Y; Shirakawa, Y; Suzuki, S; Torisu, R; Yamashita, K; Yoshimoto, K; Yoshiura, T, 2010) |
| "Temozolomide (TMZ) is the standard of care for patients with newly diagnosed glioblastoma (GBM) as well as those with recurrent anaplastic glioma (AG) and GBM." | 7.75 | Rechallenge with temozolomide in patients with recurrent gliomas. ( Bogdahn, U; Hau, P; Jauch, T; Pascher, C; Weller, M; Wick, A; Wick, W, 2009) |
| "Glioblastomas are treated by surgical resection followed by radiotherapy [X-ray therapy (XRT)] and the alkylating chemotherapeutic agent temozolomide." | 7.74 | Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment. ( Batchelor, TT; Betensky, RA; Cahill, DP; Codd, PJ; Curry, WT; Futreal, PA; Iafrate, AJ; Levine, KK; Louis, DN; Reavie, LB; Romany, CA; Stratton, MR, 2007) |
| "The aim of this study was to evaluate the efficacy and safety of carmustine (BCNU) in combination with temozolomide as first-line chemotherapy before and after radiotherapy (RT) in patients with inoperable, newly diagnosed glioblastoma multiforme (GBM)." | 7.73 | Temozolomide in combination with BCNU before and after radiotherapy in patients with inoperable newly diagnosed glioblastoma multiforme. ( Barrié, M; Braguer, D; Chinot, O; Couprie, C; Dufour, H; Figarella-Branger, D; Grisoli, F; Hoang-Xuan, K; Martin, PM; Muracciole, X; Peragut, JC, 2005) |
| "To describe the results of the treatment of recurrent glioma with temozolomide." | 7.73 | [Favourable result for temozolomide in recurrent high-grade glioma]. ( Enting, RH; Kros, JM; Sillevis Smitt, PA; Taal, W; van den Bent, MJ; van der Rijt, CD; van Heuvel, I, 2005) |
| " Pharmacokinetic testing did not show evidence of drug-drug interaction between irinotecan and alisertib." | 6.82 | Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) Trial. ( Bagatell, R; Courtier, J; Czarnecki, S; DuBois, SG; Fox, E; Goodarzian, F; Groshen, S; Hawkins, R; Kudgus, RA; Lai, H; Malvar, J; Marachelian, A; Maris, JM; Matthay, KK; Mosse, YP; Reid, JM; Shimada, H; Tsao-Wei, D; Wagner, L, 2016) |
| "Cilengitide was continued for up to 12 months or until disease progression or unacceptable toxicity." | 6.82 | Cilengitide with metronomic temozolomide, procarbazine, and standard radiotherapy in patients with glioblastoma and unmethylated MGMT gene promoter in ExCentric, an open-label phase II trial. ( Ackland, S; Back, M; Buyse, ME; Kerestes, Z; Khasraw, M; Kichenadasse, G; Lee, A; McCowatt, S; Wheeler, H, 2016) |
| "Perillyl alcohol has shown to have both chemopreventive and chemotherapeutic activities in preclinical studies." | 6.73 | Preliminary results from a phase I/II study of perillyl alcohol intranasal administration in adults with recurrent malignant gliomas. ( da Fonseca, CO; Fischer, J; Futuro, D; Gattass, CR; Nagel, J; Quirico-Santos, T; Schwartsmann, G, 2008) |
| " If further studies are to be performed, emerging data suggest that higher daily doses of lomeguatrib and a dosing period beyond that of TMZ should be evaluated." | 6.73 | A phase II trial of lomeguatrib and temozolomide in metastatic colorectal cancer. ( Khan, OA; Levitt, NC; Margison, GP; Michael, M; Middleton, MR; Midgley, R; Mortimer, P; Olver, I; Ranson, M; Watson, AJ, 2008) |
| "Brain metastases are a common complication in patients suffering from metastatic malignant melanoma." | 6.72 | Temozolomide with or without radiotherapy in melanoma with unresectable brain metastases. ( Budach, V; Hofmann, M; Kiecker, F; Schlenger, L; Sterry, W; Trefzer, U; Wurm, R, 2006) |
| "Decision making at disease progression is critical, and classical T1 and T2 imaging remain the gold standard." | 6.72 | Perfusion and diffusion MRI of glioblastoma progression in a four-year prospective temozolomide clinical trial. ( Buff, E; Leimgruber, A; Maeder, PP; Meuli, RA; Ostermann, S; Stupp, R; Yeon, EJ, 2006) |
| "Temozolomide was in general well tolerated; the most frequent side-effects were hematological." | 6.71 | Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972. ( Baron, B; Boogerd, W; Bravo Marques, J; Chinot, O; De Beule, N; Kros, JM; Taphoorn, MJ; van den Bent, MJ; van der Rijt, CC; Vecht, CJ, 2003) |
| "Temozolomide is an oral alkylating agent that can cross the blood-brain barrier and in phase II and III trials, patients with advanced metastatic melanoma achieved overall response rates of 13 to 21%." | 6.71 | The effect of temozolomide-based chemotherapy in patients with cerebral metastases from melanoma. ( Bafaloukos, D; Briassoulis, E; Christodoulou, C; Fountzilas, G; Gogas, H; Hatzichristou, H; Kalofonos, HP; Linardou, H; Panagiotou, P; Tsoutsos, D, 2004) |
| "Ifosfamide treatment might be a feasible approach, but it necessitates hospitalization." | 6.69 | Chemotherapy in the treatment of recurrent glioblastoma multiforme: ifosfamide versus temozolomide. ( Bamberg, M; Becker, G; Belka, C; Classen, J; Hoffmann, W; Kortmann, RD; Paulsen, F; Weinmann, M, 1999) |
| "The prognosis of glioma is generally poor and is the cause of primary malignancy in the brain." | 5.56 | MicroRNA-155-3p promotes glioma progression and temozolomide resistance by targeting Six1. ( Chen, G; Chen, Z; Zhao, H, 2020) |
| "Malignant glioma is a severe type of brain tumor with a poor prognosis and few options for therapy." | 5.40 | Glutathione depletion sensitizes cisplatin- and temozolomide-resistant glioma cells in vitro and in vivo. ( Belizário, JE; de Andrade-Lima, LC; Garcia, CC; Menck, CF; Munford, V; Quinet, A; Rocha, CR; Vieira, DB, 2014) |
| "Intracranial anaplastic ependymomas are a very rare entity within the group of adult CNS neoplasms." | 5.37 | Response to temozolomide in supratentorial multifocal recurrence of malignant ependymoma. ( Freyschlag, CF; Lohr, F; Schmieder, K; Seiz, M; Thomé, C; Tuettenberg, J, 2011) |
| "The median time to disease progression was 8 weeks, and the overall survival duration was 26 weeks." | 5.36 | The clinical efficacy of combination of docetaxel and temozolomide in previously treated patients with stage IV melanoma. ( Alvarado, GC; Bedikian, AY; Camacho, LH; Hwu, P; Kim, KB; McIntyre, S; Papadopoulos, NE; Yoon, C, 2010) |
| "A clinical trial using the poly (adenosine diphosphate ribose) polymerase (PARP) inhibitor veliparib concurrently with radiation therapy, followed by maintenance therapy with veliparib + temozolomide, in children with diffuse intrinsic pontine glioma was conducted by the Pediatric Brain Tumor Consortium." | 5.34 | Advanced ADC Histogram, Perfusion, and Permeability Metrics Show an Association with Survival and Pseudoprogression in Newly Diagnosed Diffuse Intrinsic Pontine Glioma: A Report from the Pediatric Brain Tumor Consortium. ( Baxter, P; Billups, C; Brown, D; Dunkel, IJ; Fangusaro, JR; Law, M; Onar-Thomas, A; Patay, Z; Poussaint, TY; Shiroishi, MS; Vajapeyam, S; Vezina, G, 2020) |
| "In this exploratory analysis of AVAglio, a randomized phase III clinical study that investigated the addition of bevacizumab (Bev) to radiotherapy/temozolomide in newly diagnosed glioblastoma, we aim to radiologically characterize glioblastoma on therapy until progression and investigate whether the type of radiologic progression differs between treatment arms and is related to survival and molecular data." | 5.27 | Radiologic progression of glioblastoma under therapy-an exploratory analysis of AVAglio. ( Abrey, LE; Bendszus, M; Chinot, OL; Cloughesy, TF; Ellingson, BM; Garcia, J; Henriksson, R; Kickingereder, P; Mason, WP; Nishikawa, R; Nowosielski, M; Platten, M; Radbruch, A; Revil, C; Sandmann, T; Saran, F; Wick, W, 2018) |
| "To determine the impact on overall survival with different salvage therapies, including no treatment, reirradiation, systemic therapy, or radiation and systemic therapy, in participants of a phase 3 clinical trial evaluating dose-dense versus standard-dose temozolomide for patients with newly diagnosed glioblastoma." | 5.27 | Investigating the Effect of Reirradiation or Systemic Therapy in Patients With Glioblastoma After Tumor Progression: A Secondary Analysis of NRG Oncology/Radiation Therapy Oncology Group Trial 0525. ( Andrews, DW; Blumenthal, DT; Brown, PD; Dignam, JJ; Gilbert, MR; Hopkins, K; Howard, SP; Lessard, N; Mehta, MP; Scannell Bryan, M; Shi, W; Souhami, L; Tzuk-Shina, T; Valeinis, E; Werner-Wasik, M; Youssef, EF, 2018) |
| "In this phase II study, we investigate clinical outcomes and tolerability of hypofractionated radiotherapy (HRT) combined with temozolomide (TMZ) to treat elderly patients with glioblastoma (GBM)." | 5.27 | Interim Results of a Phase II Study of Hypofractionated Radiotherapy with Concurrent Temozolomide Followed by Adjuvant Temozolomide in Patients over 70 Years Old with Newly Diagnosed Glioblastoma. ( Amsbaugh, M; Boakye, M; Burton, E; Hattab, EM; Nelson, M; Ugiliweneza, B; Williams, B; Woo, S; Yusuf, M, 2018) |
| "We report a longitudinal assessment of health-related quality of life (HRQOL) in patients with glioblastoma (GBM) treated on a prospective dose escalation trial of 5-fraction stereotactic radiosurgery (25-40 Gy in 5 fractions) with concurrent and adjuvant temozolomide." | 5.24 | Phase 1/2 Trial of 5-Fraction Stereotactic Radiosurgery With 5-mm Margins With Concurrent and Adjuvant Temozolomide in Newly Diagnosed Supratentorial Glioblastoma: Health-Related Quality of Life Results. ( Adler, JR; Azoulay, M; Chang, SD; Choi, CYH; Fujimoto, D; Gibbs, IC; Hancock, SL; Harraher, C; Harsh, GR; Jacobs, LR; Li, G; Modlin, LA; Nagpal, S; Pollom, EL; Recht, LD; Seiger, K; Soltys, SG; Thomas, RP; Tupper, L; von Eyben, R; Wynne, J, 2017) |
| "Bevacizumab plus bi-weekly temozolomide was well tolerated and may be a salvage regimen to be considered in a subset of patients with recurrent glioblastoma." | 5.24 | Phase II study of bi-weekly temozolomide plus bevacizumab for adult patients with recurrent glioblastoma. ( Ahmadi, MM; Badruddoja, MA; Kuzma, K; Mahadevan, D; Norton, T; Pazzi, M; Sanan, A; Schroeder, K; Scully, T, 2017) |
| "While our study failed to meet the primary endpoint for objective radiographic response, patients with high-risk low-grade glioma receiving adjuvant temozolomide demonstrated a high rate of radiographic stability and favorable survival outcomes while meaningfully delaying radiotherapy." | 5.24 | Chemotherapy for adult low-grade gliomas: clinical outcomes by molecular subtype in a phase II study of adjuvant temozolomide. ( Berger, MS; Butowski, N; Chang, SM; Clarke, JL; Costello, JF; Dayal, M; Haas-Kogan, DA; Lin, Y; Molinaro, AM; Nelson, S; Perry, A; Phillips, JJ; Prados, M; Wahl, M, 2017) |
| "In glioblastoma multiforme (GBM), both temozolomide (TMZ) and cisplatin are very active at various toxic levels." | 5.24 | Continuous dose-intense temozolomide and cisplatin in recurrent glioblastoma patients. ( Guo, Y; Kong, X; Ma, W; Wang, R; Wang, Y, 2017) |
| "In elderly patients with glioblastoma, the addition of temozolomide to short-course radiotherapy resulted in longer survival than short-course radiotherapy alone." | 5.24 | Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma. ( Back, M; Baumert, BG; Brandes, AA; Cairncross, JG; Chinot, O; Ding, K; Fariselli, L; Fay, M; Feuvret, L; Franceschi, E; Golfinopoulos, V; Hirte, H; Laigle-Donadey, F; Laperriere, N; Mason, WP; Menten, J; Nishikawa, R; O'Callaghan, CJ; Osoba, D; Perry, JR; Phillips, C; Roa, W; Rossiter, JP; Sahgal, A; Tills, M; Wick, A; Wick, W; Winch, C, 2017) |
| "The proposed use of bevacizumab with radiotherapy/temozolomide for newly diagnosed glioblastoma raised potential safety concerns." | 5.22 | Bevacizumab, temozolomide, and radiotherapy for newly diagnosed glioblastoma: comprehensive safety results during and after first-line therapy. ( Chinot, OL; Cloughesy, T; Dhar, S; Garcia, J; Henriksson, R; Mason, W; Nishikawa, R; Pozzi, E; Saran, F; Wick, W, 2016) |
| "To investigate the safety of combined Wilms tumor 1 peptide vaccination and temozolomide treatment of glioblastoma, a phase I clinical trial was designed." | 5.20 | Wilms tumor 1 peptide vaccination combined with temozolomide against newly diagnosed glioblastoma: safety and impact on immunological response. ( Arita, N; Chiba, Y; Hashimoto, N; Hosen, N; Izumoto, S; Kagawa, N; Kijima, N; Kinoshita, M; Morimoto, S; Morita, S; Nakajima, H; Nishida, S; Oji, Y; Oka, Y; Sakamoto, J; Sugiyama, H; Tsuboi, A; Yoshimine, T, 2015) |
| "Valproic acid (VPA) is an antiepileptic agent with histone deacetylase inhibitor (HDACi) activity shown to sensitize glioblastoma (GBM) cells to radiation in preclinical models." | 5.20 | A Phase 2 Study of Concurrent Radiation Therapy, Temozolomide, and the Histone Deacetylase Inhibitor Valproic Acid for Patients With Glioblastoma. ( Camphausen, K; Chang, MG; Fine, HA; Holdford, DJ; Krauze, AV; Myrehaug, SD; Shih, J; Smith, S; Tofilon, PJ, 2015) |
| "To evaluate the efficacy and safety of TTFields used in combination with temozolomide maintenance treatment after chemoradiation therapy for patients with glioblastoma." | 5.20 | Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. ( Barnett, GH; Caroli, M; Chen, TC; Desai, R; Engelhard, HH; Fink, KL; Hegi, ME; Henson, JW; Honnorat, J; Hottinger, AF; Idbaih, A; Kanner, AA; Kesari, S; Kew, Y; Kirson, ED; Landolfi, J; Lieberman, F; Palti, Y; Ram, Z; Silvani, A; Sroubek, J; Steinberg, DM; Stupp, R; Taillibert, S; Taylor, LP; Toms, SA; Tran, DD; Tran, ND; Weinberg, U; Zhu, JJ, 2015) |
| "To evaluate the efficacy of limited margins intensity-modulated radiotherapy (IMRT) with temozolomide chemotherapy in patients with malignant glioma, and explore the prognostic factors of malignant glioma." | 5.20 | [Randomized controlled study of limited margins IMRT and temozolomide chemotherapy in patients with malignant glioma]. ( Cao, Y; Sun, J; Yang, X; Zhang, W, 2015) |
| " We sought to determine whether the addition of a vascular endothelial growth factor (VEGF) signaling inhibitor (cediranib) to conventional CRT had an impact on the frequency of PsP, by comparing two groups of patients with newly diagnosed glioblastoma before, during, and after CRT." | 5.19 | Low incidence of pseudoprogression by imaging in newly diagnosed glioblastoma patients treated with cediranib in combination with chemoradiation. ( Batchelor, TT; Emblem, KE; Gerstner, ER; Jain, RK; Jennings, D; Kalpathy-Cramer, J; Pinho, MC; Polaskova, P; Rosen, BR; Sorensen, AG; Wen, PY, 2014) |
| "The integrin antagonist cilengitide has been explored as an adjunct with anti-angiogenic properties to standard of care temozolomide chemoradiotherapy (TMZ/RT → TMZ) in newly diagnosed glioblastoma." | 5.19 | Cilengitide treatment of newly diagnosed glioblastoma patients does not alter patterns of progression. ( Clément, PM; Eisele, AC; Eisele, G; Krex, D; Neyns, B; Nikkhah, G; Ochsenbein, A; Picard, M; Schlegel, U; Simon, M; Stupp, R; Tabatabai, G; Tonn, J; Weller, M; Wick, A; Wick, W, 2014) |
| "To describe the quality of life (QOL) in elderly patients with glioblastoma (GBM) treated with an abbreviated course of radiation therapy (RT; 40 Gy in 15 fractions) plus concomitant and adjuvant temozolomide (TMZ)." | 5.17 | Health-related quality of life in elderly patients with newly diagnosed glioblastoma treated with short-course radiation therapy plus concomitant and adjuvant temozolomide. ( Baldoni, A; De Sanctis, V; Enrici, RM; Esposito, V; Lanzetta, G; Minniti, G; Scaringi, C, 2013) |
| "The current standard-of-care for glioblastoma (GBM) is represented by concomitant radiotherapy (RT) and temozolomide (TMZ), according to Stupp's protocol." | 5.17 | Continuous tamoxifen and dose-dense temozolomide in recurrent glioblastoma. ( Caroli, M; Carrabba, G; DI Cristofori, A; Lanfranchi, G; Menghetti, C; Rampini, P, 2013) |
| "To evaluate in a single center retrospectively the efficacy and tolerability of a weekly regimen, which alternates temozolomide (TMZ) in patients with recurrent or progressive high-grade glioma (HGG)." | 5.17 | "One week on-one week off": efficacy and side effects of dose-intensified temozolomide chemotherapy: experiences of a single center. ( Berhorn, T; Blau, T; Dunkl, V; Fink, GR; Galldiks, N; Schroeter, M, 2013) |
| "To determine whether the pattern of progressive disease (PD) for glioblastoma multiforme (GBM) patients has changed with the introduction of the current standard of care protocol - postoperative conformal radiotherapy to a dose of 60 Gray in 30 fractions with concurrent low-dose (75-100 mg/m(2) ) temozolomide, followed by six cycles of adjuvant high-dose (150-200 mg/m(2) ) temozolomide - as compared with radiotherapy alone." | 5.16 | The addition of temozolomide does not change the pattern of progression of glioblastoma multiforme post-radiotherapy. ( Bressel, M; Gunjur, A; Ryan, G, 2012) |
| "A prospective randomized controlled multicenter phase III trial was conducted to evaluate the effects of neoadjuvant chemotherapy with nimustine (ACNU)-cisplatin (CDDP) when used in conjunction with radiotherapy plus adjuvant temozolomide in patients with newly diagnosed glioblastoma." | 5.15 | Radiotherapy followed by adjuvant temozolomide with or without neoadjuvant ACNU-CDDP chemotherapy in newly diagnosed glioblastomas: a prospective randomized controlled multicenter phase III trial. ( Han, JH; Heo, DS; Jung, HW; Kim, CY; Kim, DG; Kim, DW; Kim, IA; Kim, IH; Kim, JE; Kim, JH; Kim, TM; Kim, YJ; Lee, SH; Nam, DH; Paek, SH; Park, BJ; Park, CK; Rhee, CH, 2011) |
| "Forty-two patients with glioblastoma and 16 patients with anaplastic glioma who had received concurrent radiation and temozolomide and adjuvant temozolomide were enrolled at first relapse." | 5.15 | Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium study. ( Aldape, K; Chang, SM; Chen, A; Cloughesy, TF; de Groot, JF; Deangelis, LM; Gilbert, MR; Jackson, EF; Lamborn, KR; Lassman, AB; Lieberman, F; Mehta, MP; Prados, MD; Robins, HI; Wen, PY; Yao, J; Yung, WK, 2011) |
| "To determine whether increased uptake on 11C-methionine-PET (MET-PET) imaging obtained before radiation therapy and temozolomide is associated with the site of subsequent failure in newly diagnosed glioblastoma multiforme (GBM)." | 5.14 | Association of 11C-methionine PET uptake with site of failure after concurrent temozolomide and radiation for primary glioblastoma multiforme. ( Cao, Y; Gomez-Hassan, D; Hayman, J; Junck, L; Lawrence, TS; Lee, IH; Piert, M; Rogers, L; Ten Haken, RK; Tsien, C, 2009) |
| "In 2004, a randomised phase III trial by the European Organisation for Research and Treatment of Cancer (EORTC) and National Cancer Institute of Canada Clinical Trials Group (NCIC) reported improved median and 2-year survival for patients with glioblastoma treated with concomitant and adjuvant temozolomide and radiotherapy." | 5.14 | Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. ( Allgeier, A; Belanger, K; Brandes, AA; Cairncross, JG; Eisenhauer, E; Fisher, B; Gijtenbeek, J; Gorlia, T; Hau, P; Hegi, ME; Janzer, RC; Lacombe, D; Ludwin, SK; Marosi, C; Mason, WP; Mirimanoff, RO; Mokhtari, K; Stupp, R; Taphoorn, MJ; van den Bent, MJ; Vecht, CJ; Villa, S; Weller, M; Wesseling, P, 2009) |
| "We evaluated the pharmacodynamic effects of the O(6)-methylguanine-DNA methyltransferase (MGMT) inactivator lomeguatrib (LM) on patients with melanoma in two clinical trials." | 5.14 | O(6)-methylguanine-DNA methyltransferase depletion and DNA damage in patients with melanoma treated with temozolomide alone or with lomeguatrib. ( Beith, J; Davis, ID; Haydon, A; Hayward, O; Hersey, P; Kefford, R; Lorigan, P; Margison, GP; McArthur, G; McGown, G; Middleton, MR; Mortimer, P; Ranson, M; Sabharwal, A; Thomson, D; Thorncroft, M; Watson, AJ, 2009) |
| "Alternative dosing schedules of temozolomide may improve survival in patients with newly diagnosed glioblastoma (GBM) by increasing the therapeutic index, overcoming common mechanisms of temozolomide resistance, or both." | 5.14 | Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma. ( Abrey, LE; Clarke, JL; DeAngelis, LM; Gavrilovic, I; Hormigo, A; Iwamoto, FM; Karimi, S; Lassman, AB; Nolan, CP; Panageas, K; Sul, J, 2009) |
| "To present outcome data in a prospective study of radiotherapy (RT) with concurrent and adjuvant temozolomide (TMZ) in children with diffuse intrinsic pontine gliomas (DIPGs)." | 5.14 | Prospective evaluation of radiotherapy with concurrent and adjuvant temozolomide in children with newly diagnosed diffuse intrinsic pontine glioma. ( Arora, B; Dutta, D; Gupta, T; Jalali, R; Kurkure, P; Munshi, A; Raut, N; Sarin, R, 2010) |
| "Chemoradiotherapy followed by monthly temozolomide (TMZ) is the standard of care for patients with glioblastoma multiforme (GBM)." | 5.14 | Population-based study of pseudoprogression after chemoradiotherapy in GBM. ( Cairncross, JG; de Robles, PA; Dharmawardene, M; Easaw, JC; Forsyth, PA; Hamilton, MG; Magliocco, AM; McIntyre, JB; Parney, IF; Roldán, GB; Scott, JN; Yan, ES, 2009) |
| "To determine the maximum tolerated dose of ABT-510, a thrombospondin-1 mimetic drug with antiangiogenic properties, when used concurrently with temozolomide and radiotherapy in patients with newly diagnosed glioblastoma." | 5.14 | A phase 1 trial of ABT-510 concurrent with standard chemoradiation for patients with newly diagnosed glioblastoma. ( Fathallah-Shaykh, HM; Fiveash, JB; Gillespie, GY; Gladson, CL; Huang, Z; Johnson, MJ; Kekan, MS; Kuo, H; Markert, JM; Meleth, S; Nabors, LB, 2010) |
| "PURPOSE Concomitant temozolomide (TMZ)/radiotherapy followed by adjuvant TMZ has increased survival in patients with glioblastoma multiforme (GBM)." | 5.14 | Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study. ( Bélanger, K; Easaw, J; Eisenstat, DD; Forsyth, P; Fulton, D; Kavan, P; Kirby, S; Macdonald, DR; Mason, WP; Perry, JR; Pouliot, JF; Shields, C; Thiessen, B, 2010) |
| "Temozolomide (TMZ) a recent, oral, second generation alkylating agent is a chemotherapeutic with demonstrated efficacy for the treatment of high-grade gliomas." | 5.12 | Surgery, radiotherapy and temozolomide in treating high-grade gliomas. ( Barbarisi, M; Moraci, A; Moraci, M; Parlato, C, 2006) |
| "Based on our findings in two paediatric patients, temozolomide may be a useful agent in the management of progressive recurrent low grade spinal cord astrocytomas." | 5.12 | Role of temozolomide in spinal cord low grade astrocytomas: results in two paediatric patients. ( Abboud, MR; Al Kutoubi, AO; Alaraj, AM; Chamoun, RB; Haddad, GF, 2006) |
| "Temozolomide is an oral alkylating agent that crosses the blood-brain barrier, and has preclinical activity in breast cancer." | 5.12 | Temozolomide in metastatic breast cancer (MBC): a phase II trial of the National Cancer Institute of Canada - Clinical Trials Group (NCIC-CTG). ( Bordeleau, L; Charpentier, D; Crump, M; Eisenhauer, E; Matthews, S; Trudeau, ME; Yelle, L, 2006) |
| "The implementation of combined radiochemotherapy (RCHT) with temozolomide (TMZ) has lead to a significant increase in overall survival times in patients with Glioblastoma multiforme (GBM), however, outcome still remains unsatisfactory." | 5.12 | Treatment of primary glioblastoma multiforme with cetuximab, radiotherapy and temozolomide (GERT)--phase I/II trial: study protocol. ( Combs, SE; Debus, J; Edler, L; Haselmann, R; Heeger, S; Schulz-Ertner, D, 2006) |
| "Based on the promising results of a Phase I study with a combination of gemcitabine and DTIC performed in advanced soft tissue sarcoma (ASTS) patients, and due to the limited efficacy of second or third line therapies in those patients, we designed a Phase II study to determine the activity of this new regimen." | 5.12 | Phase II study with the combination of gemcitabine and DTIC in patients with advanced soft tissue sarcomas. ( Buesa, JM; Del Muro, JG; Escudero, P; Esteban, E; Fra, J; Gión, M; Goitia, A; López-Pousa, A; Losa, R; Maurel, J; Nadal, R; Sierra, M; Uña, E, 2007) |
| "To assess the efficacy and tolerability of extended dose temozolomide and continuous thalidomide in patients with advanced metastatic cutaneous melanoma." | 5.12 | A phase II study of extended dose temozolomide and thalidomide in previously treated patients with metastatic melanoma. ( Arce-Lara, C; Kloecker, GH; Laber, DA; McMasters, KM; Miller, DM; Okeke, RI; Schonard, CL; Taft, BS, 2006) |
| "The methylation status of the O6-methylguanine-methyltransferase promoter (MGMTP) was evaluated in 68 low-grade gliomas treated by neoadjuvant temozolomide." | 5.12 | MGMT methylation: a marker of response to temozolomide in low-grade gliomas. ( Benouaich-Amiel, A; Crinière, E; Delattre, JY; Everhard, S; Hoang-Xuan, K; Kaloshi, G; Kujas, M; Lejeune, J; Marie, Y; Mokhtari, K; Sanson, M; Thillet, J, 2006) |
| "To evaluate tumor response, pharmacodynamic effects, and safety of a combination of lomeguatrib (LM), an O6-methylguanine DNA-methyltransferase (MGMT) inactivator, and temozolomide (TMZ), TMZ alone, and LM/TMZ after disease progression on TMZ alone in patients with advanced melanoma." | 5.12 | Randomized trial of the combination of lomeguatrib and temozolomide compared with temozolomide alone in chemotherapy naive patients with metastatic cutaneous melanoma. ( Baka, S; Beith, J; Davis, ID; Harris, PA; Haydon, A; Hersey, P; Kefford, RF; Margison, GP; McArthur, GA; Middleton, MR; Mortimer, P; Ranson, M; Sabharwal, A; Seebaran, A; Thompson, D; Watson, AJ, 2007) |
| "Evaluation of toxicity and efficacy of an alternating weekly regimen of temozolomide administered 1 week on and 1 week off in patients with recurrent glioma." | 5.12 | Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma. ( Blaschke, B; Felsberg, J; Herrlinger, U; Meyermann, R; Platten, M; Reifenberger, G; Steinbach, JP; Weller, M; Wick, A; Wick, W, 2007) |
| "We report a phase II trial of cisplatinum and temozolomide (TMZ) combination in recurrent malignant glioma patients." | 5.11 | Phase II trial of cisplatin plus temozolomide, in recurrent and progressive malignant glioma patients. ( Boiardi, A; Broggi, G; Eoli, M; Lamperti, E; Maccagnano, E; Salmaggi, A; Silvani, A, 2004) |
| "Temozolomide (TMZ) and 1, 3-bis (2-chloroethyl)-1-nitrosourea (BCNU) are reported to be active agents in anaplastic glioma (AG)." | 5.11 | Phase II study of neoadjuvant 1, 3-bis (2-chloroethyl)-1-nitrosourea and temozolomide for newly diagnosed anaplastic glioma: a North American Brain Tumor Consortium Trial. ( Chang, SM; Fine, H; Fink, KL; Greenberg, H; Hess, K; Jaeckle, KA; Junck, L; Kuhn, J; Mehta, M; Prados, MD; Robins, HI; Schold, C; Yung, WK, 2004) |
| "A prospective Phase II study of temozolomide (TMZ) was conducted in 16 patients with refractory meningioma." | 5.11 | Temozolomide for treatment-resistant recurrent meningioma. ( Chamberlain, MC; Groshen, S; Tsao-Wei, DD, 2004) |
| "Twenty-one patients with recurrent or progressive glioblastoma were enrolled in a prospective phase II trial to determine the safety and efficacy of a 1-week on/1-week off regimen of temozolomide administered at 150 mg/m2 on days 1 to 7 and days 15 to 21 of 28-day treatment cycles." | 5.11 | One week on/one week off: a novel active regimen of temozolomide for recurrent glioblastoma. ( Bamberg, M; Dichgans, J; Küker, WM; Steinbach, JP; Weller, M; Wick, W, 2004) |
| "This report describes a single-centre study with temozolomide (TMZ) (200 mg m(-2) day(-1) x 5 per cycle of 28 days) in children with (recurrent) high-grade glioma." | 5.11 | Temozolomide in paediatric high-grade glioma: a key for combination therapy? ( Couanet, D; Grill, J; Kalifa, C; Lelouch-Tubiana, A; Vassal, G; Verschuur, AC, 2004) |
| "Seventy-five consecutive patients with recurrent malignant astrocytomas and glioblastomas had been treated at our institute with per os temozolomide for five days every month." | 5.11 | Temozolomide chemotherapy of patients with recurrent anaplastic astrocytomas and glioblastomas. ( Afra, D; Sipos, L; Vitanovics, D, 2004) |
| "Patients with newly diagnosed, histologically confirmed glioblastoma were randomly assigned to receive radiotherapy alone (fractionated focal irradiation in daily fractions of 2 Gy given 5 days per week for 6 weeks, for a total of 60 Gy) or radiotherapy plus continuous daily temozolomide (75 mg per square meter of body-surface area per day, 7 days per week from the first to the last day of radiotherapy), followed by six cycles of adjuvant temozolomide (150 to 200 mg per square meter for 5 days during each 28-day cycle)." | 5.11 | Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. ( Allgeier, A; Belanger, K; Bogdahn, U; Brandes, AA; Cairncross, JG; Curschmann, J; Eisenhauer, E; Fisher, B; Gorlia, T; Janzer, RC; Lacombe, D; Ludwin, SK; Marosi, C; Mason, WP; Mirimanoff, RO; Stupp, R; Taphoorn, MJ; van den Bent, MJ; Weller, M, 2005) |
| " Food and Drug Administration approved temozolomide (Temodar capsules, Schering-Plough Research Institute) for the treatment of adult patients with newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and then as maintenance treatment." | 5.11 | Food and Drug Administration Drug approval summary: temozolomide plus radiation therapy for the treatment of newly diagnosed glioblastoma multiforme. ( Cohen, MH; Johnson, JR; Pazdur, R, 2005) |
| "Temozolomide (TMZ) and 13-cis-retinoic acid (cRA) have shown activity in prior single-agent trials of recurrent malignant gliomas (MG)." | 5.10 | Phase II evaluation of temozolomide and 13-cis-retinoic acid for the treatment of recurrent and progressive malignant glioma: a North American Brain Tumor Consortium study. ( Chang, S; Cloughesy, T; Fine, H; Fink, K; Greenberg, H; Hess, KR; Jaeckle, KA; Kuhn, J; Mehta, M; Nicholas, MK; Pollack, IF; Prados, M; Schiff, D; Yung, WK, 2003) |
| "Temozolomide is an imidazotetrazine with a mechanism of action similar to dacarbazine and equivalent activity in melanoma." | 5.10 | Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma. ( Arance, A; Ashcroft, L; Clamp, A; Danson, S; Hodgetts, J; Lomax, L; Lorigan, P; Middleton, MR; Ranson, M; Thatcher, N, 2003) |
| "The aim of this study was to assess the efficacy of temozolomide in patients with World Health Organisation (WHO) grade II gliomas treated with surgery alone using imaging and clinical criteria." | 5.10 | Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas. ( Abson, C; Ashley, S; Brada, M; Britton, J; Gonsalves, A; Hines, F; Sardell, S; Traish, D; Viviers, L; Westbury, C; Wilkins, P, 2003) |
| "Forty-three patients affected with LGG (29 astrocytoma, four oligodendroglioma and 10 mixed oligo-astrocytoma) were treated with temozolomide (TMZ) at the time of documented clinical and radiological progression." | 5.10 | Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and radiological response. ( Canalini, P; Carapella, CM; Carosi, M; Cianciulli, AM; Galiè, E; Giannarelli, D; Jandolo, B; Pace, A; Telera, S; Vidiri, A, 2003) |
| "To determine whether chemotherapy with temozolomide (TMZ) versus procarbazine (PCB) for recurrent glioblastoma multiforme (GBM) was associated with improvement in health-related quality of life (HRQOL)." | 5.09 | Health-related quality of life in patients treated with temozolomide versus procarbazine for recurrent glioblastoma multiforme. ( Brada, M; Osoba, D; Prados, M; Yung, WK, 2000) |
| "One of the objectives of this phase II study was to determine whether temozolomide (TMZ) improved the health-related quality of life (HRQL) of patients with recurrent anaplastic astrocytoma (AA)." | 5.09 | Health-related quality of life in patients with anaplastic astrocytoma during treatment with temozolomide. ( Brada, M; Osoba, D; Prados, MD; Yung, WK, 2000) |
| "Forty-one patients with high-grade glioma, at second recurrence or progression, of which twenty-two (54%) had glioblastoma multiforme, ten (24%) anaplastic astrocytoma, and nine (22%) anaplastic oligodendroglioma were administered temozolomide, 150 mg/m2/daily for five days every four weeks." | 5.09 | Temozolomide as a second-line systemic regimen in recurrent high-grade glioma: a phase II study. ( Amistà, P; Basso, U; Berti, F; Brandes, AA; Ermani, M; Gardiman, M; Monfardini, S; Pinna, G; Rotilio, A; Scienza, R, 2001) |
| "To assess the effectiveness and safety of procarbazine, lomustine, and vincristine (PCV) chemotherapy with other interventions in adults with recurrent high-grade glioma." | 4.95 | Procarbazine, lomustine and vincristine for recurrent high-grade glioma. ( Guo, J; Parasramka, S; Rosenfeld, M; Talari, G; Villano, JL, 2017) |
| "Glioblastoma (GBM) has proven to be incurable despite recent progress on its standard of care using temozolomide (TMZ) as the main trunk of initial therapy for newly diagnosed GBM." | 4.91 | Dose-dense temozolomide: is it still promising? ( Nagane, M, 2015) |
| " More recently, temozolomide, a second generation oral alkylating agent, has shown therapeutic promise for aggressive pituitary adenomas and carcinomas with favorable clinical and radiographic responses." | 4.91 | The role of temozolomide in the treatment of aggressive pituitary tumors. ( Eloy, JA; Liu, JK; Patel, J, 2015) |
| "The Avastin in Glioblastoma trial has shown that patients newly diagnosed with glioblastoma multiforme (GBM) treated with bevacizumab plus radiotherapy and temozolomide versus radiotherapy and temozolomide alone showed improvement in progression-free survival, possibly leading to a new indication for first-line use of bevacizumab in GBM." | 4.91 | Economic Evaluation of Bevacizumab for the First-Line Treatment of Newly Diagnosed Glioblastoma Multiforme. ( Kovic, B; Xie, F, 2015) |
| "Temozolomide is recommended as superior to procarbazine in patients with first relapse of glioblastoma after having received nitrosourea chemotherapy or no prior cytotoxic chemotherapy at the time of initial therapy." | 4.90 | The role of cytotoxic chemotherapy in the management of progressive glioblastoma : a systematic review and evidence-based clinical practice guideline. ( Kalkanis, SN; Nayak, L; Olson, JJ; Ormond, DR; Wen, PY, 2014) |
| " Two chemotherapeutic regimens are commonly used for the palliative treatment of malignant melanoma: intravenous administration of single-agent dacarbazine or oral administration of temozolomide." | 4.89 | Efficacy and side effects of dacarbazine in comparison with temozolomide in the treatment of malignant melanoma: a meta-analysis consisting of 1314 patients. ( Abdollahi, M; Nikfar, S; Teimouri, F, 2013) |
| "Glioblastoma is a brain tumor with poor prognosis in the therapy of which operation, postoperative temozolomide sensitized radiochemotherapy followed by temozolomide monotherapy offer the best chances." | 4.88 | [Use of angioneogenesis inhibitor monoclonal antibody following standard therapy in recurrent or progressive glioblastoma multiforme]. ( Bassam, A; Nagy, KA; Pikó, B; Puskásné Szatmári, K; Török, E; Vághy, R; Vargáné Tamás, R, 2012) |
| " In this paper we address different clinical outcomes measures separately and we illustrate the value of multiple outcome measures using the results of a recent clinical trial comparing temozolomide with procarbazine in the treatment of Glioblastoma Multiforme." | 4.82 | Benefit of temozolomide compared to procarbazine in treatment of glioblastoma multiforme at first relapse: effect on neurological functioning, performance status, and health related quality of life. ( Kiebert, G; Macdonald, DR; Olson, J; Prados, M; Yung, A, 2005) |
| "The aim of this study was to clarify whether PET with 11C-methyl-l-methionine (11C-met PET) can predict consequential outcomes at the time of discontinuing temozolomide (TMZ)-adjuvant chemotherapy in patients with residual isocitrate dehydrogenase gene (IDH)-mutant lower-grade glioma." | 4.12 | PET With 11C-Methyl-l-Methionine as a Predictor of Consequential Outcomes at the Time of Discontinuing Temozolomide-Adjuvant Chemotherapy in Patients With Residual IDH-Mutant Lower-Grade Glioma. ( Beppu, T; Fujiwara, S; Iwaya, T; Nomura, JI; Ogasawara, K; Sasaki, T; Sato, Y; Sugai, T; Terasaki, K; Yamada, N, 2022) |
| "We included 41 patients with isocitrate dehydrogenase 1/2-wildtype glioblastoma, who received 12 or more cycles of temozolomide therapy between June 2006 and December 2019." | 4.12 | Continuing maintenance temozolomide therapy beyond 12 cycles confers no clinical benefit over discontinuation at 12 cycles in patients with IDH1/2-wildtype glioblastoma. ( Miyakita, Y; Narita, Y; Ohno, M; Takahashi, M; Tamura, Y; Yanagisawa, S, 2022) |
| "Drug resistance strikingly limits the therapeutic effect of temozolomide (TMZ) (a common drug for glioma)." | 4.02 | A positive feedback loop of lncRNA-RMRP/ZNRF3 axis and Wnt/β-catenin signaling regulates the progression and temozolomide resistance in glioma. ( Han, B; Hu, J; Jia, W; Liu, T; Tan, S; Xin, Y, 2021) |
| "Irinotecan and temozolomide (IT) is a widely used regimen for relapsed Ewing sarcoma (ES), although studies are largely limited to paediatric populations." | 4.02 | Irinotecan and temozolomide chemotherapy in paediatric and adult populations with relapsed Ewing Sarcoma. ( Abuhijla, F; Abuhijlih, R; Alnsour, A; Halalsheh, H; Ismail, T; Khozouz, O; Lewin, J; Salah, S; Shahin, O; Sultan, I; To, YH; Yaser, S, 2021) |
| "Improving the chemotherapy resistance of temozolomide (TMZ) is of great significance in the treatment of glioblastoma multiforme (GBM)." | 4.02 | Long noncoding RNA just proximal to X-inactive specific transcript facilitates aerobic glycolysis and temozolomide chemoresistance by promoting stability of PDK1 mRNA in an m6A-dependent manner in glioblastoma multiforme cells. ( Jiang, XB; Li, XD; Wang, MJ; Wang, X; Wu, YH; Zheng, JL, 2021) |
| "A generally used chemotherapeutic drug for glioma, a frequently diagnosed brain tumour, is temozolomide (TMZ)." | 3.96 | miR-152-5p suppresses glioma progression and tumorigenesis and potentiates temozolomide sensitivity by targeting FBXL7. ( Cao, Y; Fang, Y; He, R; Kong, S; Wang, B; Zhao, Z, 2020) |
| "Despite the clinical success of temozolomide (TMZ), its sensitivity remains a major challenge in glioblastoma (GBM)." | 3.91 | PLK4 is a determinant of temozolomide sensitivity through phosphorylation of IKBKE in glioblastoma. ( Han, L; Huang, K; Liang, H; Liu, Y; Wang, G; Wang, Q; Wang, Z; Wei, C; Zhang, A; Zhang, W; Zhang, Z; Zhen, Y; Zhou, J, 2019) |
| "Glioma is a frequently diagnosed brain tumors and Temozolomide (TMZ) is a common chemotherapeutic drug for glioma." | 3.91 | MicroRNA-34a-5p suppresses tumorigenesis and progression of glioma and potentiates Temozolomide-induced cytotoxicity for glioma cells by targeting HMGA2. ( Fu, T; Gao, M; Ma, S; Zhao, S, 2019) |
| "Our study tested the diagnostic accuracy of increased signal intensity (SI) within FLAIR MR images of resection cavities in differentiating early progressive disease (ePD) from pseudoprogression (PsP) in patients with glioblastoma treated with radiotherapy with concomitant temozolomide therapy." | 3.88 | Increased signal intensity within glioblastoma resection cavities on fluid-attenuated inversion recovery imaging to detect early progressive disease in patients receiving radiotherapy with concomitant temozolomide therapy. ( Agrawal, JP; Erickson, BJ; Korfiatis, P; Perry, LA, 2018) |
| "Although upfront temozolomide (TMZ) has been widely-used to treat 1p/19q-codeleted diffuse low-grade gliomas (LGG), its long-term impact on the growth kinetics of these tumors has not been determined." | 3.88 | Long-term impact of temozolomide on 1p/19q-codeleted low-grade glioma growth kinetics. ( Alentorn, A; Barritault, M; Bruna, J; Delattre, JY; Ducray, F; Honnorat, J; Idbaih, A; Izquierdo, C; Kaloshi, G; Meyronet, D; Ricard, D; Simó, M, 2018) |
| "Temozolomide (TMZ) is an alkylating agent frequently used in well-differentiated metastatic pancreatic neuroendocrine tumors (PNETs) with very variable responses." | 3.85 | Short article: Evaluation of O6-methylguanine-DNA methyltransferase as a predicting factor of response to temozolomide-based chemotherapy in well-differentiated metastatic pancreatic neuroendocrine tumors. ( Caroli-Bosc, FX; Cauchin, E; Dumars, C; Foubert, F; Girot, P; Matysiak-Budnik, T; Mosnier, JF; Muzellec, L; Regenet, N; Senellart, H; Touchefeu, Y, 2017) |
| "Radiation with concurrent and adjuvant (6 cycles) temozolomide (TMZ) is the established standard of postsurgical care for newly diagnosed glioblastoma (GBM)." | 3.85 | Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma: a secondary analysis of EORTC and NRG Oncology/RTOG. ( Baumert, BG; Blumenthal, DT; Brown, PD; Burt Nabors, L; Corn, BW; Erridge, SC; Gilbert, MR; Golfinopoulos, V; Gorlia, T; Hegi, ME; Hyun Nam, D; Kim, MM; Mason, WP; Mehta, MP; Mirimanoff, RO; Perry, JR; Reardon, DA; Stupp, R; van den Bent, MJ; Weller, M; Zhang, P, 2017) |
| "Assessment of perfusion in early post-treatment MR imaging can stratify TTP in patients with glioblastoma for adjuvant temozolomide therapy." | 3.85 | Perfusion of surgical cavity wall enhancement in early post-treatment MR imaging may stratify the time-to-progression in glioblastoma. ( Choi, CG; Jung, SC; Kim, HS; Kim, HW; Kim, JH; Kim, SJ; Park, JE; Ryu, KH; Shim, WH, 2017) |
| "We retrospectively analyzed the data of 5 adult patients treated with temozolomide between 2008 and 2015 for a grade II intramedullary astrocytoma with progression after surgery." | 3.85 | [Contribution of temozolomide chemotherapy for intramedullary grade II spinal cord astrocytomas in adults: Our experience]. ( Chaskis, E; De Witte, O; Devriendt, D; Goldman, S; Lefranc, F; Luce, S; Minichini, V; Sadeghi, N, 2017) |
| "We performed a retrospective case series to evaluate the feasibility of adding temozolomide to pazopanib in advanced sarcoma patients following single-agent pazopanib failure." | 3.85 | Temozolomide post pazopanib treatment failure in patients with advanced sarcoma: A case series. ( Bupathi, M; Chen, JL; Hays, JL, 2017) |
| " When treated with temozolomide (TMZ), an oral alkylating chemotherapy drug, most low-grade gliomas (LGG) show an initial volume decrease but this effect is rarely long lasting." | 3.85 | Analysis of temozolomide resistance in low-grade gliomas using a mechanistic mathematical model. ( Alentorn, A; Delattre, JY; Ducray, F; Grenier, E; Honnorat, J; Idbaih, A; Kaloshi, G; Mazzocco, P; Ollier, E; Psimaras, D; Ricard, D; Samson, A, 2017) |
| "Glioblastoma has a dismal prognosis, with an average overall survival of about one year despite maximal safe resection, concomitant radiochemotherapy with temozolomide followed by adjuvant temozolomide therapy." | 3.83 | Slowing down glioblastoma progression in mice by running or the anti-malarial drug dihydroartemisinin? Induction of oxidative stress in murine glioblastoma therapy. ( Blaes, J; Dong, Z; Green, E; Hertenstein, A; Jugold, M; Lemke, D; Löw, S; Ott, M; Platten, M; Pledl, HW; Sahm, F; Steffen, AC; Weiler, M; Wick, W; Winkler, F; Zorn, M, 2016) |
| "To analyze the enhancement patterns and apparent diffusion coefficient (ADC) values of non-measurable surgical cavity wall enhancement pattern, newly appearing after completion of standard concurrent chemoradiotherapy (CCRT) with temozolomide in glioblastoma patients for the prognosis prediction." | 3.83 | MR Imaging Analysis of Non-Measurable Enhancing Lesions Newly Appearing after Concomitant Chemoradiotherapy in Glioblastoma Patients for Prognosis Prediction. ( Choi, SH; Kim, BR; Kim, IH; Kim, JH; Kim, TM; Lee, ST; Park, CK; Park, SH; Park, SW; Sohn, CH; Yun, TJ, 2016) |
| "To explore the role of dynamic contrast material-enhanced magnetic resonance (MR) imaging in the differentiation of true progression from pseudoprogression in patients with glioblastoma on the basis of findings in entirely newly developed or enlarged enhancing lesions after concurrent radiation therapy and chemotherapy with temozolomide and to evaluate the diagnostic performance of the quantitative pharmacokinetic parameters obtained at dynamic contrast-enhanced MR imaging, such as the volume transfer constant (K(trans)), the extravascular extracellular space per unit volume of tissue(ve), and the blood plasma volume per unit volume of tissue(vp)." | 3.81 | Glioblastoma treated with concurrent radiation therapy and temozolomide chemotherapy: differentiation of true progression from pseudoprogression with quantitative dynamic contrast-enhanced MR imaging. ( Choi, SH; Kim, IH; Kim, JH; Kim, TM; Lee, SH; Park, CK; Park, SH; Sohn, CH; Yun, TJ, 2015) |
| "The purpose of this study was to assess the efficacy and toxicity of radiotherapy (RT) with concurrent temozolomide (TMZ) chemotherapy followed by adjuvant TMZ in children with diffuse intrinsic pontine glioma (DIPG)." | 3.81 | Temozolomide in the treatment of newly diagnosed diffuse brainstem glioma in children: a broken promise? ( Attinà, G; Balducci, M; Caldarelli, M; Colosimo, C; Lazzareschi, I; Mastrangelo, S; Maurizi, P; Riccardi, R; Ridola, V; Rizzo, D; Ruggiero, A; Scalzone, M, 2015) |
| "We retrospectively identified 68 consecutive patients with high-grade gliomas treated by surgical resection followed by radiation therapy and temozolomide, who then developed increasing enhancing mass lesions indeterminate for treatment-related changes versus recurrent tumor." | 3.81 | Diffusion and perfusion MRI to differentiate treatment-related changes including pseudoprogression from recurrent tumors in high-grade gliomas with histopathologic evidence. ( Beal, K; Martinez, N; Omuro, A; Prager, AJ; Young, RJ; Zhang, Z, 2015) |
| "Temozolomide (TMZ) increases the overall survival of patients with glioblastoma (GBM), but its role in the clinical management of diffuse low-grade gliomas (LGG) is still being defined." | 3.81 | Evolution of DNA repair defects during malignant progression of low-grade gliomas after temozolomide treatment. ( Aburatani, H; Aihara, K; Berger, MS; Chang, SM; Costello, JF; Fouse, SD; Hallbeck, M; Heimans, JJ; Hong, C; Johnson, BE; Kloezeman, JJ; Lamfers, ML; Malmström, A; Mazor, T; Molinaro, AM; Mukasa, A; Reijneveld, JC; Saito, N; Söderkvist, P; Stenmark-Askmalm, M; Taylor, BS; van Thuijl, HF; Wesseling, P; Ylstra, B, 2015) |
| "A total of nine patients with malignant glioma, postoperatively presenting with a Karnofsky performance score (KPS) below 70, were treated with standalone metronomic low-dose chemotherapy with temozolomide and celecoxib (cyclo-oxygenase-2 inhibitor)." | 3.81 | Dual Anti-angiogenic Chemotherapy with Temozolomide and Celecoxib in Selected Patients with Malignant Glioma Not Eligible for Standard Treatment. ( Brawanski, KR; Freyschlag, CF; Grams, AE; Kerschbaumer, J; Nowosielski, M; Petr, O; Pinggera, D; Schmidt, FA; Seiz, M; Thomé, C; Tuettenberg, J, 2015) |
| " Our aim was to determine whether the subependymal enhancement pattern and ADC can differentiate true progression from pseudoprogression in patients with glioblastoma multiforme treated with concurrent chemoradiotherapy by using temozolomide." | 3.81 | Independent Poor Prognostic Factors for True Progression after Radiation Therapy and Concomitant Temozolomide in Patients with Glioblastoma: Subependymal Enhancement and Low ADC Value. ( Choi, SH; Kim, IH; Kim, JH; Kim, TM; Lee, SH; Park, CK; Park, SH; Sohn, CH; Yoo, RE; Yun, TJ, 2015) |
| " Interestingly, our findings showed an association of metformin therapy and prolonged progression-free survival in glioblastoma patients with diabetes and therefore serve as a foundation for further preclinical and clinical investigations." | 3.81 | Metformin influences progression in diabetic glioblastoma patients. ( Adeberg, S; Ben Harrabi, S; Bernhardt, D; Bostel, T; Debus, J; Diehl, C; Koelsche, C; Mohr, A; Rieken, S, 2015) |
| "Our purpose was to analyze the pattern of failure in glioblastoma (GBM) patients at first recurrence after radiotherapy and temozolomide and its relationship with different factors." | 3.80 | Factors associated with a higher rate of distant failure after primary treatment for glioblastoma. ( Aldave, G; de Gallego, J; Díez-Valle, R; Domínguez, PD; Gállego Pérez-Larraya, J; Marigil, M; Tejada, S, 2014) |
| "We report the case of severe liver toxicity with jaundice during radiochemotherapy with temozolomide likely due to interaction with a popular Chinese herbal formula after surgery for glioblastoma." | 3.80 | Liver toxicity during temozolomide chemotherapy caused by Chinese herbs. ( Egle, A; Greil, R; Grundbichler, M; Hufnagl, C; Magnes, T; Melchardt, T; Moik, M; Strasser, M; Weiss, L, 2014) |
| "Eighteen patients with newly diagnosed, histologically confirmed glioblastoma had 3D-MR proton spectroscopic imaging (MRSI) along with T2 and T1 gadolinium-enhanced MR images at simulation and at boost treatment planning after 17 to 20 fractions of radiation therapy." | 3.80 | 3-Dimensional magnetic resonance spectroscopic imaging at 3 Tesla for early response assessment of glioblastoma patients during external beam radiation therapy. ( Anderson, CM; Bayouth, JE; Buatti, JM; Capizzano, AA; Clerkin, PP; Magnotta, V; McGuire, SM; Morris, A; Muruganandham, M; Smith, BJ; Smith, MC, 2014) |
| "Twenty-three consecutive high-grade glioma patients were treated with radiotherapy (2 Gy/60 Gy) with concomitant and adjuvant temozolomide." | 3.80 | ADC texture--an imaging biomarker for high-grade glioma? ( Asklund, T; Birgander, R; Brynolfsson, P; Garpebring, A; Hauksson, J; Henriksson, R; Karlsson, M; Nilsson, D; Nyholm, T; Trygg, J, 2014) |
| "To explore the role of histogram analysis of apparent diffusion coefficient (ADC) maps obtained at standard- and high-b-value (1000 and 3000 sec/mm(2), respectively) diffusion-weighted (DW) imaging in the differentiation of true progression from pseudoprogression in glioblastoma treated with radiation therapy and concomitant temozolomide." | 3.79 | Differentiation of true progression from pseudoprogression in glioblastoma treated with radiation therapy and concomitant temozolomide: comparison study of standard and high-b-value diffusion-weighted imaging. ( Choi, SH; Chu, HH; Jung, SC; Kim, IH; Kim, JH; Kim, SC; Kim, TM; Lee, AL; Lee, SH; Park, CK; Park, SH; Ryoo, I; Shin, H; Sohn, CH; Yeom, JA; Yoon, TJ, 2013) |
| " We retrospectively surveyed 32 patients with GBM or GBM with oligodendroglioma component (GBMO) who underwent biopsy or maximal tumor resection followed by concurrent radiotherapy and temozolomide (TMZ)." | 3.79 | IDH1 mutation as a potential novel biomarker for distinguishing pseudoprogression from true progression in patients with glioblastoma treated with temozolomide and radiotherapy. ( Houkin, K; Kamoshima, Y; Kobayashi, H; Motegi, H; Murata, J; Tanino, M; Terasaka, S; Yamaguchi, S, 2013) |
| "Combined temozolomide (TMZ) and radiation therapy (RT) is often used as initial treatment for anaplastic glioma." | 3.79 | Combined temozolomide and radiation as an initial treatment for anaplastic glioma. ( Chong, DQ; Chua, ET; Lim, KH; Ng, WH; See, SJ; Tan, SH; Tham, CK; Thomas, J, 2013) |
| "We report retrospective data on the feasibility and efficacy of prolonging adjuvant temozolomide (TMZ) more than 6 months after chemoradiotherapy completion in patients with glioblastoma (GBM)." | 3.78 | Prolonged temozolomide for treatment of glioblastoma: preliminary clinical results and prognostic value of p53 overexpression. ( Auberdiac, P; Cartier, L; Chargari, C; Forest, F; Fotso, MJ; Magné, N; Malkoun, N; Nuti, C; Pacaut, C; Peoc'h, M; Schmitt, T; Thorin, J, 2012) |
| "Two glioblastoma multiforme patients underwent (18)F-FMISO (fluoromisonidazole) positron emission tomography study to access the tumor oxygenation status before and immediately after fractionated radiotherapy concomitant with temozolomide chemotherapy." | 3.78 | Reoxygenation of glioblastoma multiforme treated with fractionated radiotherapy concomitant with temozolomide: changes defined by 18F-fluoromisonidazole positron emission tomography: two case reports. ( Aoyama, H; Hirata, K; Houkin, K; Kobayashi, H; Murata, J; Narita, T; Onodera, S; Shiga, T; Tanaka, S; Terasaka, S, 2012) |
| "The standard of care for newly diagnosed glioblastoma multiforme (GBM) is temozolomide (TMZ) chemotherapy given concurrently with radiation for 6 weeks followed by 6 months of adjuvant TMZ." | 3.78 | Extended adjuvant temozolomide for treatment of newly diagnosed glioblastoma multiforme. ( Easaw, JC; Roldán Urgoiti, GB; Singh, AD, 2012) |
| " Concurrent temozolomide (TMZ) improves survival in non-elderly patients with glioblastoma treated with standard schedule of 60 Gy in 30 fractions." | 3.78 | Abbreviated course of radiation therapy with concurrent temozolomide for high-grade glioma in patients of advanced age or poor functional status. ( Beal, K; Chan, TA; Gutin, PH; Lassman, AB; Reyngold, M; Yamada, Y, 2012) |
| "We analyzed 62 consecutive patients with newly diagnosed glioblastoma treated between 2006 and 2008 with standard fractionation to a total dose of 60 Gy with concurrent temozolomide (97%) or arsenic trioxide (3%)." | 3.77 | Pattern of failure after limited margin radiotherapy and temozolomide for glioblastoma. ( Crocker, IR; Curran, WJ; McDonald, MW; Shu, HK, 2011) |
| "We investigated pseudoprogression (psPD) in patients with malignant gliomas treated with radiotherapy (RT) and maintenance temozolomide (TMZ) in terms of incidence, outcomes, and predictive and prognostic factors." | 3.77 | Pseudoprogression in patients with malignant gliomas treated with concurrent temozolomide and radiotherapy: potential role of p53. ( Choe, GY; Han, JH; Kang, HC; Kim, CY; Kim, IA; Kim, JH, 2011) |
| "To evaluate the safety and efficacy of hypofractionated radiotherapy (RT) with a standard temozolomide (TMZ) regimen for adults with newly diagnosed glioblastoma multiforme (GBM), twenty-six consecutive adults (range 39-79 years) who met our enrollment criteria received short courses of hypofractionated RT (45 Gy in 15 fractions over three weeks) with concomitant TMZ at 75 mg/m(2)/d." | 3.77 | A pilot study of hypofractionated radiation therapy with temozolomide for adults with glioblastoma multiforme. ( Eto, T; Nakashima, S; Ogo, E; Okada, Y; Shigemori, M; Sugita, Y; Terasaki, M; Tokutomi, T, 2011) |
| "Temozolomide (TMZ) is an oral alkylating agent with proven antitumoral activity in preclinical and clinical studies in adults with high-grade glioma (HGG)." | 3.77 | Feasibility study of 21-day-on/7-day-off temozolomide in children with brain tumors. ( Barone, G; Lazzareschi, I; Riccardi, R; Ridola, V; Rizzo, D; Ruggiero, A, 2011) |
| "It is controversial if distant recurrence of glioblastoma is more common after temozolomide (TMZ) concurrent with radiotherapy (RT)." | 3.77 | Glioblastoma: patterns of recurrence and efficacy of salvage treatments. ( Aviv, R; Davey, P; Lam, K; Oh, J; Perry, JR; Sahgal, A; Sanghera, P; Symons, S; Tsao, MN, 2011) |
| "Prolonged administration of temozolomide is widely used in patients with glioblastoma; whereas the treatment of anaplastic glioma differs between neurooncological centres." | 3.77 | Prolonged administration of temozolomide in adult patients with anaplastic glioma. ( Freyschlag, CF; Janzen, E; Lohr, F; Schmieder, K; Seiz, M; Smolczyk, DR; Thomé, C; Tuettenberg, J; Weiss, C; Wenz, F, 2011) |
| "Our objective was to retrospectively review temozolomide in advanced and recurrent uterine leiomyosarcoma and to determine if tumor O-methylguanine DNA methyltransferase (MGMT) expression correlated with clinical response." | 3.76 | Temozolomide in advanced and recurrent uterine leiomyosarcoma and correlation with o6-methylguanine DNA methyltransferase expression: a case series. ( Atkins, KA; Ferriss, JS; Jazaeri, AA; Lachance, JA; Modesitt, SC, 2010) |
| "Pseudoprogression (psPD) is now recognised following radiotherapy with concurrent temozolomide (RT/TMZ) for glioblastoma multiforme (GBM)." | 3.76 | Pseudoprogression following chemoradiotherapy for glioblastoma multiforme. ( Aviv, R; Davey, P; Lam, K; Morrison, M; Perry, J; Sahgal, A; Sanghera, P; Symons, S; Tsao, MN, 2010) |
| "One hundred and fourteen patients with glioblastoma multiforme received a median of 6 cycles of adjuvant first-line temozolomide (range 1-57)." | 3.76 | Long-term adjuvant administration of temozolomide in patients with glioblastoma multiforme: experience of a single institution. ( Freyschlag, CF; Krafft, U; Lohr, F; Schmieder, K; Seiz, M; Thomé, C; Tuettenberg, J; Weiss, C; Wenz, F, 2010) |
| "The purpose of this study was to evaluate diffusion parameters at pre-, mid-, and post-radiation therapy (RT) in contrast-enhancing and nonenhancing lesions of postsurgical glioblastoma multiforme patients treated with the standard of care RT concurrently with temozolomide (TMZ) followed by adjuvant TMZ and an antiangiogenic drug." | 3.76 | Evaluation of diffusion parameters as early biomarkers of disease progression in glioblastoma multiforme. ( Butowski, NA; Cha, S; Chang, SM; Elkhaled, A; Jalbert, L; Khayal, IS; Nelson, SJ; Polley, MY, 2010) |
| "We report a case of prolonged survival in a patient with cervical intramedullary glioblastoma multiforme (GBM) treated with total resection, radiotherapy, and temozolomide." | 3.76 | Prolonged survival of a patient with cervical intramedullary glioblastoma multiforme treated with total resection, radiation therapy, and temozolomide. ( Huang, CY; Kuo, LT; Lien, HC; Liu, KL; Liu, MT; Tseng, HM, 2010) |
| "Concurrent temozolomide (TMZ) and radiotherapy became the new standard of care for patients diagnosed with glioblastoma multiforme (GBM)." | 3.76 | Pseudoprogression following concurrent temozolomide and radiotherapy in a patient with glioblastoma: findings on functional imaging techniques. ( Abe, K; Amano, T; Hiwatashi, A; Honda, H; Kamano, H; Nakamizo, A; Shioyama, Y; Shirakawa, Y; Suzuki, S; Torisu, R; Yamashita, K; Yoshimoto, K; Yoshiura, T, 2010) |
| "Recently, there has been greater awareness that combination radiation and temozolomide used to treat glioblastomas may cause increased contrast enhancement on the first post radiation MRI scan." | 3.75 | Effect of adding temozolomide to radiation therapy on the incidence of pseudo-progression. ( Gerstner, ER; Lafrankie, D; McNamara, MB; Norden, AD; Wen, PY, 2009) |
| "Temozolomide (TMZ) is the standard of care for patients with newly diagnosed glioblastoma (GBM) as well as those with recurrent anaplastic glioma (AG) and GBM." | 3.75 | Rechallenge with temozolomide in patients with recurrent gliomas. ( Bogdahn, U; Hau, P; Jauch, T; Pascher, C; Weller, M; Wick, A; Wick, W, 2009) |
| "Glioblastomas are treated by surgical resection followed by radiotherapy [X-ray therapy (XRT)] and the alkylating chemotherapeutic agent temozolomide." | 3.74 | Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment. ( Batchelor, TT; Betensky, RA; Cahill, DP; Codd, PJ; Curry, WT; Futreal, PA; Iafrate, AJ; Levine, KK; Louis, DN; Reavie, LB; Romany, CA; Stratton, MR, 2007) |
| "Standard therapy for glioblastoma (GBM) is temozolomide (TMZ) administration, initially concurrent with radiotherapy (RT), and subsequently as maintenance therapy." | 3.74 | MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. ( Andreoli, A; Bartolini, S; Bertorelle, R; Blatt, V; Brandes, AA; Calbucci, F; Ermani, M; Franceschi, E; Frezza, G; Leonardi, M; Pession, A; Spagnolli, F; Tallini, G; Tosoni, A, 2008) |
| "The aim of this study was to evaluate the efficacy and safety of carmustine (BCNU) in combination with temozolomide as first-line chemotherapy before and after radiotherapy (RT) in patients with inoperable, newly diagnosed glioblastoma multiforme (GBM)." | 3.73 | Temozolomide in combination with BCNU before and after radiotherapy in patients with inoperable newly diagnosed glioblastoma multiforme. ( Barrié, M; Braguer, D; Chinot, O; Couprie, C; Dufour, H; Figarella-Branger, D; Grisoli, F; Hoang-Xuan, K; Martin, PM; Muracciole, X; Peragut, JC, 2005) |
| "To describe the results of the treatment of recurrent glioma with temozolomide." | 3.73 | [Favourable result for temozolomide in recurrent high-grade glioma]. ( Enting, RH; Kros, JM; Sillevis Smitt, PA; Taal, W; van den Bent, MJ; van der Rijt, CD; van Heuvel, I, 2005) |
| " Pharmacokinetic testing did not show evidence of drug-drug interaction between irinotecan and alisertib." | 2.82 | Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) Trial. ( Bagatell, R; Courtier, J; Czarnecki, S; DuBois, SG; Fox, E; Goodarzian, F; Groshen, S; Hawkins, R; Kudgus, RA; Lai, H; Malvar, J; Marachelian, A; Maris, JM; Matthay, KK; Mosse, YP; Reid, JM; Shimada, H; Tsao-Wei, D; Wagner, L, 2016) |
| "Cilengitide was continued for up to 12 months or until disease progression or unacceptable toxicity." | 2.82 | Cilengitide with metronomic temozolomide, procarbazine, and standard radiotherapy in patients with glioblastoma and unmethylated MGMT gene promoter in ExCentric, an open-label phase II trial. ( Ackland, S; Back, M; Buyse, ME; Kerestes, Z; Khasraw, M; Kichenadasse, G; Lee, A; McCowatt, S; Wheeler, H, 2016) |
| "The rate of dying after disease progression is about 6." | 2.80 | Variation over time and interdependence between disease progression and death among patients with glioblastoma on RTOG 0525. ( Curran, W; Dignam, JJ; Gilbert, MR; Mehta, M; Wang, M; Won, M, 2015) |
| "Uveal melanoma is characterized by mutations in GNAQ and GNA11, resulting in mitogen-activated protein kinase pathway activation." | 2.79 | Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial. ( Abramson, DH; Albertini, MR; Ambrosini, G; Ancell, K; Bluth, M; Carvajal, RD; Chapman, PB; Dickson, MA; Doyle, A; Erinjeri, J; Flynn, PJ; Gajewski, TF; Hedvat, C; Joshua, AM; Kudchadkar, RR; Lao, CD; Lawson, DH; Lewis, K; Linette, GP; Lutzky, J; Marr, B; Milhem, MM; Panageas, KS; Quevedo, JF; Sato, T; Schwartz, GK; Sosman, JA; Wolchok, JD, 2014) |
| "Thalidomide 100 mg was kept stable for all cohorts." | 2.73 | A phase I study of thalidomide, capecitabine and temozolomide in advanced cancer. ( Khan, MI; Kloecker, GH; Laber, DA; Salvador, C; Schonard, C; Taft, BS, 2007) |
| "Perillyl alcohol has shown to have both chemopreventive and chemotherapeutic activities in preclinical studies." | 2.73 | Preliminary results from a phase I/II study of perillyl alcohol intranasal administration in adults with recurrent malignant gliomas. ( da Fonseca, CO; Fischer, J; Futuro, D; Gattass, CR; Nagel, J; Quirico-Santos, T; Schwartsmann, G, 2008) |
| " If further studies are to be performed, emerging data suggest that higher daily doses of lomeguatrib and a dosing period beyond that of TMZ should be evaluated." | 2.73 | A phase II trial of lomeguatrib and temozolomide in metastatic colorectal cancer. ( Khan, OA; Levitt, NC; Margison, GP; Michael, M; Middleton, MR; Midgley, R; Mortimer, P; Olver, I; Ranson, M; Watson, AJ, 2008) |
| "Brain metastases are a common complication in patients suffering from metastatic malignant melanoma." | 2.72 | Temozolomide with or without radiotherapy in melanoma with unresectable brain metastases. ( Budach, V; Hofmann, M; Kiecker, F; Schlenger, L; Sterry, W; Trefzer, U; Wurm, R, 2006) |
| "Decision making at disease progression is critical, and classical T1 and T2 imaging remain the gold standard." | 2.72 | Perfusion and diffusion MRI of glioblastoma progression in a four-year prospective temozolomide clinical trial. ( Buff, E; Leimgruber, A; Maeder, PP; Meuli, RA; Ostermann, S; Stupp, R; Yeon, EJ, 2006) |
| "Temozolomide was in general well tolerated; the most frequent side-effects were hematological." | 2.71 | Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972. ( Baron, B; Boogerd, W; Bravo Marques, J; Chinot, O; De Beule, N; Kros, JM; Taphoorn, MJ; van den Bent, MJ; van der Rijt, CC; Vecht, CJ, 2003) |
| "Oral ondansetron (8 mg) was given 1 h prior to temozolomide administration." | 2.71 | Dose-dense regimen of temozolomide given every other week in patients with primary central nervous system tumors. ( Abdulkarim, B; Armand, JP; Cioloca, C; Djafari, L; Djazouli, K; Faivre, S; Guillamo, JS; Osorio, M; Parker, F; Raymond, E; Vera, K, 2004) |
| "Because of the diffuse nature of gliomatosis cerebri (GC), surgery is not suitable, and large field radiotherapy carries the risk of severe toxicity." | 2.71 | Initial chemotherapy in gliomatosis cerebri. ( Carpentier, A; Cartalat-Carel, S; Chinot, O; Cougnard, J; Delattre, JY; Djafari, L; Duffau, H; Gervais, H; Hoang-Xuan, K; Honnorat, J; Laigle, F; Mokhtari, K; Napolitano, M; Sanson, M; Taillandier, L; Taillibert, S, 2004) |
| "The optimal therapy for gliomatosis cerebri is unclear, and the rate of response to chemotherapy is not known." | 2.71 | Chemotherapy as initial treatment in gliomatosis cerebri: results with temozolomide. ( Gomori, JM; Levin, N; Siegal, T, 2004) |
| "Temozolomide is an oral alkylating agent that can cross the blood-brain barrier and in phase II and III trials, patients with advanced metastatic melanoma achieved overall response rates of 13 to 21%." | 2.71 | The effect of temozolomide-based chemotherapy in patients with cerebral metastases from melanoma. ( Bafaloukos, D; Briassoulis, E; Christodoulou, C; Fountzilas, G; Gogas, H; Hatzichristou, H; Kalofonos, HP; Linardou, H; Panagiotou, P; Tsoutsos, D, 2004) |
| " The recommended dosage for TEMO for a phase II study of this combination is 200 mg/m2 per day for 5 days." | 2.70 | Phase I study of Gliadel wafers plus temozolomide in adults with recurrent supratentorial high-grade gliomas. ( Affronti, ML; Cokgor, L; Early, M; Edwards, S; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; McLendon, RE; Provenzale, JM; Quinn, JA; Rich, JN; Sampson, JH; Stafford-Fox, V; Tourt-Uhlig, S; Zaknoen, S, 2001) |
| "Ifosfamide treatment might be a feasible approach, but it necessitates hospitalization." | 2.69 | Chemotherapy in the treatment of recurrent glioblastoma multiforme: ifosfamide versus temozolomide. ( Bamberg, M; Becker, G; Belka, C; Classen, J; Hoffmann, W; Kortmann, RD; Paulsen, F; Weinmann, M, 1999) |
| "Treatment with temozolomide was generally well tolerated, with occasionally moderate toxicity." | 2.69 | A phase II study of temozolomide in hormone-refractory prostate cancer. ( Busstra, MB; Catsburg, T; Lang, MS; Mickisch, GH; Schröder, FH; van Brussel, JP, 2000) |
| "Brain tissue necrosis (treatment necrosis [TN]) as a consequence of brain directed cancer therapy remains an insufficiently characterized condition with diagnostic and therapeutic difficulties and is frequently associated with significant patient morbidity." | 2.61 | Treatment-induced brain tissue necrosis: a clinical challenge in neuro-oncology. ( Batchelor, TT; Dietrich, J; Loebel, F; Loeffler, J; Martinez-Lage, M; Vajkoczy, P; Winter, SF, 2019) |
| "Atypical pituitary adenomas (APAs) are aggressive tumors, harboring a Ki-67 (MIB-1) staining index of 3% or more, and positive immunohistochemical staining for p53 protein, according to the World Health Organization (WHO) classification in 2004." | 2.50 | Treatment of pituitary carcinomas and atypical pituitary adenomas: a review. ( Hirohata, T; Ishii, Y; Matsuno, A, 2014) |
| "Additionally, there is evidence that treatment-related necrosis occurs more frequently and earlier after temozolomide chemotherapy than after radiotherapy alone." | 2.44 | Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. ( Brandsma, D; Sminia, P; Stalpers, L; Taal, W; van den Bent, MJ, 2008) |
| "The prognosis for patients with malignant primary brain tumors has been poor, and until recently, there was little evidence that chemotherapy was beneficial." | 2.43 | Advances in the treatment of primary brain tumors: dawn of a new era? ( Gilbert, MR, 2006) |
| "As long as metastasis is confined to one organ system and is removable, surgery remains the treatment of first choice." | 2.42 | [Therapy of malignant melanoma at the stage of distant metastasis]. ( Eigentler, TK; Garbe, C, 2004) |
| "Temozolomide was effective in delaying disease progression and maintaining health-related quality of life." | 2.41 | Temozolomide in malignant gliomas. ( Yung, WK, 2000) |
| "Brain cancer is a devastating disease given its extreme invasiveness and intricate location." | 1.62 | Gradient hydrogels for screening stiffness effects on patient-derived glioblastoma xenograft cellfates in 3D. ( Grant, GA; Li, J; Trinh, P; Yang, F; Zhu, D, 2021) |
| "The prognosis of glioma is generally poor and is the cause of primary malignancy in the brain." | 1.56 | MicroRNA-155-3p promotes glioma progression and temozolomide resistance by targeting Six1. ( Chen, G; Chen, Z; Zhao, H, 2020) |
| "Glioblastoma is the worst and most common primary brain tumor." | 1.51 | CD73 Downregulation Decreases In Vitro and In Vivo Glioblastoma Growth. ( Azambuja, JH; Battastini, AMO; Beckenkamp, LR; Braganhol, E; de Oliveira, FH; Fernandes, MC; Figueiró, F; Gelsleichter, NE; Iser, IC; Scholl, JN; Sévigny, J; Spanevello, RM; Stefani, MA; Teixeira, HF; Wink, MR, 2019) |
| " In vivo, systemic treatment with pacritinib demonstrated blood-brain barrier penetration and led to improved overall median survival in combination with TMZ, in mice orthotopically xenografted with an aggressive recurrent GBM BTIC culture." | 1.46 | The JAK2/STAT3 inhibitor pacritinib effectively inhibits patient-derived GBM brain tumor initiating cells in vitro and when used in combination with temozolomide increases survival in an orthotopic xenograft model. ( Aman, A; Cseh, O; Jensen, KV; Luchman, HA; Weiss, S, 2017) |
| "Temozolomide (TMZ) is an oral alkylating agent that has been used over the past 8 years to treat aggressive pituitary tumors resistant to conventional therapy." | 1.43 | Temozolomide for aggressive ACTH pituitary tumors: failure of a second course of treatment. ( Aller, J; Campderá, M; Estrada, J; Lilienfeld, H; Magallón, R; Martín, P; Palacios, N; Saucedo, G, 2016) |
| " As a comparison group 33 patients with bevacizumab for at least 6 months continuously dosed at 10 mg/kg every 2 weeks were selected." | 1.43 | Impact of tapering and discontinuation of bevacizumab in patients with progressive glioblastoma. ( Hertenstein, A; Hielscher, T; Menn, O; Platten, M; Wick, A; Wick, W; Wiestler, B; Winkler, F, 2016) |
| "Only pituitary tumors with cerebrospinal and/or systemic metastasis are considered malignant carcinomas." | 1.43 | Refractory pituitary adenoma: a novel classification for pituitary tumors. ( Bao, X; Dai, C; Deng, K; Feng, M; Lian, W; Liu, X; Ma, S; Ma, W; Sun, B; Wang, R; Wang, Y; Xing, B; Yao, Y; Zhong, D, 2016) |
| "Glioblastoma multiforme is the most common malignant brain tumor." | 1.42 | An image guided small animal radiation therapy platform (SmART) to monitor glioblastoma progression and therapy response. ( Barbeau, LM; Granton, PV; Paesmans, K; Theys, J; van Hoof, SJ; Verhaegen, F; Vooijs, M; Yahyanejad, S, 2015) |
| "Malignant glioma is a severe type of brain tumor with a poor prognosis and few options for therapy." | 1.40 | Glutathione depletion sensitizes cisplatin- and temozolomide-resistant glioma cells in vitro and in vivo. ( Belizário, JE; de Andrade-Lima, LC; Garcia, CC; Menck, CF; Munford, V; Quinet, A; Rocha, CR; Vieira, DB, 2014) |
| "Glioblastoma are highly aggressive brain tumors with poor prognosis." | 1.40 | Suppressor of fused (Sufu) represses Gli1 transcription and nuclear accumulation, inhibits glioma cell proliferation, invasion and vasculogenic mimicry, improving glioma chemo-sensitivity and prognosis. ( Cai, J; Chang, L; Chen, L; Cui, Y; Dou, Z; Du, W; Jiang, C; Liu, X; Liu, Y; Wang, G; Wang, H; Wang, X; Yi, L; Zhang, P, 2014) |
| "Pseudoprogression (PP) during adjuvant treatment of glioblastoma (GBM) is frequent and is a clinically and radiologically challenging problem." | 1.39 | Is there pseudoprogression in secondary glioblastomas? ( Cerhova, J; Chakravarti, A; Engellandt, K; Geiger, KD; Juratli, TA; Krex, D; Lautenschlaeger, T; Schackert, G; von Kummer, R, 2013) |
| "Glioblastoma multiforme is the most common primary malignant brain tumour, with a median survival of about one year." | 1.38 | A restricted cell population propagates glioblastoma growth after chemotherapy. ( Burns, DK; Chen, J; Kernie, SG; Li, Y; McKay, RM; Parada, LF; Yu, TS, 2012) |
| "Treatment with temozolomide alone or in combination with capecitabine and bevacizumab has recently shown promising results." | 1.38 | Temozolomide as second or third line treatment of patients with neuroendocrine carcinomas. ( Federspiel, B; Hansen, CP; Kjaer, A; Knigge, U; Langer, SW; Olsen, IH; Sørensen, JB, 2012) |
| "Histological examination revealed anaplastic astrocytoma." | 1.38 | Radiation-induced spinal cord anaplastic astrocytoma subsequent to radiotherapy for testicular seminoma. ( Hoshimaru, M; Kawanabe, Y; Kihara, S; Koizumi, T; Sasaki, N; Sawada, M; Ueda, S; Yukawa, H, 2012) |
| "Extracranial metastasis of primary brain tumors is rarely observed." | 1.38 | Breast metastasis of anaplastic oligodendroglioma: a case report. ( Alacacioglu, A; Canpolat, S; Coskun, A; Karatas, A; Oztekin, O; Postaci, H; Sop, G; Unal, S; Yurt, A, 2012) |
| "Treatment with temozolomide alone or in combination with capecitabine and bevacizumab resulted in objective response or stabilization in 71% of PDEC patients who failed on first-line chemotherapy." | 1.37 | Clinical effect of temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy. ( Busch, C; Knappskog, S; Oberg, K; Sebjornsen, S; Sorbye, H; Welin, S, 2011) |
| "Intracranial anaplastic ependymomas are a very rare entity within the group of adult CNS neoplasms." | 1.37 | Response to temozolomide in supratentorial multifocal recurrence of malignant ependymoma. ( Freyschlag, CF; Lohr, F; Schmieder, K; Seiz, M; Thomé, C; Tuettenberg, J, 2011) |
| "The median time to disease progression was 8 weeks, and the overall survival duration was 26 weeks." | 1.36 | The clinical efficacy of combination of docetaxel and temozolomide in previously treated patients with stage IV melanoma. ( Alvarado, GC; Bedikian, AY; Camacho, LH; Hwu, P; Kim, KB; McIntyre, S; Papadopoulos, NE; Yoon, C, 2010) |
| "Temozolomide is a well-tolerated oral chemotherapy in patients with malignant DET, including those who have already received treatment." | 1.35 | Temozolomide: a safe and effective treatment for malignant digestive endocrine tumors. ( Couvelard, A; Faivre, S; Hammel, P; Hentic, O; Larroque, B; Lévy, P; Maire, F; Raymond, E; Ruszniewski, P; Yapur, L; Zappa, M, 2009) |
| "Gliomatosis cerebri is a rare primary cerebral tumour entity characterized by diffuse infiltrative growth patterns representing a WHO grade III malignancy." | 1.35 | First experiences with low-dose anti-angiogenic treatment in gliomatosis cerebri with signs of angiogenic activity. ( Brockmann, MA; Hermes, P; Kohlhof, P; Neumaier-Probst, E; Schmieder, K; Seiz, M; Tuettenberg, J; Vajkoczy, P; VON Deimling, A, 2009) |
| "Sixty four patients with melanoma brain metastases were treated in our department within a 15-year period." | 1.33 | Cerebral metastases of malignant melanoma: contemporary treatment modalities and survival outcome. ( Bafaloukos, DI; Brountzos, EN; Kelekis, DA; Panagiotou, IE; Papathanasiou, MA, 2005) |
| "The patient remained free from disease progression for a total of 15 months when she was treated for dehydration and a computed tomography (CT) scan showed new small bilateral pleural effusions and enlarging subcarinal, right hilar, and left infrahilar lymph nodes." | 1.33 | Response to temozolomide in second-line treatment of recurrent nonsmall cell lung carcinoma: case report. ( Langer, CJ; Somer, RA, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (0.35) | 18.2507 |
| 2000's | 89 (31.12) | 29.6817 |
| 2010's | 175 (61.19) | 24.3611 |
| 2020's | 21 (7.34) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, T | 1 |
| Hu, J | 3 |
| Han, B | 2 |
| Tan, S | 1 |
| Jia, W | 1 |
| Xin, Y | 1 |
| Pai, FC | 1 |
| Huang, HW | 1 |
| Tsai, YL | 1 |
| Tsai, WC | 1 |
| Cheng, YC | 1 |
| Chang, HH | 1 |
| Chen, Y | 5 |
| Beppu, T | 1 |
| Iwaya, T | 1 |
| Sato, Y | 1 |
| Nomura, JI | 1 |
| Terasaki, K | 1 |
| Sasaki, T | 1 |
| Yamada, N | 1 |
| Fujiwara, S | 1 |
| Sugai, T | 1 |
| Ogasawara, K | 1 |
| Ohno, M | 1 |
| Miyakita, Y | 1 |
| Takahashi, M | 2 |
| Yanagisawa, S | 1 |
| Tamura, Y | 1 |
| Narita, Y | 1 |
| Khristov, V | 3 |
| Nesterova, D | 3 |
| Trifoi, M | 3 |
| Clegg, T | 3 |
| Daya, A | 3 |
| Barrett, T | 3 |
| Tufano, E | 3 |
| Shenoy, G | 3 |
| Pandya, B | 3 |
| Beselia, G | 3 |
| Smith, N | 3 |
| Mrowczynski, O | 3 |
| Zacharia, B | 3 |
| Waite, K | 3 |
| Lathia, J | 3 |
| Barnholtz-Sloan, J | 3 |
| Connor, J | 3 |
| Ma, F | 1 |
| Zhang, Z | 5 |
| Guo, Y | 2 |
| Shen, H | 1 |
| Chen, H | 2 |
| Andrade, LNS | 1 |
| Otake, AH | 1 |
| Cardim, SGB | 1 |
| da Silva, FI | 1 |
| Ikoma Sakamoto, MM | 1 |
| Furuya, TK | 1 |
| Uno, M | 1 |
| Pasini, FS | 1 |
| Chammas, R | 1 |
| Sachdeva, R | 1 |
| Wu, M | 3 |
| Johnson, K | 1 |
| Kim, H | 2 |
| Celebre, A | 1 |
| Shahzad, U | 1 |
| Graham, MS | 1 |
| Kessler, JA | 1 |
| Chuang, JH | 1 |
| Karamchandani, J | 1 |
| Bredel, M | 1 |
| Verhaak, R | 1 |
| Das, S | 2 |
| Karachaliou, GS | 1 |
| Ayvali, F | 1 |
| Collichio, FA | 1 |
| Lee, CB | 1 |
| Ivanova, A | 1 |
| Ollila, DW | 1 |
| Moschos, SJ | 1 |
| Rulseh, AM | 1 |
| Vymazal, J | 1 |
| Jammula, S | 1 |
| Katz-Summercorn, AC | 1 |
| Li, X | 12 |
| Linossi, C | 1 |
| Smyth, E | 1 |
| Killcoyne, S | 1 |
| Biasci, D | 1 |
| Subash, VV | 1 |
| Abbas, S | 1 |
| Blasko, A | 1 |
| Devonshire, G | 1 |
| Grantham, A | 1 |
| Wronowski, F | 1 |
| O'Donovan, M | 1 |
| Grehan, N | 1 |
| Eldridge, MD | 1 |
| Tavaré, S | 1 |
| Fitzgerald, RC | 1 |
| Kong, S | 1 |
| Fang, Y | 1 |
| Wang, B | 1 |
| Cao, Y | 3 |
| He, R | 1 |
| Zhao, Z | 3 |
| Chen, G | 3 |
| Chen, Z | 1 |
| Zhao, H | 3 |
| Vajapeyam, S | 1 |
| Brown, D | 2 |
| Billups, C | 1 |
| Patay, Z | 1 |
| Vezina, G | 1 |
| Shiroishi, MS | 1 |
| Law, M | 1 |
| Baxter, P | 1 |
| Onar-Thomas, A | 1 |
| Fangusaro, JR | 1 |
| Dunkel, IJ | 1 |
| Poussaint, TY | 1 |
| Bergquist, JR | 1 |
| Li, AY | 1 |
| Chang, EM | 1 |
| Scott, GD | 1 |
| Dua, MM | 1 |
| Visser, BC | 1 |
| Ngo, MT | 1 |
| Karvelis, E | 1 |
| Harley, BAC | 1 |
| Gudbergsson, JM | 1 |
| Christensen, E | 1 |
| Kostrikov, S | 1 |
| Moos, T | 1 |
| Duroux, M | 1 |
| Kjær, A | 1 |
| Johnsen, KB | 1 |
| Andresen, TL | 1 |
| Salah, S | 1 |
| To, YH | 1 |
| Khozouz, O | 1 |
| Ismail, T | 1 |
| Yaser, S | 1 |
| Alnsour, A | 1 |
| Shahin, O | 1 |
| Sultan, I | 1 |
| Abuhijlih, R | 1 |
| Halalsheh, H | 1 |
| Abuhijla, F | 1 |
| Lewin, J | 1 |
| Zhu, D | 1 |
| Trinh, P | 1 |
| Li, J | 10 |
| Grant, GA | 1 |
| Yang, F | 1 |
| Nguépy Keubo, FR | 1 |
| Mboua, PC | 1 |
| Djifack Tadongfack, T | 1 |
| Fokouong Tchoffo, E | 1 |
| Tasson Tatang, C | 1 |
| Ide Zeuna, J | 1 |
| Noupoue, EM | 1 |
| Tsoplifack, CB | 1 |
| Folefack, GO | 1 |
| Kettani, M | 1 |
| Bandelier, P | 1 |
| Huo, J | 1 |
| Li, H | 5 |
| Yu, D | 1 |
| Arulsamy, N | 1 |
| AlAbbad, S | 1 |
| Sardot, T | 1 |
| Lekashvili, O | 1 |
| Decato, D | 1 |
| Lelj, F | 1 |
| Alexander Ross, JB | 1 |
| Rosenberg, E | 1 |
| Nazir, H | 1 |
| Muthuswamy, N | 1 |
| Louis, C | 1 |
| Jose, S | 1 |
| Prakash, J | 1 |
| Buan, MEM | 1 |
| Flox, C | 1 |
| Chavan, S | 1 |
| Shi, X | 1 |
| Kauranen, P | 1 |
| Kallio, T | 1 |
| Maia, G | 1 |
| Tammeveski, K | 1 |
| Lymperopoulos, N | 1 |
| Carcadea, E | 1 |
| Veziroglu, E | 1 |
| Iranzo, A | 1 |
| M Kannan, A | 1 |
| Arunamata, A | 1 |
| Tacy, TA | 1 |
| Kache, S | 1 |
| Mainwaring, RD | 1 |
| Ma, M | 1 |
| Maeda, K | 1 |
| Punn, R | 1 |
| Noguchi, S | 1 |
| Hahn, S | 3 |
| Iwasa, Y | 3 |
| Ling, J | 2 |
| Voccio, JP | 2 |
| Kim, Y | 3 |
| Song, J | 4 |
| Bascuñán, J | 2 |
| Chu, Y | 1 |
| Tomita, M | 1 |
| Cazorla, M | 1 |
| Herrera, E | 1 |
| Palomeque, E | 1 |
| Saud, N | 1 |
| Hoplock, LB | 1 |
| Lobchuk, MM | 1 |
| Lemoine, J | 1 |
| Henson, MA | 1 |
| Unsihuay, D | 1 |
| Qiu, J | 1 |
| Swaroop, S | 1 |
| Nagornov, KO | 1 |
| Kozhinov, AN | 1 |
| Tsybin, YO | 1 |
| Kuang, S | 1 |
| Laskin, J | 1 |
| Zin, NNINM | 1 |
| Mohamad, MN | 1 |
| Roslan, K | 1 |
| Abdul Wafi, S | 1 |
| Abdul Moin, NI | 1 |
| Alias, A | 1 |
| Zakaria, Y | 1 |
| Abu-Bakar, N | 1 |
| Naveed, A | 1 |
| Jilani, K | 1 |
| Siddique, AB | 1 |
| Akbar, M | 1 |
| Riaz, M | 1 |
| Mushtaq, Z | 1 |
| Sikandar, M | 1 |
| Ilyas, S | 1 |
| Bibi, I | 1 |
| Asghar, A | 1 |
| Rasool, G | 1 |
| Irfan, M | 1 |
| Li, XY | 1 |
| Zhao, S | 2 |
| Fan, XH | 1 |
| Chen, KP | 1 |
| Hua, W | 1 |
| Liu, ZM | 1 |
| Xue, XD | 1 |
| Zhou, B | 1 |
| Zhang, S | 2 |
| Xing, YL | 1 |
| Chen, MA | 1 |
| Sun, Y | 3 |
| Neradilek, MB | 1 |
| Wu, XT | 1 |
| Zhang, D | 2 |
| Huang, W | 1 |
| Cui, Y | 2 |
| Yang, QQ | 1 |
| Li, HW | 1 |
| Zhao, XQ | 1 |
| Hossein Rashidi, B | 1 |
| Tarafdari, A | 1 |
| Ghazimirsaeed, ST | 1 |
| Shahrokh Tehraninezhad, E | 1 |
| Keikha, F | 1 |
| Eslami, B | 1 |
| Ghazimirsaeed, SM | 1 |
| Jafarabadi, M | 1 |
| Silvani, Y | 1 |
| Lovita, AND | 1 |
| Maharani, A | 1 |
| Wiyasa, IWA | 1 |
| Sujuti, H | 1 |
| Ratnawati, R | 1 |
| Raras, TYM | 1 |
| Lemin, AS | 1 |
| Rahman, MM | 1 |
| Pangarah, CA | 1 |
| Kiyu, A | 1 |
| Zeng, C | 2 |
| Du, H | 1 |
| Lin, D | 1 |
| Jalan, D | 1 |
| Rubagumya, F | 1 |
| Hopman, WM | 1 |
| Vanderpuye, V | 1 |
| Lopes, G | 1 |
| Seruga, B | 1 |
| Booth, CM | 1 |
| Berry, S | 1 |
| Hammad, N | 1 |
| Sajo, EA | 1 |
| Okunade, KS | 1 |
| Olorunfemi, G | 1 |
| Rabiu, KA | 1 |
| Anorlu, RI | 1 |
| Xu, C | 2 |
| Xiang, Y | 1 |
| Xu, X | 1 |
| Zhou, L | 2 |
| Dong, X | 1 |
| Tang, S | 1 |
| Gao, XC | 1 |
| Wei, CH | 1 |
| Zhang, RG | 1 |
| Cai, Q | 1 |
| He, Y | 1 |
| Tong, F | 1 |
| Dong, JH | 1 |
| Wu, G | 1 |
| Dong, XR | 1 |
| Tang, X | 1 |
| Tao, F | 1 |
| Xiang, W | 1 |
| Zhao, Y | 2 |
| Jin, L | 1 |
| Tao, H | 1 |
| Lei, Y | 1 |
| Gan, H | 1 |
| Huang, Y | 1 |
| Chen, L | 4 |
| Shan, A | 1 |
| Ma, Q | 1 |
| Wang, J | 5 |
| Zhang, E | 1 |
| Zhang, J | 4 |
| Li, Y | 7 |
| Xue, F | 1 |
| Deng, L | 1 |
| Liu, L | 2 |
| Yan, Z | 2 |
| Wang, Y | 4 |
| Meng, J | 1 |
| Anastassiadou, M | 1 |
| Bernasconi, G | 1 |
| Brancato, A | 1 |
| Carrasco Cabrera, L | 1 |
| Greco, L | 1 |
| Jarrah, S | 1 |
| Kazocina, A | 1 |
| Leuschner, R | 1 |
| Magrans, JO | 1 |
| Miron, I | 1 |
| Nave, S | 1 |
| Pedersen, R | 1 |
| Reich, H | 1 |
| Rojas, A | 1 |
| Sacchi, A | 1 |
| Santos, M | 1 |
| Theobald, A | 1 |
| Vagenende, B | 1 |
| Verani, A | 1 |
| Du, L | 1 |
| Liu, X | 3 |
| Ren, Y | 1 |
| Li, P | 1 |
| Jiao, Q | 1 |
| Meng, P | 1 |
| Wang, F | 3 |
| Wang, YS | 1 |
| Wang, C | 3 |
| Zhou, X | 3 |
| Wang, W | 2 |
| Wang, S | 3 |
| Hou, J | 1 |
| Zhang, A | 2 |
| Lv, B | 1 |
| Gao, C | 1 |
| Pang, D | 1 |
| Lu, K | 1 |
| Ahmad, NH | 1 |
| Wang, L | 2 |
| Zhu, J | 2 |
| Zhang, L | 3 |
| Zhuang, T | 1 |
| Tu, J | 1 |
| Qu, Y | 2 |
| Yao, H | 1 |
| Wang, X | 7 |
| Lee, DF | 1 |
| Shen, J | 3 |
| Wen, L | 1 |
| Huang, G | 2 |
| Xie, X | 1 |
| Zhao, Q | 1 |
| Hu, W | 1 |
| Zhang, Y | 4 |
| Wu, X | 1 |
| Lu, J | 2 |
| Li, M | 1 |
| Li, W | 2 |
| Wu, W | 2 |
| Du, F | 1 |
| Ji, H | 1 |
| Yang, X | 3 |
| Xu, Z | 1 |
| Wan, L | 1 |
| Wen, Q | 1 |
| Cho, CH | 1 |
| Zou, C | 1 |
| Xiao, Z | 1 |
| Liao, J | 1 |
| Su, X | 1 |
| Bi, Z | 1 |
| Su, Q | 1 |
| Huang, H | 1 |
| Wei, Y | 2 |
| Gao, Y | 2 |
| Na, KJ | 1 |
| Choi, H | 1 |
| Oh, HR | 1 |
| Kim, YH | 1 |
| Lee, SB | 1 |
| Jung, YJ | 1 |
| Koh, J | 1 |
| Park, S | 1 |
| Lee, HJ | 1 |
| Jeon, YK | 1 |
| Chung, DH | 1 |
| Paeng, JC | 1 |
| Park, IK | 1 |
| Kang, CH | 1 |
| Cheon, GJ | 1 |
| Kang, KW | 1 |
| Lee, DS | 1 |
| Kim, YT | 1 |
| Pajuelo-Lozano, N | 1 |
| Alcalá, S | 1 |
| Sainz, B | 1 |
| Perona, R | 1 |
| Sanchez-Perez, I | 1 |
| Logotheti, S | 1 |
| Marquardt, S | 1 |
| Gupta, SK | 1 |
| Richter, C | 1 |
| Edelhäuser, BAH | 1 |
| Engelmann, D | 1 |
| Brenmoehl, J | 1 |
| Söhnchen, C | 1 |
| Murr, N | 1 |
| Alpers, M | 1 |
| Singh, KP | 1 |
| Wolkenhauer, O | 1 |
| Heckl, D | 1 |
| Spitschak, A | 1 |
| Pützer, BM | 1 |
| Liao, Y | 1 |
| Cheng, J | 1 |
| Kong, X | 2 |
| Li, S | 1 |
| Zhang, M | 5 |
| Zhang, H | 1 |
| Yang, T | 2 |
| Dong, Y | 1 |
| Xu, Y | 1 |
| Yuan, Z | 1 |
| Cao, J | 1 |
| Zheng, Y | 1 |
| Luo, Z | 1 |
| Mei, Z | 1 |
| Yao, Y | 2 |
| Liu, Z | 2 |
| Liang, C | 1 |
| Yang, H | 1 |
| Song, Y | 2 |
| Yu, K | 1 |
| Zhu, C | 1 |
| Huang, Z | 2 |
| Qian, J | 1 |
| Ge, J | 1 |
| Wang, H | 4 |
| Liu, Y | 7 |
| Mi, Y | 1 |
| Kong, H | 1 |
| Xi, D | 1 |
| Yan, W | 1 |
| Luo, X | 1 |
| Ning, Q | 1 |
| Chang, X | 2 |
| Zhang, T | 2 |
| Wang, Q | 3 |
| Rathore, MG | 1 |
| Reddy, K | 1 |
| Shin, SH | 1 |
| Ma, WY | 1 |
| Bode, AM | 1 |
| Dong, Z | 2 |
| Mu, W | 1 |
| Liu, C | 3 |
| Gao, F | 1 |
| Qi, Y | 1 |
| Lu, H | 1 |
| Zhang, X | 5 |
| Cai, X | 1 |
| Ji, RY | 1 |
| Hou, Y | 3 |
| Tian, J | 2 |
| Shi, Y | 1 |
| Ying, S | 1 |
| Tan, M | 1 |
| Feng, G | 1 |
| Kuang, Y | 1 |
| Chen, D | 1 |
| Wu, D | 3 |
| Zhu, ZQ | 1 |
| Tang, HX | 1 |
| Shi, ZE | 1 |
| Kang, J | 1 |
| Liu, Q | 1 |
| Qi, J | 2 |
| Mu, J | 1 |
| Cong, Z | 1 |
| Chen, S | 2 |
| Fu, D | 1 |
| Li, Z | 2 |
| Celestrin, CP | 1 |
| Rocha, GZ | 1 |
| Stein, AM | 1 |
| Guadagnini, D | 1 |
| Tadelle, RM | 1 |
| Saad, MJA | 1 |
| Oliveira, AG | 1 |
| Bianconi, V | 1 |
| Bronzo, P | 1 |
| Banach, M | 1 |
| Sahebkar, A | 1 |
| Mannarino, MR | 1 |
| Pirro, M | 1 |
| Patsourakos, NG | 1 |
| Kouvari, M | 1 |
| Kotidis, A | 1 |
| Kalantzi, KI | 1 |
| Tsoumani, ME | 1 |
| Anastasiadis, F | 1 |
| Andronikos, P | 1 |
| Aslanidou, T | 1 |
| Efraimidis, P | 1 |
| Georgiopoulos, A | 1 |
| Gerakiou, K | 1 |
| Grigoriadou-Skouta, E | 1 |
| Grigoropoulos, P | 1 |
| Hatzopoulos, D | 1 |
| Kartalis, A | 1 |
| Lyras, A | 1 |
| Markatos, G | 1 |
| Mikrogeorgiou, A | 1 |
| Myroforou, I | 1 |
| Orkopoulos, A | 1 |
| Pavlidis, P | 1 |
| Petras, C | 1 |
| Riga, M | 1 |
| Skouloudi, M | 1 |
| Smyrnioudis, N | 1 |
| Thomaidis, K | 1 |
| Tsikouri, GE | 1 |
| Tsikouris, EI | 1 |
| Zisimos, K | 1 |
| Vavoulis, P | 1 |
| Vitali, MG | 1 |
| Vitsas, G | 1 |
| Vogiatzidis, C | 1 |
| Chantanis, S | 1 |
| Fousas, S | 1 |
| Panagiotakos, DB | 1 |
| Tselepis, AD | 1 |
| Jungen, C | 1 |
| Alken, FA | 1 |
| Eickholt, C | 1 |
| Scherschel, K | 1 |
| Kuklik, P | 1 |
| Klatt, N | 1 |
| Schwarzl, J | 1 |
| Moser, J | 1 |
| Jularic, M | 1 |
| Akbulak, RO | 1 |
| Schaeffer, B | 1 |
| Willems, S | 1 |
| Meyer, C | 1 |
| Nowak, JK | 1 |
| Szczepanik, M | 1 |
| Trypuć, M | 1 |
| Pogorzelski, A | 1 |
| Bobkowski, W | 1 |
| Grytczuk, M | 1 |
| Minarowska, A | 1 |
| Wójciak, R | 1 |
| Walkowiak, J | 1 |
| Lu, Y | 1 |
| Xi, J | 1 |
| Li, C | 1 |
| Chen, W | 2 |
| Hu, X | 1 |
| Zhang, F | 1 |
| Wei, H | 1 |
| Wang, Z | 2 |
| Gurzu, S | 1 |
| Jung, I | 1 |
| Sugimura, H | 2 |
| Stefan-van Staden, RI | 1 |
| Yamada, H | 1 |
| Natsume, H | 1 |
| Iwashita, Y | 1 |
| Szodorai, R | 1 |
| Szederjesi, J | 1 |
| Yari, D | 1 |
| Ehsanbakhsh, Z | 1 |
| Validad, MH | 1 |
| Langroudi, FH | 1 |
| Esfandiari, H | 1 |
| Prager, A | 1 |
| Hassanpour, K | 1 |
| Kurup, SP | 1 |
| Mets-Halgrimson, R | 1 |
| Yoon, H | 1 |
| Zeid, JL | 1 |
| Mets, MB | 1 |
| Rahmani, B | 1 |
| Araujo-Castillo, RV | 1 |
| Culquichicón, C | 1 |
| Solis Condor, R | 1 |
| Efendi, F | 1 |
| Sebayang, SK | 1 |
| Astutik, E | 1 |
| Hadisuyatmana, S | 1 |
| Has, EMM | 1 |
| Kuswanto, H | 1 |
| Foroutan, T | 1 |
| Ahmadi, F | 1 |
| Moayer, F | 1 |
| Khalvati, S | 1 |
| Zhang, Q | 2 |
| Lyu, Y | 1 |
| Huang, J | 1 |
| Yu, N | 1 |
| Wen, Z | 1 |
| Hou, H | 1 |
| Zhao, T | 1 |
| Gupta, A | 1 |
| Khosla, N | 1 |
| Govindasamy, V | 1 |
| Saini, A | 1 |
| Annapurna, K | 1 |
| Dhakate, SR | 1 |
| Akkaya, Ö | 1 |
| Chandgude, AL | 1 |
| Dömling, A | 1 |
| Harnett, J | 1 |
| Oakes, K | 1 |
| Carè, J | 1 |
| Leach, M | 1 |
| Cramer, H | 1 |
| Pinder, TA | 1 |
| Steel, A | 1 |
| Anheyer, D | 1 |
| Cantu, J | 1 |
| Valle, J | 1 |
| Flores, K | 1 |
| Gonzalez, D | 1 |
| Valdes, C | 1 |
| Lopez, J | 1 |
| Padilla, V | 1 |
| Alcoutlabi, M | 1 |
| Parsons, J | 1 |
| Núñez, K | 1 |
| Hamed, M | 1 |
| Fort, D | 1 |
| Bruce, D | 1 |
| Thevenot, P | 1 |
| Cohen, A | 1 |
| Weber, P | 1 |
| Menezes, AMB | 1 |
| Gonçalves, H | 1 |
| Perez-Padilla, R | 1 |
| Jarvis, D | 1 |
| de Oliveira, PD | 1 |
| Wehrmeister, FC | 1 |
| Mir, S | 1 |
| Wong, J | 1 |
| Ryan, CM | 1 |
| Bellingham, G | 1 |
| Singh, M | 2 |
| Waseem, R | 1 |
| Eckert, DJ | 1 |
| Chung, F | 1 |
| Hegde, H | 1 |
| Shimpi, N | 1 |
| Panny, A | 1 |
| Glurich, I | 1 |
| Christie, P | 1 |
| Acharya, A | 1 |
| English, KL | 1 |
| Downs, M | 1 |
| Goetchius, E | 1 |
| Buxton, R | 1 |
| Ryder, JW | 1 |
| Ploutz-Snyder, R | 1 |
| Guilliams, M | 1 |
| Scott, JM | 1 |
| Ploutz-Snyder, LL | 1 |
| Martens, C | 1 |
| Goplen, FK | 1 |
| Aasen, T | 1 |
| Gjestad, R | 1 |
| Nordfalk, KF | 1 |
| Nordahl, SHG | 1 |
| Inoue, T | 1 |
| Soshi, S | 1 |
| Kubota, M | 1 |
| Marumo, K | 1 |
| Mortensen, NP | 1 |
| Caffaro, MM | 1 |
| Patel, PR | 2 |
| Uddin, MJ | 1 |
| Aravamudhan, S | 1 |
| Sumner, SJ | 1 |
| Fennell, TR | 1 |
| Gal, RL | 1 |
| Cohen, NJ | 1 |
| Kruger, D | 1 |
| Beck, RW | 1 |
| Bergenstal, RM | 1 |
| Calhoun, P | 1 |
| Cushman, T | 1 |
| Haban, A | 1 |
| Hood, K | 1 |
| Johnson, ML | 1 |
| McArthur, T | 1 |
| Olson, BA | 1 |
| Weinstock, RS | 1 |
| Oser, SM | 1 |
| Oser, TK | 1 |
| Bugielski, B | 1 |
| Strayer, H | 1 |
| Aleppo, G | 1 |
| Maruyama, H | 1 |
| Hirayama, K | 1 |
| Yamashita, M | 1 |
| Ohgi, K | 1 |
| Tsujimoto, R | 1 |
| Takayasu, M | 1 |
| Shimohata, H | 1 |
| Kobayashi, M | 1 |
| Buscagan, TM | 1 |
| Rees, DC | 1 |
| Jaborek, JR | 1 |
| Zerby, HN | 1 |
| Wick, MP | 1 |
| Fluharty, FL | 1 |
| Moeller, SJ | 1 |
| Razavi, P | 1 |
| Dickler, MN | 1 |
| Shah, PD | 1 |
| Toy, W | 1 |
| Brown, DN | 1 |
| Won, HH | 1 |
| Li, BT | 1 |
| Shen, R | 1 |
| Vasan, N | 1 |
| Modi, S | 1 |
| Jhaveri, K | 1 |
| Caravella, BA | 1 |
| Patil, S | 1 |
| Selenica, P | 1 |
| Zamora, S | 1 |
| Cowan, AM | 1 |
| Comen, E | 1 |
| Singh, A | 1 |
| Covey, A | 1 |
| Berger, MF | 1 |
| Hudis, CA | 1 |
| Norton, L | 1 |
| Nagy, RJ | 1 |
| Odegaard, JI | 1 |
| Lanman, RB | 1 |
| Solit, DB | 1 |
| Robson, ME | 1 |
| Lacouture, ME | 1 |
| Brogi, E | 1 |
| Reis-Filho, JS | 1 |
| Moynahan, ME | 1 |
| Scaltriti, M | 1 |
| Chandarlapaty, S | 1 |
| Papouskova, K | 1 |
| Moravcova, M | 1 |
| Masrati, G | 1 |
| Ben-Tal, N | 1 |
| Sychrova, H | 1 |
| Zimmermannova, O | 1 |
| Fang, J | 1 |
| Fan, Y | 1 |
| Luo, T | 2 |
| Su, H | 1 |
| Tsetseris, L | 1 |
| Anthopoulos, TD | 1 |
| Liu, SF | 1 |
| Zhao, K | 1 |
| Sacan, O | 1 |
| Turkyilmaz, IB | 1 |
| Bayrak, BB | 1 |
| Mutlu, O | 1 |
| Akev, N | 1 |
| Yanardag, R | 1 |
| Gruber, S | 1 |
| Kamnoedboon, P | 1 |
| Özcan, M | 1 |
| Srinivasan, M | 1 |
| Jo, YH | 1 |
| Oh, HK | 1 |
| Jeong, SY | 1 |
| Lee, BG | 1 |
| Zheng, J | 1 |
| Guan, H | 1 |
| Li, D | 2 |
| Tan, H | 1 |
| Maji, TK | 1 |
| J R, A | 1 |
| Mukherjee, S | 1 |
| Alexander, R | 1 |
| Mondal, A | 1 |
| Sharma, RK | 1 |
| Chakraborty, NK | 1 |
| Dasgupta, K | 1 |
| Sharma, AMR | 1 |
| Hawaldar, R | 1 |
| Pandey, M | 1 |
| Naik, A | 1 |
| Majumdar, K | 1 |
| Pal, SK | 1 |
| Adarsh, KV | 1 |
| Ray, SK | 1 |
| Karmakar, D | 1 |
| Ma, Y | 2 |
| Gao, W | 1 |
| Ma, S | 3 |
| Lin, W | 1 |
| Zhou, T | 1 |
| Wu, T | 1 |
| Wu, Q | 1 |
| Ye, C | 1 |
| He, X | 1 |
| Jiang, F | 1 |
| Yuan, D | 1 |
| Chen, Q | 2 |
| Hong, M | 1 |
| Chen, K | 2 |
| Hussain, M | 1 |
| Razi, SS | 1 |
| Yildiz, EA | 1 |
| Zhao, J | 1 |
| Yaglioglu, HG | 1 |
| Donato, MD | 1 |
| Jiang, J | 1 |
| Jamil, MI | 1 |
| Zhan, X | 1 |
| Chen, F | 1 |
| Cheng, D | 1 |
| Wu, CT | 1 |
| Utsunomiya, T | 1 |
| Ichii, T | 1 |
| Fujinami, S | 1 |
| Nakajima, K | 1 |
| Sanchez, DM | 1 |
| Raucci, U | 1 |
| Ferreras, KN | 1 |
| Martínez, TJ | 1 |
| Mordi, NA | 1 |
| Mordi, IR | 1 |
| Singh, JS | 1 |
| McCrimmon, RJ | 1 |
| Struthers, AD | 1 |
| Lang, CC | 1 |
| Wang, XW | 1 |
| Yuan, LJ | 1 |
| Yang, Y | 1 |
| Chen, WF | 1 |
| Luo, R | 1 |
| Yang, K | 1 |
| Amarasiri, SS | 1 |
| Attanayake, AP | 1 |
| Arawwawala, LDAM | 1 |
| Jayatilaka, KAPW | 1 |
| Mudduwa, LKB | 1 |
| Ogunsuyi, O | 2 |
| Akanni, O | 1 |
| Alabi, O | 1 |
| Alimba, C | 1 |
| Adaramoye, O | 1 |
| Cambier, S | 1 |
| Eswara, S | 1 |
| Gutleb, AC | 1 |
| Bakare, A | 1 |
| Gu, Z | 1 |
| Cong, J | 1 |
| Pellegrini, M | 1 |
| Palmieri, S | 1 |
| Ricci, A | 1 |
| Serio, A | 1 |
| Paparella, A | 1 |
| Lo Sterzo, C | 1 |
| Jadeja, SD | 1 |
| Vaishnav, J | 1 |
| Mansuri, MS | 1 |
| Shah, C | 1 |
| Mayatra, JM | 1 |
| Shah, A | 1 |
| Begum, R | 1 |
| Song, H | 2 |
| Lian, Y | 1 |
| Wan, T | 1 |
| Schultz-Lebahn, A | 1 |
| Skipper, MT | 1 |
| Hvas, AM | 1 |
| Larsen, OH | 1 |
| Hijazi, Z | 1 |
| Granger, CB | 1 |
| Hohnloser, SH | 1 |
| Westerbergh, J | 1 |
| Lindbäck, J | 1 |
| Alexander, JH | 1 |
| Keltai, M | 1 |
| Parkhomenko, A | 1 |
| López-Sendón, JL | 1 |
| Lopes, RD | 1 |
| Siegbahn, A | 1 |
| Wallentin, L | 1 |
| El-Tarabany, MS | 1 |
| Saleh, AA | 1 |
| El-Araby, IE | 1 |
| El-Magd, MA | 1 |
| van Ginkel, MPH | 1 |
| Schijven, MP | 1 |
| van Grevenstein, WMU | 1 |
| Schreuder, HWR | 1 |
| Pereira, EDM | 1 |
| da Silva, J | 1 |
| Carvalho, PDS | 1 |
| Grivicich, I | 1 |
| Picada, JN | 1 |
| Salgado Júnior, IB | 1 |
| Vasques, GJ | 1 |
| Pereira, MADS | 1 |
| Reginatto, FH | 1 |
| Ferraz, ABF | 1 |
| Vasilenko, EA | 1 |
| Gorshkova, EN | 1 |
| Astrakhantseva, IV | 1 |
| Drutskaya, MS | 1 |
| Tillib, SV | 1 |
| Nedospasov, SA | 1 |
| Mokhonov, VV | 1 |
| Nam, YW | 1 |
| Cui, M | 1 |
| Orfali, R | 1 |
| Viegas, A | 1 |
| Nguyen, M | 1 |
| Mohammed, EHM | 1 |
| Zoghebi, KA | 1 |
| Rahighi, S | 1 |
| Parang, K | 1 |
| Patterson, KC | 1 |
| Kahanovitch, U | 1 |
| Gonçalves, CM | 1 |
| Hablitz, JJ | 1 |
| Staruschenko, A | 1 |
| Mulkey, DK | 1 |
| Olsen, ML | 1 |
| Gu, L | 1 |
| Cao, X | 1 |
| Mukhtar, A | 1 |
| Wu, K | 1 |
| Zhang, YY | 1 |
| Zhu, Y | 1 |
| Lu, DZ | 1 |
| Dong, W | 1 |
| Bi, WJ | 1 |
| Feng, XJ | 1 |
| Wen, LM | 1 |
| Sun, H | 1 |
| Qi, MC | 1 |
| Chang, CC | 1 |
| Dinh, TK | 1 |
| Lee, YA | 1 |
| Wang, FN | 1 |
| Sung, YC | 1 |
| Yu, PL | 1 |
| Chiu, SC | 1 |
| Shih, YC | 1 |
| Wu, CY | 1 |
| Huang, YD | 1 |
| Lu, TT | 1 |
| Wan, D | 1 |
| Sakizadeh, J | 1 |
| Cline, JP | 1 |
| Snyder, MA | 1 |
| Kiely, CJ | 1 |
| McIntosh, S | 1 |
| Jiang, X | 1 |
| Cao, JW | 1 |
| Zhao, CK | 1 |
| Yang, R | 1 |
| Zhang, QY | 1 |
| Chen, KJ | 2 |
| Liu, H | 1 |
| He, Z | 1 |
| Chen, B | 2 |
| Wu, J | 1 |
| Du, X | 1 |
| Moore, J | 1 |
| Blank, BR | 1 |
| Eksterowicz, J | 1 |
| Sutimantanapi, D | 1 |
| Yuen, N | 1 |
| Metzger, T | 1 |
| Chan, B | 1 |
| Huang, T | 1 |
| Chen, X | 1 |
| Duong, F | 1 |
| Kong, W | 1 |
| Chang, JH | 3 |
| Sun, J | 2 |
| Zavorotinskaya, T | 1 |
| Ye, Q | 1 |
| Junttila, MR | 1 |
| Ndubaku, C | 1 |
| Friedman, LS | 1 |
| Fantin, VR | 1 |
| Sun, D | 1 |
| Fei, P | 1 |
| Xie, Q | 1 |
| Jiang, Y | 1 |
| Feng, H | 1 |
| Chang, Y | 1 |
| Kang, H | 1 |
| Xing, M | 1 |
| Chen, J | 2 |
| Shao, Z | 1 |
| Yuan, C | 1 |
| Wu, Y | 1 |
| Allan, R | 1 |
| Canham, K | 1 |
| Wallace, R | 1 |
| Singh, D | 1 |
| Ward, J | 1 |
| Cooper, A | 1 |
| Newcomb, C | 1 |
| Nammour, S | 1 |
| El Mobadder, M | 1 |
| Maalouf, E | 1 |
| Namour, M | 1 |
| Namour, A | 1 |
| Rey, G | 1 |
| Matamba, P | 1 |
| Matys, J | 1 |
| Zeinoun, T | 1 |
| Grzech-Leśniak, K | 1 |
| Segabinazi Peserico, C | 1 |
| Garozi, L | 1 |
| Zagatto, AM | 1 |
| Machado, FA | 1 |
| Hirth, JM | 1 |
| Dinehart, EE | 1 |
| Lin, YL | 1 |
| Kuo, YF | 1 |
| Nouri, SS | 1 |
| Ritchie, C | 1 |
| Volow, A | 1 |
| Li, B | 2 |
| McSpadden, S | 1 |
| Dearman, K | 1 |
| Kotwal, A | 1 |
| Sudore, RL | 1 |
| Ward, L | 1 |
| Thakur, A | 1 |
| Kondadasula, SV | 1 |
| Ji, K | 1 |
| Schalk, DL | 1 |
| Bliemeister, E | 1 |
| Ung, J | 1 |
| Aboukameel, A | 1 |
| Casarez, E | 1 |
| Sloane, BF | 1 |
| Lum, LG | 1 |
| Xiao, M | 1 |
| Feng, X | 1 |
| Gao, R | 1 |
| Du, B | 1 |
| Brooks, T | 1 |
| Zwirner, J | 1 |
| Hammer, N | 1 |
| Ondruschka, B | 1 |
| Jermy, M | 1 |
| Luengo, A | 1 |
| Marzo, I | 1 |
| Reback, M | 1 |
| Daubit, IM | 1 |
| Fernández-Moreira, V | 1 |
| Metzler-Nolte, N | 1 |
| Gimeno, MC | 1 |
| Tonchev, I | 1 |
| Heberman, D | 1 |
| Peretz, A | 1 |
| Medvedovsky, AT | 1 |
| Gotsman, I | 1 |
| Rashi, Y | 1 |
| Poles, L | 1 |
| Goland, S | 1 |
| Perlman, GY | 1 |
| Danenberg, HD | 1 |
| Beeri, R | 1 |
| Shuvy, M | 1 |
| Fu, Q | 1 |
| Yang, D | 1 |
| Sarapulova, A | 1 |
| Pang, Q | 1 |
| Meng, Y | 1 |
| Wei, L | 1 |
| Ehrenberg, H | 1 |
| Kim, CC | 1 |
| Jeong, SH | 1 |
| Oh, KH | 1 |
| Nam, KT | 1 |
| Sun, JY | 1 |
| Ning, J | 1 |
| Duan, Z | 1 |
| Kershaw, SV | 1 |
| Rogach, AL | 1 |
| Gao, Z | 1 |
| Wang, T | 1 |
| Li, Q | 2 |
| Cao, T | 1 |
| Guo, L | 1 |
| Fu, Y | 1 |
| Seeger, ZL | 1 |
| Izgorodina, EI | 1 |
| Hue, S | 1 |
| Beldi-Ferchiou, A | 1 |
| Bendib, I | 1 |
| Surenaud, M | 1 |
| Fourati, S | 1 |
| Frapard, T | 1 |
| Rivoal, S | 1 |
| Razazi, K | 1 |
| Carteaux, G | 1 |
| Delfau-Larue, MH | 1 |
| Mekontso-Dessap, A | 1 |
| Audureau, E | 1 |
| de Prost, N | 1 |
| Gao, SS | 1 |
| Duangthip, D | 1 |
| Lo, ECM | 1 |
| Chu, CH | 1 |
| Roberts, W | 1 |
| Rosenheck, RA | 1 |
| Miyake, T | 1 |
| Kimoto, E | 1 |
| Luo, L | 1 |
| Mathialagan, S | 1 |
| Horlbogen, LM | 1 |
| Ramanathan, R | 1 |
| Wood, LS | 1 |
| Johnson, JG | 1 |
| Le, VH | 1 |
| Vourvahis, M | 1 |
| Rodrigues, AD | 1 |
| Muto, C | 1 |
| Furihata, K | 1 |
| Sugiyama, Y | 1 |
| Kusuhara, H | 1 |
| Gong, Q | 1 |
| Song, W | 1 |
| Sun, B | 2 |
| Cao, P | 1 |
| Gu, S | 1 |
| Sun, X | 1 |
| Zhou, G | 1 |
| Toma, C | 1 |
| Khandhar, S | 1 |
| Zalewski, AM | 1 |
| D'Auria, SJ | 1 |
| Tu, TM | 1 |
| Jaber, WA | 1 |
| Cho, J | 2 |
| Suwandaratne, NS | 1 |
| Razek, S | 1 |
| Choi, YH | 1 |
| Piper, LFJ | 1 |
| Watson, DF | 1 |
| Banerjee, S | 1 |
| Xie, S | 1 |
| Lindsay, AP | 1 |
| Bates, FS | 1 |
| Lodge, TP | 1 |
| Hao, Y | 1 |
| Chapovetsky, A | 1 |
| Liu, JJ | 1 |
| Welborn, M | 1 |
| Luna, JM | 1 |
| Do, T | 1 |
| Haiges, R | 1 |
| Miller Iii, TF | 1 |
| Marinescu, SC | 1 |
| Lopez, SA | 1 |
| Compter, I | 1 |
| Eekers, DBP | 1 |
| Hoeben, A | 1 |
| Rouschop, KMA | 1 |
| Reymen, B | 1 |
| Ackermans, L | 1 |
| Beckervordersantforth, J | 1 |
| Bauer, NJC | 1 |
| Anten, MM | 1 |
| Wesseling, P | 3 |
| Postma, AA | 1 |
| De Ruysscher, D | 1 |
| Lambin, P | 1 |
| Qiang, L | 1 |
| Yang, S | 1 |
| Cui, YH | 1 |
| He, YY | 1 |
| Kumar, SK | 1 |
| Jacobus, SJ | 1 |
| Cohen, AD | 1 |
| Weiss, M | 1 |
| Callander, N | 1 |
| Singh, AK | 1 |
| Parker, TL | 1 |
| Menter, A | 1 |
| Parsons, B | 1 |
| Kumar, P | 1 |
| Kapoor, P | 1 |
| Rosenberg, A | 1 |
| Zonder, JA | 1 |
| Faber, E | 1 |
| Lonial, S | 1 |
| Anderson, KC | 1 |
| Richardson, PG | 1 |
| Orlowski, RZ | 1 |
| Wagner, LI | 1 |
| Rajkumar, SV | 1 |
| Li, G | 2 |
| Hou, G | 1 |
| Cui, J | 1 |
| Xie, H | 1 |
| Sun, Z | 1 |
| Fang, Z | 1 |
| Dunstand-Guzmán, E | 1 |
| Hallal-Calleros, C | 1 |
| Hernández-Velázquez, VM | 1 |
| Canales-Vargas, EJ | 1 |
| Domínguez-Roldan, R | 1 |
| Pedernera, M | 1 |
| Peña-Chora, G | 1 |
| Flores-Pérez, I | 1 |
| Kim, MJ | 1 |
| Han, C | 1 |
| White, K | 1 |
| Park, HJ | 1 |
| Ding, D | 1 |
| Boyd, K | 1 |
| Rothenberger, C | 1 |
| Bose, U | 1 |
| Carmichael, P | 1 |
| Linser, PJ | 1 |
| Tanokura, M | 1 |
| Salvi, R | 1 |
| Someya, S | 1 |
| Samuni, A | 1 |
| Goldstein, S | 1 |
| Divya, KP | 1 |
| Dharuman, V | 1 |
| Feng, J | 2 |
| Qian, Y | 1 |
| Cheng, Q | 1 |
| Ma, H | 1 |
| Ren, X | 1 |
| Wei, Q | 1 |
| Pan, W | 1 |
| Guo, J | 2 |
| Situ, B | 1 |
| An, T | 1 |
| Zheng, L | 1 |
| Augusto, S | 1 |
| Ratola, N | 1 |
| Tarín-Carrasco, P | 1 |
| Jiménez-Guerrero, P | 1 |
| Turco, M | 1 |
| Schuhmacher, M | 1 |
| Costa, S | 1 |
| Teixeira, JP | 1 |
| Costa, C | 1 |
| Syed, A | 1 |
| Marraiki, N | 1 |
| Al-Rashed, S | 1 |
| Elgorban, AM | 1 |
| Yassin, MT | 1 |
| Chankhanittha, T | 1 |
| Nanan, S | 1 |
| Sorokina, KN | 1 |
| Samoylova, YV | 1 |
| Gromov, NV | 1 |
| Ogorodnikova, OL | 1 |
| Parmon, VN | 1 |
| Ye, J | 1 |
| Liao, W | 1 |
| Zhang, P | 3 |
| Nabi, M | 1 |
| Cai, Y | 1 |
| Li, F | 1 |
| Alsbou, EM | 1 |
| Omari, KW | 1 |
| Adeosun, WA | 1 |
| Asiri, AM | 1 |
| Marwani, HM | 1 |
| Barral, M | 1 |
| Jemal-Turki, A | 1 |
| Beuvon, F | 1 |
| Soyer, P | 1 |
| Camparo, P | 1 |
| Cornud, F | 1 |
| Atwater, BD | 1 |
| Jones, WS | 1 |
| Loring, Z | 1 |
| Friedman, DJ | 1 |
| Namburath, M | 1 |
| Papirio, S | 1 |
| Moscariello, C | 1 |
| Di Costanzo, N | 1 |
| Pirozzi, F | 1 |
| Alappat, BJ | 1 |
| Sreekrishnan, TR | 1 |
| Volpin, F | 1 |
| Woo, YC | 1 |
| Freguia, S | 1 |
| Jeong, N | 1 |
| Choi, JS | 1 |
| Phuntsho, S | 1 |
| Shon, HK | 1 |
| Domínguez-Zambrano, E | 1 |
| Pedraza-Chaverri, J | 1 |
| López-Santos, AL | 1 |
| Medina-Campos, ON | 1 |
| Cruz-Rivera, C | 1 |
| Bueno-Hernández, F | 1 |
| Espinosa-Cuevas, A | 1 |
| Bulavaitė, A | 1 |
| Dalgediene, I | 1 |
| Michailoviene, V | 1 |
| Pleckaityte, M | 1 |
| Sauerbier, P | 1 |
| Köhler, R | 1 |
| Renner, G | 1 |
| Militz, H | 1 |
| Werner, JM | 1 |
| Weller, J | 1 |
| Ceccon, G | 1 |
| Schaub, C | 1 |
| Tscherpel, C | 1 |
| Lohmann, P | 1 |
| Bauer, EK | 1 |
| Schäfer, N | 2 |
| Stoffels, G | 1 |
| Baues, C | 1 |
| Celik, E | 1 |
| Marnitz, S | 1 |
| Kabbasch, C | 1 |
| Gielen, GH | 1 |
| Fink, GR | 2 |
| Langen, KJ | 2 |
| Herrlinger, U | 3 |
| Galldiks, N | 2 |
| Lania, A | 1 |
| Ferraù, F | 1 |
| Rubino, M | 1 |
| Modica, R | 1 |
| Colao, A | 1 |
| Faggiano, A | 1 |
| Li, XD | 1 |
| Wang, MJ | 1 |
| Zheng, JL | 1 |
| Wu, YH | 1 |
| Jiang, XB | 1 |
| Girot, P | 1 |
| Dumars, C | 1 |
| Mosnier, JF | 1 |
| Muzellec, L | 1 |
| Senellart, H | 1 |
| Foubert, F | 1 |
| Caroli-Bosc, FX | 1 |
| Cauchin, E | 1 |
| Regenet, N | 1 |
| Matysiak-Budnik, T | 1 |
| Touchefeu, Y | 1 |
| Blumenthal, DT | 2 |
| Gorlia, T | 4 |
| Gilbert, MR | 5 |
| Kim, MM | 1 |
| Burt Nabors, L | 1 |
| Mason, WP | 8 |
| Hegi, ME | 3 |
| Golfinopoulos, V | 2 |
| Perry, JR | 4 |
| Hyun Nam, D | 1 |
| Erridge, SC | 1 |
| Corn, BW | 1 |
| Mirimanoff, RO | 3 |
| Brown, PD | 3 |
| Baumert, BG | 3 |
| Mehta, MP | 4 |
| van den Bent, MJ | 10 |
| Reardon, DA | 4 |
| Weller, M | 8 |
| Stupp, R | 8 |
| Xu, B | 1 |
| Ye, MH | 1 |
| Lv, SG | 1 |
| Wang, QX | 1 |
| Wu, MJ | 1 |
| Xiao, B | 1 |
| Kang, CS | 1 |
| Zhu, XG | 1 |
| Lan, T | 1 |
| Fan, X | 1 |
| Zhan, Q | 1 |
| Yu, C | 1 |
| Trogrlić, I | 1 |
| Trogrlić, D | 1 |
| Trogrlić, Z | 1 |
| Wee, CW | 1 |
| Kim, E | 1 |
| Kim, TM | 9 |
| Park, CK | 9 |
| Kim, JW | 2 |
| Choi, SH | 10 |
| Yoo, RE | 4 |
| Lee, ST | 3 |
| Kim, IH | 8 |
| Pollom, EL | 1 |
| Fujimoto, D | 1 |
| Wynne, J | 1 |
| Seiger, K | 1 |
| Modlin, LA | 1 |
| Jacobs, LR | 1 |
| Azoulay, M | 1 |
| von Eyben, R | 1 |
| Tupper, L | 1 |
| Gibbs, IC | 1 |
| Hancock, SL | 1 |
| Chang, SD | 1 |
| Adler, JR | 1 |
| Harsh, GR | 1 |
| Harraher, C | 1 |
| Nagpal, S | 1 |
| Thomas, RP | 1 |
| Recht, LD | 1 |
| Choi, CYH | 1 |
| Soltys, SG | 1 |
| Saito, T | 1 |
| Sugiyama, K | 2 |
| Hama, S | 1 |
| Yamasaki, F | 1 |
| Takayasu, T | 1 |
| Nosaka, R | 1 |
| Onishi, S | 1 |
| Muragaki, Y | 1 |
| Kawamata, T | 1 |
| Kurisu, K | 1 |
| Raj, N | 1 |
| Klimstra, DS | 1 |
| Horvat, N | 1 |
| Chou, JF | 1 |
| Capanu, M | 1 |
| Basturk, O | 1 |
| Do, RKG | 1 |
| Allen, PJ | 1 |
| Reidy-Lagunes, D | 1 |
| Park, JE | 2 |
| Ryu, KH | 1 |
| Kim, HS | 3 |
| Kim, HW | 1 |
| Shim, WH | 3 |
| Jung, SC | 2 |
| Choi, CG | 2 |
| Kim, SJ | 3 |
| Kim, JH | 13 |
| Parasramka, S | 1 |
| Talari, G | 1 |
| Rosenfeld, M | 1 |
| Villano, JL | 1 |
| Badruddoja, MA | 1 |
| Pazzi, M | 1 |
| Sanan, A | 1 |
| Schroeder, K | 1 |
| Kuzma, K | 1 |
| Norton, T | 1 |
| Scully, T | 1 |
| Mahadevan, D | 1 |
| Ahmadi, MM | 1 |
| Chaskis, E | 1 |
| Minichini, V | 1 |
| Luce, S | 1 |
| Devriendt, D | 1 |
| Goldman, S | 1 |
| De Witte, O | 1 |
| Sadeghi, N | 1 |
| Lefranc, F | 2 |
| Shiraki, Y | 1 |
| Mii, S | 1 |
| Enomoto, A | 1 |
| Momota, H | 1 |
| Han, YP | 1 |
| Kato, T | 1 |
| Ushida, K | 1 |
| Kato, A | 1 |
| Asai, N | 1 |
| Murakumo, Y | 1 |
| Aoki, K | 1 |
| Suzuki, H | 1 |
| Ohka, F | 1 |
| Wakabayashi, T | 1 |
| Todo, T | 2 |
| Ogawa, S | 1 |
| Natsume, A | 1 |
| Nowosielski, M | 2 |
| Ellingson, BM | 1 |
| Chinot, OL | 4 |
| Garcia, J | 2 |
| Revil, C | 2 |
| Radbruch, A | 1 |
| Nishikawa, R | 5 |
| Henriksson, R | 5 |
| Saran, F | 5 |
| Kickingereder, P | 1 |
| Platten, M | 4 |
| Sandmann, T | 1 |
| Abrey, LE | 4 |
| Cloughesy, TF | 3 |
| Bendszus, M | 2 |
| Wick, W | 14 |
| Adeberg, S | 2 |
| Bernhardt, D | 2 |
| Harrabi, SB | 1 |
| Uhl, M | 1 |
| Paul, A | 1 |
| Bougatf, N | 1 |
| Verma, V | 1 |
| Unterberg, A | 1 |
| Haberer, T | 1 |
| Combs, SE | 3 |
| Herfarth, K | 1 |
| Debus, J | 4 |
| Rieken, S | 2 |
| Nam, JG | 1 |
| Kang, KM | 1 |
| Lim, WH | 1 |
| Yun, TJ | 4 |
| Sohn, CH | 5 |
| Shi, W | 2 |
| Scannell Bryan, M | 1 |
| Valeinis, E | 1 |
| Hopkins, K | 1 |
| Souhami, L | 1 |
| Andrews, DW | 1 |
| Tzuk-Shina, T | 1 |
| Howard, SP | 1 |
| Youssef, EF | 1 |
| Lessard, N | 1 |
| Dignam, JJ | 2 |
| Werner-Wasik, M | 1 |
| Perry, LA | 1 |
| Korfiatis, P | 1 |
| Agrawal, JP | 1 |
| Erickson, BJ | 1 |
| Bupathi, M | 1 |
| Hays, JL | 1 |
| Chen, JL | 1 |
| Izquierdo, C | 1 |
| Alentorn, A | 2 |
| Idbaih, A | 3 |
| Simó, M | 1 |
| Kaloshi, G | 3 |
| Ricard, D | 2 |
| Barritault, M | 1 |
| Meyronet, D | 1 |
| Bruna, J | 1 |
| Honnorat, J | 4 |
| Delattre, JY | 5 |
| Ducray, F | 2 |
| Puente, P | 1 |
| Fettig, N | 1 |
| Luderer, MJ | 1 |
| Jin, A | 1 |
| Shah, S | 1 |
| Muz, B | 1 |
| Kapoor, V | 1 |
| Goddu, SM | 1 |
| Salama, NN | 1 |
| Tsien, C | 2 |
| Thotala, D | 1 |
| Shoghi, K | 1 |
| Rogers, B | 1 |
| Azab, AK | 1 |
| Jensen, KV | 1 |
| Cseh, O | 1 |
| Aman, A | 1 |
| Weiss, S | 1 |
| Luchman, HA | 1 |
| Mehrabian, H | 1 |
| Myrehaug, S | 1 |
| Soliman, H | 1 |
| Sahgal, A | 4 |
| Stanisz, GJ | 1 |
| Choi, S | 1 |
| Yu, Y | 1 |
| Grimmer, MR | 1 |
| Wahl, M | 2 |
| Chang, SM | 8 |
| Costello, JF | 3 |
| Yusuf, M | 1 |
| Ugiliweneza, B | 1 |
| Amsbaugh, M | 1 |
| Boakye, M | 1 |
| Williams, B | 1 |
| Nelson, M | 1 |
| Hattab, EM | 1 |
| Woo, S | 1 |
| Burton, E | 1 |
| Kim, JY | 1 |
| Jo, Y | 1 |
| Nam, SJ | 1 |
| Azambuja, JH | 1 |
| Gelsleichter, NE | 1 |
| Beckenkamp, LR | 1 |
| Iser, IC | 1 |
| Fernandes, MC | 1 |
| Figueiró, F | 1 |
| Battastini, AMO | 1 |
| Scholl, JN | 1 |
| de Oliveira, FH | 1 |
| Spanevello, RM | 1 |
| Sévigny, J | 1 |
| Wink, MR | 1 |
| Stefani, MA | 1 |
| Teixeira, HF | 1 |
| Braganhol, E | 1 |
| Jin, T | 1 |
| Zhou, Y | 1 |
| Eisemann, T | 1 |
| Costa, B | 1 |
| Harter, PN | 1 |
| Mittelbronn, M | 1 |
| Angel, P | 1 |
| Peterziel, H | 1 |
| Dworkin, M | 1 |
| Mehan, W | 1 |
| Niemierko, A | 1 |
| Kamran, SC | 1 |
| Lamba, N | 1 |
| Dietrich, J | 2 |
| Martinez-Lage, M | 2 |
| Oh, KS | 1 |
| Batchelor, TT | 5 |
| Wen, PY | 7 |
| Loeffler, JS | 1 |
| Shih, HA | 1 |
| Huang, K | 1 |
| Wei, C | 1 |
| Zhou, J | 1 |
| Zhang, W | 3 |
| Liang, H | 1 |
| Wang, G | 3 |
| Zhen, Y | 1 |
| Han, L | 1 |
| Nazha, B | 1 |
| Owonikoko, TK | 1 |
| Winter, SF | 1 |
| Loebel, F | 1 |
| Loeffler, J | 1 |
| Vajkoczy, P | 2 |
| Fu, T | 1 |
| Gao, M | 1 |
| van Leyen, K | 1 |
| Roelcke, U | 1 |
| Gruber, P | 1 |
| Remonda, L | 1 |
| Berberat, J | 2 |
| Fujita, M | 1 |
| Yamamoto, T | 1 |
| Iyoda, T | 1 |
| Fujisawa, T | 1 |
| Sasada, M | 1 |
| Nagai, R | 1 |
| Kudo, C | 1 |
| Otsuka, K | 1 |
| Kamiya, S | 1 |
| Kodama, H | 1 |
| Fukai, F | 1 |
| Yu, L | 1 |
| Gui, S | 1 |
| Qiu, X | 1 |
| Zhang, G | 1 |
| Pan, J | 1 |
| Fan, J | 1 |
| Qi, S | 1 |
| Qiu, B | 1 |
| Agarwal, A | 1 |
| Kumar, S | 1 |
| Narang, J | 1 |
| Schultz, L | 1 |
| Mikkelsen, T | 2 |
| Siddiqui, S | 1 |
| Poptani, H | 1 |
| Jain, R | 1 |
| Kruser, TJ | 1 |
| Robins, HI | 4 |
| Massimino, M | 1 |
| Casanova, M | 1 |
| Polastri, D | 1 |
| Biassoni, V | 1 |
| Modena, P | 1 |
| Pecori, E | 1 |
| Schiavello, E | 1 |
| De Pava, MV | 1 |
| Indini, A | 1 |
| Rampini, P | 2 |
| Bauer, D | 1 |
| Catania, S | 1 |
| Podda, M | 1 |
| Gandola, L | 1 |
| Minniti, G | 2 |
| Scaringi, C | 2 |
| Baldoni, A | 1 |
| Lanzetta, G | 2 |
| De Sanctis, V | 2 |
| Esposito, V | 1 |
| Enrici, RM | 2 |
| Niibori-Nambu, A | 1 |
| Midorikawa, U | 1 |
| Mizuguchi, S | 1 |
| Hide, T | 1 |
| Nagai, M | 1 |
| Komohara, Y | 1 |
| Nagayama, M | 1 |
| Hirayama, M | 1 |
| Kobayashi, D | 1 |
| Tsubota, N | 1 |
| Takezaki, T | 1 |
| Makino, K | 1 |
| Nakamura, H | 1 |
| Takeya, M | 1 |
| Kuratsu, J | 1 |
| Araki, N | 1 |
| Chu, HH | 1 |
| Ryoo, I | 1 |
| Kim, SC | 1 |
| Yeom, JA | 1 |
| Shin, H | 1 |
| Lee, AL | 1 |
| Yoon, TJ | 1 |
| Lee, SH | 8 |
| Park, SH | 6 |
| Teimouri, F | 1 |
| Nikfar, S | 1 |
| Abdollahi, M | 1 |
| DI Cristofori, A | 1 |
| Carrabba, G | 1 |
| Lanfranchi, G | 1 |
| Menghetti, C | 1 |
| Caroli, M | 2 |
| Zustovich, F | 1 |
| Landi, L | 1 |
| Lombardi, G | 1 |
| Porta, C | 1 |
| Galli, L | 1 |
| Fontana, A | 1 |
| Amoroso, D | 1 |
| Galli, C | 1 |
| Andreuccetti, M | 1 |
| Falcone, A | 1 |
| Zagonel, V | 1 |
| Tejada, S | 1 |
| Aldave, G | 1 |
| Marigil, M | 1 |
| Gállego Pérez-Larraya, J | 1 |
| de Gallego, J | 1 |
| Domínguez, PD | 1 |
| Díez-Valle, R | 1 |
| Juratli, TA | 1 |
| Engellandt, K | 1 |
| Lautenschlaeger, T | 1 |
| Geiger, KD | 1 |
| von Kummer, R | 1 |
| Cerhova, J | 1 |
| Chakravarti, A | 1 |
| Krex, D | 2 |
| Schackert, G | 1 |
| Pinho, MC | 1 |
| Polaskova, P | 1 |
| Kalpathy-Cramer, J | 1 |
| Jennings, D | 1 |
| Emblem, KE | 1 |
| Jain, RK | 1 |
| Rosen, BR | 1 |
| Sorensen, AG | 1 |
| Gerstner, ER | 2 |
| Eisele, G | 1 |
| Wick, A | 5 |
| Eisele, AC | 1 |
| Clément, PM | 1 |
| Tonn, J | 1 |
| Tabatabai, G | 1 |
| Ochsenbein, A | 1 |
| Schlegel, U | 1 |
| Neyns, B | 2 |
| Simon, M | 2 |
| Nikkhah, G | 1 |
| Picard, M | 1 |
| Walker, MS | 1 |
| Reyes, C | 1 |
| Kerr, J | 1 |
| Satram-Hoang, S | 1 |
| Stepanski, EJ | 1 |
| Melchardt, T | 1 |
| Magnes, T | 1 |
| Weiss, L | 1 |
| Grundbichler, M | 1 |
| Strasser, M | 1 |
| Hufnagl, C | 1 |
| Moik, M | 1 |
| Greil, R | 1 |
| Egle, A | 1 |
| Bozzao, A | 1 |
| Romano, A | 1 |
| Valeriani, M | 1 |
| Osti, M | 1 |
| Olson, JJ | 1 |
| Nayak, L | 1 |
| Ormond, DR | 1 |
| Kalkanis, SN | 1 |
| Carvajal, RD | 1 |
| Sosman, JA | 1 |
| Quevedo, JF | 1 |
| Milhem, MM | 1 |
| Joshua, AM | 1 |
| Kudchadkar, RR | 1 |
| Linette, GP | 1 |
| Gajewski, TF | 1 |
| Lutzky, J | 1 |
| Lawson, DH | 1 |
| Lao, CD | 1 |
| Flynn, PJ | 1 |
| Albertini, MR | 1 |
| Sato, T | 1 |
| Lewis, K | 1 |
| Doyle, A | 1 |
| Ancell, K | 1 |
| Panageas, KS | 2 |
| Bluth, M | 1 |
| Hedvat, C | 1 |
| Erinjeri, J | 1 |
| Ambrosini, G | 1 |
| Marr, B | 1 |
| Abramson, DH | 1 |
| Dickson, MA | 1 |
| Wolchok, JD | 1 |
| Chapman, PB | 1 |
| Schwartz, GK | 1 |
| Muruganandham, M | 1 |
| Clerkin, PP | 1 |
| Smith, BJ | 1 |
| Anderson, CM | 1 |
| Morris, A | 1 |
| Capizzano, AA | 1 |
| Magnotta, V | 1 |
| McGuire, SM | 1 |
| Smith, MC | 1 |
| Bayouth, JE | 1 |
| Buatti, JM | 1 |
| Mansour, J | 1 |
| Fields, B | 1 |
| Macomson, S | 1 |
| Rixe, O | 1 |
| Oh, T | 1 |
| Rutkowski, MJ | 1 |
| Safaee, M | 1 |
| Sun, MZ | 1 |
| Sayegh, ET | 1 |
| Bloch, O | 1 |
| Tihan, T | 1 |
| Parsa, AT | 1 |
| Nagaishi, M | 1 |
| Sugiura, Y | 1 |
| Takano, I | 1 |
| Tanaka, Y | 1 |
| Suzuki, K | 1 |
| Yokoo, H | 1 |
| Hyodo, A | 1 |
| Ajlan, A | 1 |
| Recht, L | 1 |
| Brynolfsson, P | 1 |
| Nilsson, D | 1 |
| Hauksson, J | 1 |
| Karlsson, M | 1 |
| Garpebring, A | 1 |
| Birgander, R | 1 |
| Trygg, J | 1 |
| Nyholm, T | 1 |
| Asklund, T | 1 |
| Rocha, CR | 1 |
| Garcia, CC | 1 |
| Vieira, DB | 1 |
| Quinet, A | 1 |
| de Andrade-Lima, LC | 1 |
| Munford, V | 1 |
| Belizário, JE | 1 |
| Menck, CF | 1 |
| Du, W | 1 |
| Dou, Z | 1 |
| Chang, L | 1 |
| Yi, L | 2 |
| Cai, J | 2 |
| Jiang, C | 2 |
| Breshears, JD | 1 |
| Ivan, ME | 1 |
| Cotter, JA | 1 |
| Bollen, AW | 1 |
| Theodosopoulos, PV | 1 |
| Berger, MS | 3 |
| Hirohata, T | 1 |
| Ishii, Y | 1 |
| Matsuno, A | 1 |
| Rizzo, D | 2 |
| Scalzone, M | 1 |
| Ruggiero, A | 2 |
| Maurizi, P | 1 |
| Attinà, G | 1 |
| Mastrangelo, S | 1 |
| Lazzareschi, I | 2 |
| Ridola, V | 2 |
| Colosimo, C | 1 |
| Caldarelli, M | 1 |
| Balducci, M | 2 |
| Riccardi, R | 2 |
| Prager, AJ | 1 |
| Martinez, N | 1 |
| Beal, K | 2 |
| Omuro, A | 1 |
| Young, RJ | 2 |
| Kim, HR | 1 |
| Kim, KH | 1 |
| Kong, DS | 1 |
| Seol, HJ | 2 |
| Nam, DH | 3 |
| Lim, DH | 2 |
| Lee, JI | 1 |
| Wang, M | 1 |
| Won, M | 1 |
| Curran, W | 1 |
| Mehta, M | 3 |
| van Thuijl, HF | 1 |
| Mazor, T | 1 |
| Johnson, BE | 1 |
| Fouse, SD | 1 |
| Aihara, K | 1 |
| Hong, C | 1 |
| Malmström, A | 1 |
| Hallbeck, M | 1 |
| Heimans, JJ | 1 |
| Kloezeman, JJ | 1 |
| Stenmark-Askmalm, M | 1 |
| Lamfers, ML | 1 |
| Saito, N | 2 |
| Aburatani, H | 1 |
| Mukasa, A | 1 |
| Söderkvist, P | 1 |
| Taylor, BS | 1 |
| Molinaro, AM | 2 |
| Reijneveld, JC | 2 |
| Ylstra, B | 1 |
| Favero, F | 1 |
| McGranahan, N | 1 |
| Salm, M | 1 |
| Birkbak, NJ | 1 |
| Sanborn, JZ | 1 |
| Benz, SC | 1 |
| Becq, J | 1 |
| Peden, JF | 1 |
| Kingsbury, Z | 1 |
| Grocok, RJ | 1 |
| Humphray, S | 1 |
| Bentley, D | 1 |
| Spencer-Dene, B | 1 |
| Gutteridge, A | 1 |
| Brada, M | 4 |
| Roger, S | 1 |
| Dietrich, PY | 1 |
| Forshew, T | 1 |
| Gerlinger, M | 1 |
| Rowan, A | 1 |
| Stamp, G | 1 |
| Eklund, AC | 1 |
| Szallasi, Z | 1 |
| Swanton, C | 1 |
| Turner, KM | 1 |
| Ji, P | 1 |
| Granberg, KJ | 1 |
| Bernard, B | 1 |
| Hu, L | 1 |
| Cogdell, DE | 1 |
| Yli-Harja, O | 1 |
| Nykter, M | 1 |
| Shmulevich, I | 1 |
| Yung, WK | 7 |
| Fuller, GN | 1 |
| Nagane, M | 1 |
| Hashimoto, N | 2 |
| Tsuboi, A | 1 |
| Kagawa, N | 1 |
| Chiba, Y | 1 |
| Izumoto, S | 1 |
| Kinoshita, M | 1 |
| Kijima, N | 1 |
| Oka, Y | 1 |
| Morimoto, S | 1 |
| Nakajima, H | 1 |
| Morita, S | 1 |
| Sakamoto, J | 1 |
| Nishida, S | 1 |
| Hosen, N | 1 |
| Oji, Y | 1 |
| Arita, N | 1 |
| Yoshimine, T | 1 |
| Sugiyama, H | 1 |
| Liu, JK | 1 |
| Patel, J | 1 |
| Eloy, JA | 1 |
| Sonoda, Y | 1 |
| Kazda, T | 1 |
| Pospisil, P | 1 |
| Vrzal, M | 1 |
| Sevela, O | 1 |
| Prochazka, T | 1 |
| Jancalek, R | 1 |
| Slampa, P | 1 |
| Laack, NN | 1 |
| Schiff, D | 4 |
| Tabouret, E | 1 |
| Tchoghandjian, A | 1 |
| Denicolai, E | 1 |
| Delfino, C | 1 |
| Metellus, P | 1 |
| Graillon, T | 1 |
| Boucard, C | 1 |
| Nanni, I | 1 |
| Padovani, L | 1 |
| Ouafik, L | 1 |
| Figarella-Branger, D | 2 |
| Chinot, O | 7 |
| Kovic, B | 1 |
| Xie, F | 1 |
| Taphoorn, MJ | 5 |
| Bottomley, A | 1 |
| Cloughesy, T | 4 |
| Hilton, M | 1 |
| Theodore-Oklota, C | 1 |
| Ravelo, A | 1 |
| Yahyanejad, S | 1 |
| van Hoof, SJ | 1 |
| Theys, J | 1 |
| Barbeau, LM | 1 |
| Granton, PV | 1 |
| Paesmans, K | 1 |
| Verhaegen, F | 1 |
| Vooijs, M | 1 |
| Krauze, AV | 1 |
| Myrehaug, SD | 1 |
| Chang, MG | 1 |
| Holdford, DJ | 1 |
| Smith, S | 1 |
| Shih, J | 1 |
| Tofilon, PJ | 1 |
| Fine, HA | 1 |
| Camphausen, K | 1 |
| Kerschbaumer, J | 1 |
| Schmidt, FA | 1 |
| Grams, AE | 1 |
| Pinggera, D | 1 |
| Brawanski, KR | 1 |
| Petr, O | 1 |
| Thomé, C | 4 |
| Tuettenberg, J | 5 |
| Seiz, M | 5 |
| Freyschlag, CF | 4 |
| Thomas, AA | 1 |
| Arevalo-Perez, J | 1 |
| Kaley, T | 1 |
| Lyo, J | 1 |
| Peck, KK | 1 |
| Ben Harrabi, S | 1 |
| Bostel, T | 1 |
| Mohr, A | 1 |
| Koelsche, C | 1 |
| Diehl, C | 1 |
| Dullea, A | 1 |
| Marignol, L | 1 |
| Campderá, M | 1 |
| Palacios, N | 1 |
| Aller, J | 1 |
| Magallón, R | 1 |
| Martín, P | 1 |
| Saucedo, G | 1 |
| Lilienfeld, H | 1 |
| Estrada, J | 1 |
| Taillibert, S | 2 |
| Kanner, AA | 1 |
| Kesari, S | 2 |
| Steinberg, DM | 1 |
| Toms, SA | 1 |
| Taylor, LP | 1 |
| Lieberman, F | 2 |
| Silvani, A | 3 |
| Fink, KL | 2 |
| Barnett, GH | 1 |
| Zhu, JJ | 1 |
| Henson, JW | 1 |
| Engelhard, HH | 1 |
| Chen, TC | 2 |
| Tran, DD | 1 |
| Sroubek, J | 1 |
| Tran, ND | 1 |
| Hottinger, AF | 1 |
| Landolfi, J | 1 |
| Desai, R | 1 |
| Kew, Y | 1 |
| Kirson, ED | 1 |
| Weinberg, U | 1 |
| Palti, Y | 1 |
| Ram, Z | 1 |
| Mason, W | 2 |
| Dhar, S | 1 |
| Pozzi, E | 1 |
| Kushal, S | 1 |
| Vaikari, VP | 1 |
| Kota, R | 1 |
| Yeh, TS | 1 |
| Jhaveri, N | 1 |
| Groshen, SL | 1 |
| Olenyuk, BZ | 1 |
| Hofman, FM | 1 |
| Shih, JC | 1 |
| DuBois, SG | 1 |
| Marachelian, A | 1 |
| Fox, E | 1 |
| Kudgus, RA | 1 |
| Reid, JM | 1 |
| Groshen, S | 2 |
| Malvar, J | 1 |
| Bagatell, R | 1 |
| Wagner, L | 1 |
| Maris, JM | 1 |
| Hawkins, R | 1 |
| Courtier, J | 1 |
| Lai, H | 1 |
| Goodarzian, F | 1 |
| Shimada, H | 1 |
| Czarnecki, S | 1 |
| Tsao-Wei, D | 1 |
| Matthay, KK | 1 |
| Mosse, YP | 1 |
| Khasraw, M | 1 |
| Lee, A | 1 |
| McCowatt, S | 1 |
| Kerestes, Z | 1 |
| Buyse, ME | 1 |
| Back, M | 2 |
| Kichenadasse, G | 1 |
| Ackland, S | 1 |
| Wheeler, H | 1 |
| Li, R | 1 |
| Feng, Y | 1 |
| Tian, Y | 1 |
| Carceller, F | 1 |
| Fowkes, LA | 1 |
| Khabra, K | 1 |
| Moreno, L | 1 |
| Burford, A | 1 |
| Mackay, A | 1 |
| Jones, DT | 1 |
| Hovestadt, V | 1 |
| Marshall, LV | 1 |
| Vaidya, S | 1 |
| Mandeville, H | 1 |
| Jerome, N | 1 |
| Bridges, LR | 1 |
| Laxton, R | 1 |
| Al-Sarraj, S | 1 |
| Pfister, SM | 1 |
| Leach, MO | 1 |
| Pearson, AD | 1 |
| Jones, C | 1 |
| Koh, DM | 1 |
| Zacharoulis, S | 1 |
| Hernandez-Lain, A | 1 |
| Hilario, A | 1 |
| Sepulveda, JM | 1 |
| Cantero, D | 1 |
| Ramos, A | 1 |
| Perez-Nuñez, A | 1 |
| Kim, BS | 1 |
| Cho, YH | 1 |
| Yoon, SM | 1 |
| Kang, SG | 1 |
| Kim, EH | 1 |
| Suh, CO | 2 |
| Jung, TY | 1 |
| Lee, KH | 1 |
| Kim, CY | 4 |
| Kim, IA | 3 |
| Hong, CK | 1 |
| Yoo, H | 1 |
| Kang, SH | 1 |
| Kang, MK | 1 |
| Kim, EY | 1 |
| Kim, SH | 4 |
| Chung, DS | 1 |
| Hwang, SC | 1 |
| Song, JH | 1 |
| Cho, SJ | 1 |
| Lee, SI | 1 |
| Lee, YS | 1 |
| Ahn, KJ | 1 |
| Gwak, HS | 1 |
| Hong, YK | 1 |
| Hertenstein, A | 2 |
| Hielscher, T | 1 |
| Menn, O | 1 |
| Wiestler, B | 1 |
| Winkler, F | 2 |
| Kim, C | 1 |
| Lemke, D | 1 |
| Pledl, HW | 1 |
| Zorn, M | 1 |
| Jugold, M | 1 |
| Green, E | 1 |
| Blaes, J | 1 |
| Löw, S | 1 |
| Ott, M | 1 |
| Sahm, F | 1 |
| Steffen, AC | 1 |
| Weiler, M | 1 |
| Kerloeguen, Y | 1 |
| Phillips, JJ | 1 |
| Lin, Y | 1 |
| Perry, A | 1 |
| Haas-Kogan, DA | 1 |
| Dayal, M | 1 |
| Butowski, N | 2 |
| Clarke, JL | 3 |
| Prados, M | 5 |
| Nelson, S | 1 |
| Hattermann, K | 1 |
| Flüh, C | 1 |
| Engel, D | 1 |
| Mehdorn, HM | 1 |
| Synowitz, M | 1 |
| Mentlein, R | 1 |
| Held-Feindt, J | 1 |
| Cheng, G | 1 |
| Kim, BR | 1 |
| Park, SW | 1 |
| Yang, JK | 1 |
| Yang, JP | 1 |
| Tong, J | 1 |
| Jing, SY | 1 |
| Fan, B | 1 |
| Sun, GZ | 1 |
| Jiao, BH | 1 |
| Dai, C | 1 |
| Feng, M | 1 |
| Bao, X | 1 |
| Deng, K | 1 |
| Xing, B | 1 |
| Lian, W | 1 |
| Zhong, D | 1 |
| Ma, W | 2 |
| Wang, R | 2 |
| Ollier, E | 1 |
| Mazzocco, P | 1 |
| Psimaras, D | 1 |
| Grenier, E | 1 |
| Samson, A | 1 |
| Chang, JS | 1 |
| Cho, JH | 1 |
| Bogdańska, MU | 1 |
| Bodnar, M | 1 |
| Belmonte-Beitia, J | 1 |
| Murek, M | 1 |
| Schucht, P | 1 |
| Beck, J | 1 |
| Pérez-García, VM | 1 |
| Laperriere, N | 1 |
| O'Callaghan, CJ | 1 |
| Brandes, AA | 7 |
| Menten, J | 2 |
| Phillips, C | 1 |
| Fay, M | 1 |
| Cairncross, JG | 5 |
| Roa, W | 1 |
| Osoba, D | 3 |
| Rossiter, JP | 1 |
| Hirte, H | 1 |
| Laigle-Donadey, F | 1 |
| Franceschi, E | 3 |
| Fariselli, L | 1 |
| Feuvret, L | 1 |
| Tills, M | 1 |
| Winch, C | 1 |
| Ding, K | 1 |
| Bracht, LK | 1 |
| Wen, P | 1 |
| Meyerhardt, JA | 1 |
| Kulke, MH | 1 |
| Hornick, JL | 1 |
| Redston, M | 1 |
| LaFrankie, DC | 1 |
| Black, PM | 1 |
| Norden, A | 1 |
| Drappatz, J | 1 |
| Lee, IH | 1 |
| Piert, M | 1 |
| Gomez-Hassan, D | 1 |
| Junck, L | 2 |
| Rogers, L | 1 |
| Hayman, J | 1 |
| Ten Haken, RK | 1 |
| Lawrence, TS | 1 |
| Krishnan, S | 1 |
| Sarkaria, JN | 1 |
| Jaeckle, KA | 3 |
| Uhm, JH | 1 |
| Geoffroy, FJ | 1 |
| Arusell, R | 1 |
| Kitange, G | 1 |
| Jenkins, RB | 1 |
| Kugler, JW | 1 |
| Morton, RF | 1 |
| Rowland, KM | 1 |
| Mischel, P | 1 |
| Yong, WH | 1 |
| Scheithauer, BW | 1 |
| Giannini, C | 1 |
| Buckner, JC | 1 |
| Chaskis, C | 1 |
| Michotte, A | 1 |
| De Ridder, M | 1 |
| Everaert, H | 1 |
| McNamara, MB | 1 |
| Norden, AD | 1 |
| Lafrankie, D | 1 |
| Pascher, C | 1 |
| Jauch, T | 1 |
| Bogdahn, U | 3 |
| Hau, P | 2 |
| Mathieu, V | 1 |
| Pirker, C | 1 |
| Martin de Lassalle, E | 1 |
| Vernier, M | 1 |
| Mijatovic, T | 1 |
| DeNeve, N | 1 |
| Gaussin, JF | 1 |
| Dehoux, M | 1 |
| Berger, W | 1 |
| Kiss, R | 1 |
| Cahill, DP | 2 |
| Codd, PJ | 2 |
| Curry, WT | 2 |
| Louis, DN | 3 |
| Janzer, RC | 2 |
| Ludwin, SK | 2 |
| Allgeier, A | 3 |
| Fisher, B | 2 |
| Belanger, K | 3 |
| Gijtenbeek, J | 1 |
| Marosi, C | 2 |
| Vecht, CJ | 2 |
| Mokhtari, K | 3 |
| Villa, S | 1 |
| Eisenhauer, E | 3 |
| Lacombe, D | 2 |
| Watson, AJ | 3 |
| Middleton, MR | 4 |
| McGown, G | 1 |
| Thorncroft, M | 1 |
| Ranson, M | 4 |
| Hersey, P | 2 |
| McArthur, G | 1 |
| Davis, ID | 2 |
| Thomson, D | 1 |
| Beith, J | 2 |
| Haydon, A | 2 |
| Kefford, R | 1 |
| Lorigan, P | 2 |
| Mortimer, P | 3 |
| Sabharwal, A | 2 |
| Hayward, O | 1 |
| Margison, GP | 3 |
| Iwamoto, FM | 2 |
| Sul, J | 1 |
| Panageas, K | 1 |
| Lassman, AB | 4 |
| DeAngelis, LM | 3 |
| Hormigo, A | 1 |
| Nolan, CP | 1 |
| Gavrilovic, I | 1 |
| Karimi, S | 1 |
| Maire, F | 1 |
| Hammel, P | 1 |
| Faivre, S | 3 |
| Hentic, O | 1 |
| Yapur, L | 1 |
| Larroque, B | 1 |
| Couvelard, A | 1 |
| Zappa, M | 1 |
| Raymond, E | 3 |
| Lévy, P | 1 |
| Ruszniewski, P | 1 |
| Fabi, A | 1 |
| Russillo, M | 1 |
| Metro, G | 1 |
| Vidiri, A | 2 |
| Di Giovanni, S | 1 |
| Cognetti, F | 1 |
| Jalali, R | 1 |
| Raut, N | 1 |
| Arora, B | 1 |
| Gupta, T | 1 |
| Dutta, D | 1 |
| Munshi, A | 1 |
| Sarin, R | 1 |
| Kurkure, P | 1 |
| Kohlhof, P | 1 |
| Brockmann, MA | 1 |
| Neumaier-Probst, E | 1 |
| Hermes, P | 1 |
| VON Deimling, A | 2 |
| Schmieder, K | 4 |
| D'Agostino, GR | 1 |
| Manfrida, S | 1 |
| De Renzi, F | 1 |
| Colicchio, G | 1 |
| Apicella, G | 1 |
| Mangiola, A | 1 |
| Fiorentino, A | 1 |
| Frascino, V | 1 |
| Mantini, G | 1 |
| De Bari, B | 1 |
| Pompucci, A | 1 |
| Valentini, V | 1 |
| Anile, C | 1 |
| Cellini, N | 1 |
| Brandsma, D | 3 |
| Roldán, GB | 2 |
| Scott, JN | 1 |
| McIntyre, JB | 1 |
| Dharmawardene, M | 1 |
| de Robles, PA | 1 |
| Magliocco, AM | 1 |
| Yan, ES | 1 |
| Parney, IF | 1 |
| Forsyth, PA | 1 |
| Hamilton, MG | 1 |
| Easaw, JC | 2 |
| Mandonnet, E | 1 |
| Pallud, J | 1 |
| Fontaine, D | 1 |
| Taillandier, L | 2 |
| Bauchet, L | 1 |
| Peruzzi, P | 1 |
| Guyotat, J | 1 |
| Bernier, V | 1 |
| Baron, MH | 1 |
| Duffau, H | 2 |
| Capelle, L | 1 |
| Park, TS | 1 |
| Suh, B | 1 |
| Jang, SJ | 1 |
| Lee, CH | 1 |
| Choi, JR | 1 |
| Hartmann, C | 1 |
| Engel, C | 1 |
| Stoffels, M | 1 |
| Felsberg, J | 2 |
| Stockhammer, F | 1 |
| Sabel, MC | 1 |
| Koeppen, S | 1 |
| Ketter, R | 2 |
| Meyermann, R | 2 |
| Rapp, M | 1 |
| Meisner, C | 1 |
| Kortmann, RD | 2 |
| Pietsch, T | 2 |
| Wiestler, OD | 1 |
| Ernemann, U | 1 |
| Bamberg, M | 3 |
| Reifenberger, G | 2 |
| Yoon, C | 1 |
| Papadopoulos, NE | 1 |
| Camacho, LH | 1 |
| McIntyre, S | 1 |
| Alvarado, GC | 1 |
| Bedikian, AY | 1 |
| Hwu, P | 1 |
| Kim, KB | 1 |
| Verhoeff, JJC | 1 |
| Lavini, C | 1 |
| van Linde, ME | 1 |
| Stalpers, LJA | 1 |
| Majoie, CBLM | 1 |
| van Furth, WR | 1 |
| Richel, DJ | 1 |
| Ferriss, JS | 1 |
| Atkins, KA | 1 |
| Lachance, JA | 1 |
| Modesitt, SC | 1 |
| Jazaeri, AA | 1 |
| Sanghera, P | 2 |
| Perry, J | 1 |
| Symons, S | 2 |
| Aviv, R | 2 |
| Morrison, M | 1 |
| Lam, K | 2 |
| Davey, P | 2 |
| Tsao, MN | 2 |
| Krafft, U | 1 |
| Weiss, C | 2 |
| Lohr, F | 3 |
| Wenz, F | 2 |
| Nabors, LB | 1 |
| Fiveash, JB | 1 |
| Markert, JM | 1 |
| Kekan, MS | 1 |
| Gillespie, GY | 1 |
| Johnson, MJ | 1 |
| Meleth, S | 1 |
| Kuo, H | 1 |
| Gladson, CL | 1 |
| Fathallah-Shaykh, HM | 1 |
| Fulton, D | 1 |
| Kavan, P | 1 |
| Easaw, J | 1 |
| Shields, C | 1 |
| Kirby, S | 1 |
| Macdonald, DR | 2 |
| Eisenstat, DD | 1 |
| Thiessen, B | 1 |
| Forsyth, P | 1 |
| Pouliot, JF | 1 |
| McDonald, MW | 1 |
| Shu, HK | 1 |
| Curran, WJ | 1 |
| Crocker, IR | 1 |
| Khayal, IS | 1 |
| Polley, MY | 3 |
| Jalbert, L | 1 |
| Elkhaled, A | 1 |
| Cha, S | 2 |
| Butowski, NA | 2 |
| Nelson, SJ | 2 |
| Kang, HC | 1 |
| Han, JH | 3 |
| Choe, GY | 1 |
| Terasaki, M | 1 |
| Eto, T | 1 |
| Nakashima, S | 1 |
| Okada, Y | 1 |
| Ogo, E | 1 |
| Sugita, Y | 1 |
| Tokutomi, T | 1 |
| Shigemori, M | 1 |
| Barone, G | 1 |
| Tseng, HM | 1 |
| Kuo, LT | 1 |
| Lien, HC | 1 |
| Liu, KL | 1 |
| Liu, MT | 1 |
| Huang, CY | 1 |
| Thompson, EM | 1 |
| Dosa, E | 1 |
| Kraemer, DF | 1 |
| Neuwelt, EA | 1 |
| Fateh, S | 1 |
| Schell, TD | 1 |
| Gingrich, R | 1 |
| Neves, RI | 1 |
| Drabick, JJ | 1 |
| Essock-Burns, E | 1 |
| Lupo, JM | 1 |
| Heo, DS | 2 |
| Rhee, CH | 1 |
| Kim, DW | 1 |
| Kim, JE | 1 |
| Paek, SH | 1 |
| Kim, DG | 2 |
| Kim, YJ | 1 |
| Park, BJ | 1 |
| Jung, HW | 3 |
| Kim, J | 1 |
| Yim, SY | 1 |
| Lee, AR | 1 |
| Kim, SK | 1 |
| Payer, F | 1 |
| Shcherbenko, OI | 1 |
| Govorina, EV | 1 |
| Zelinskaia, NI | 1 |
| Parkhomenko, RA | 1 |
| Abbasova, EV | 1 |
| Rodionov, MV | 1 |
| Welin, S | 1 |
| Sorbye, H | 1 |
| Sebjornsen, S | 1 |
| Knappskog, S | 1 |
| Busch, C | 1 |
| Oberg, K | 1 |
| Shirakawa, Y | 1 |
| Yoshiura, T | 1 |
| Hiwatashi, A | 1 |
| Yamashita, K | 1 |
| Kamano, H | 1 |
| Shioyama, Y | 1 |
| Abe, K | 1 |
| Amano, T | 1 |
| Nakamizo, A | 1 |
| Yoshimoto, K | 1 |
| Honda, H | 2 |
| Torisu, R | 1 |
| Suzuki, S | 1 |
| Cuneo, KC | 1 |
| Vredenburgh, JJ | 2 |
| Sampson, JH | 3 |
| Desjardins, A | 3 |
| Peters, KB | 2 |
| Friedman, HS | 4 |
| Willett, CG | 1 |
| Kirkpatrick, JP | 1 |
| Mateos, ME | 1 |
| López-Laso, E | 1 |
| Izquierdo, L | 1 |
| Pérez-Navero, JL | 1 |
| García, S | 1 |
| Garzás, C | 1 |
| de Groot, JF | 1 |
| Lamborn, KR | 2 |
| Aldape, K | 1 |
| Yao, J | 1 |
| Jackson, EF | 1 |
| Chen, A | 1 |
| Prados, MD | 3 |
| Aldape, KD | 1 |
| Rivera, AL | 1 |
| Eichler, AF | 1 |
| Paleologos, NA | 1 |
| Fisher, BJ | 1 |
| Ashby, LS | 1 |
| Ligon, KL | 1 |
| Rocque, BG | 1 |
| Chamberlain, MC | 3 |
| Weaver, SA | 1 |
| Green, RM | 1 |
| Kamar, FG | 1 |
| Jhanwar, SC | 1 |
| Rosenblum, MK | 1 |
| Oh, J | 1 |
| Malkoun, N | 1 |
| Chargari, C | 1 |
| Forest, F | 1 |
| Fotso, MJ | 1 |
| Cartier, L | 1 |
| Auberdiac, P | 1 |
| Thorin, J | 1 |
| Pacaut, C | 1 |
| Peoc'h, M | 1 |
| Nuti, C | 1 |
| Schmitt, T | 1 |
| Magné, N | 1 |
| Rogers, S | 1 |
| Merlo, A | 1 |
| Bodis, S | 1 |
| Niewald, M | 1 |
| Berdel, C | 1 |
| Fleckenstein, J | 1 |
| Licht, N | 1 |
| Rübe, C | 1 |
| Smolczyk, DR | 1 |
| Janzen, E | 1 |
| Narita, T | 1 |
| Aoyama, H | 1 |
| Hirata, K | 1 |
| Onodera, S | 1 |
| Shiga, T | 1 |
| Kobayashi, H | 2 |
| Murata, J | 2 |
| Terasaka, S | 2 |
| Tanaka, S | 1 |
| Houkin, K | 2 |
| Herndon, JE | 3 |
| Coan, A | 1 |
| Gururangan, S | 3 |
| McLendon, R | 1 |
| Sathornsumetee, S | 1 |
| Rich, JN | 2 |
| Lipp, ES | 1 |
| Janney, D | 1 |
| Roldán Urgoiti, GB | 1 |
| Singh, AD | 1 |
| Gil, MJ | 1 |
| de Las Peñas, R | 1 |
| Reynés, G | 1 |
| Balañá, C | 2 |
| Peréz-Segura, P | 1 |
| García-Velasco, A | 1 |
| Mesia, C | 1 |
| Gallego, O | 1 |
| Fernández-Chacón, C | 1 |
| Martínez-García, M | 1 |
| Herrero, A | 1 |
| Andrés, R | 1 |
| Benavides, M | 1 |
| Quintanar, T | 1 |
| Pérez-Martin, X | 1 |
| Stuplich, M | 1 |
| Hadizadeh, DR | 1 |
| Kuchelmeister, K | 2 |
| Scorzin, J | 1 |
| Filss, C | 1 |
| Mack, F | 1 |
| Schüller, H | 1 |
| Glas, M | 1 |
| Urbach, H | 1 |
| Motegi, H | 1 |
| Kamoshima, Y | 1 |
| Yamaguchi, S | 1 |
| Tanino, M | 1 |
| Yu, TS | 1 |
| McKay, RM | 1 |
| Burns, DK | 1 |
| Kernie, SG | 1 |
| Parada, LF | 1 |
| Dreyer, C | 1 |
| Olsen, IH | 1 |
| Sørensen, JB | 1 |
| Federspiel, B | 1 |
| Kjaer, A | 1 |
| Hansen, CP | 1 |
| Knigge, U | 1 |
| Langer, SW | 1 |
| Reyngold, M | 1 |
| Chan, TA | 1 |
| Yamada, Y | 1 |
| Gutin, PH | 1 |
| Kawanabe, Y | 1 |
| Sawada, M | 1 |
| Yukawa, H | 1 |
| Ueda, S | 1 |
| Sasaki, N | 1 |
| Koizumi, T | 1 |
| Kihara, S | 1 |
| Hoshimaru, M | 1 |
| Pikó, B | 1 |
| Bassam, A | 1 |
| Nagy, KA | 1 |
| Török, E | 1 |
| Vághy, R | 1 |
| Vargáné Tamás, R | 1 |
| Puskásné Szatmári, K | 1 |
| Gunjur, A | 1 |
| Bressel, M | 1 |
| Ryan, G | 1 |
| Vajtai, I | 1 |
| Vassella, E | 1 |
| Hewer, E | 1 |
| Kappeler, A | 1 |
| Reinert, MM | 1 |
| Tanaka, M | 1 |
| Tsuno, NH | 1 |
| Fujii, T | 1 |
| Takahashi, K | 1 |
| Wu, BJ | 1 |
| Li, WP | 1 |
| Qian, C | 1 |
| Ding, W | 1 |
| Zhou, ZW | 1 |
| Jiang, H | 1 |
| Morana, G | 1 |
| Piccardo, A | 1 |
| Garrè, ML | 1 |
| Nozza, P | 1 |
| Consales, A | 1 |
| Rossi, A | 1 |
| Tham, CK | 1 |
| See, SJ | 1 |
| Tan, SH | 1 |
| Lim, KH | 1 |
| Ng, WH | 1 |
| Thomas, J | 1 |
| Chong, DQ | 1 |
| Chua, ET | 1 |
| Berhorn, T | 1 |
| Blau, T | 1 |
| Dunkl, V | 1 |
| Schroeter, M | 1 |
| Alacacioglu, A | 1 |
| Unal, S | 1 |
| Canpolat, S | 1 |
| Yurt, A | 1 |
| Oztekin, O | 1 |
| Coskun, A | 1 |
| Karatas, A | 1 |
| Postaci, H | 1 |
| Sop, G | 1 |
| Boogerd, W | 1 |
| Bravo Marques, J | 1 |
| Kros, JM | 3 |
| van der Rijt, CC | 2 |
| De Beule, N | 1 |
| Baron, B | 1 |
| Ramirez, JL | 1 |
| Taron, M | 1 |
| Roussos, Y | 1 |
| Ariza, A | 1 |
| Ballester, R | 1 |
| Sarries, C | 1 |
| Mendez, P | 1 |
| Sanchez, JJ | 1 |
| Rosell, R | 1 |
| Hess, KR | 1 |
| Greenberg, H | 2 |
| Fine, H | 2 |
| Pollack, IF | 1 |
| Kuhn, J | 2 |
| Fink, K | 1 |
| Nicholas, MK | 1 |
| Chang, S | 1 |
| Frenay, M | 1 |
| Vecht, ChJ | 1 |
| Danson, S | 1 |
| Arance, A | 1 |
| Clamp, A | 1 |
| Hodgetts, J | 1 |
| Lomax, L | 1 |
| Ashcroft, L | 1 |
| Thatcher, N | 1 |
| Brown, P | 1 |
| Buckner, J | 1 |
| Rojas-Marcos, I | 1 |
| Calvet, D | 1 |
| Janoray, P | 1 |
| Aoki, T | 1 |
| Mizutani, T | 1 |
| Ishikawa, M | 1 |
| Viviers, L | 1 |
| Abson, C | 1 |
| Hines, F | 1 |
| Britton, J | 1 |
| Ashley, S | 1 |
| Sardell, S | 1 |
| Traish, D | 1 |
| Gonsalves, A | 1 |
| Wilkins, P | 1 |
| Westbury, C | 1 |
| Pace, A | 1 |
| Galiè, E | 1 |
| Carosi, M | 1 |
| Telera, S | 1 |
| Cianciulli, AM | 1 |
| Canalini, P | 1 |
| Giannarelli, D | 1 |
| Jandolo, B | 1 |
| Carapella, CM | 1 |
| Vera, K | 1 |
| Djafari, L | 2 |
| Guillamo, JS | 1 |
| Djazouli, K | 1 |
| Osorio, M | 1 |
| Parker, F | 1 |
| Cioloca, C | 1 |
| Abdulkarim, B | 1 |
| Armand, JP | 1 |
| Eoli, M | 2 |
| Salmaggi, A | 2 |
| Lamperti, E | 2 |
| Maccagnano, E | 1 |
| Broggi, G | 2 |
| Boiardi, A | 2 |
| Garbe, C | 1 |
| Eigentler, TK | 1 |
| Hess, K | 1 |
| Schold, C | 1 |
| Tsao-Wei, DD | 1 |
| Rosenthal, MA | 1 |
| Ashley, DL | 1 |
| Cher, L | 1 |
| Steinbach, JP | 2 |
| Küker, WM | 1 |
| Dichgans, J | 1 |
| Verschuur, AC | 1 |
| Grill, J | 1 |
| Lelouch-Tubiana, A | 1 |
| Couanet, D | 1 |
| Kalifa, C | 1 |
| Vassal, G | 1 |
| Sanson, M | 2 |
| Cartalat-Carel, S | 1 |
| Napolitano, M | 1 |
| Cougnard, J | 1 |
| Gervais, H | 1 |
| Laigle, F | 1 |
| Carpentier, A | 1 |
| Hoang-Xuan, K | 3 |
| Levin, N | 2 |
| Gomori, JM | 1 |
| Siegal, T | 2 |
| de Wit, MC | 1 |
| de Bruin, HG | 2 |
| Eijkenboom, W | 1 |
| Sillevis Smitt, PA | 2 |
| Bafaloukos, D | 1 |
| Tsoutsos, D | 1 |
| Fountzilas, G | 1 |
| Linardou, H | 1 |
| Christodoulou, C | 1 |
| Kalofonos, HP | 1 |
| Briassoulis, E | 1 |
| Panagiotou, P | 1 |
| Hatzichristou, H | 1 |
| Gogas, H | 1 |
| Sipos, L | 1 |
| Vitanovics, D | 1 |
| Afra, D | 1 |
| Curschmann, J | 1 |
| Athanassiou, H | 1 |
| Synodinou, M | 1 |
| Maragoudakis, E | 1 |
| Paraskevaidis, M | 1 |
| Verigos, C | 1 |
| Misailidou, D | 1 |
| Antonadou, D | 1 |
| Saris, G | 1 |
| Beroukas, K | 1 |
| Karageorgis, P | 1 |
| Panagiotou, IE | 1 |
| Brountzos, EN | 1 |
| Kelekis, DA | 1 |
| Papathanasiou, MA | 1 |
| Bafaloukos, DI | 1 |
| Somer, RA | 1 |
| Langer, CJ | 1 |
| Kiebert, G | 1 |
| Yung, A | 1 |
| Olson, J | 1 |
| Barrié, M | 1 |
| Couprie, C | 1 |
| Dufour, H | 1 |
| Muracciole, X | 1 |
| Braguer, D | 1 |
| Martin, PM | 1 |
| Peragut, JC | 1 |
| Grisoli, F | 1 |
| Taal, W | 3 |
| van der Rijt, CD | 1 |
| van Heuvel, I | 1 |
| Enting, RH | 1 |
| Hofmann, M | 1 |
| Kiecker, F | 1 |
| Wurm, R | 1 |
| Schlenger, L | 1 |
| Budach, V | 1 |
| Sterry, W | 1 |
| Trefzer, U | 1 |
| Koch, HJ | 1 |
| Roeber, S | 1 |
| Zimmermann, UW | 1 |
| Schäfer, C | 1 |
| Villarrubia, V | 1 |
| Schachenmayr, W | 1 |
| Steinbrecher, A | 1 |
| Quinn, JA | 2 |
| Weingart, J | 1 |
| Brem, H | 1 |
| Dolan, ME | 1 |
| Delaney, SM | 1 |
| Vredenburgh, J | 1 |
| Rich, J | 1 |
| Friedman, AH | 2 |
| Pegg, AE | 1 |
| Moschel, RC | 1 |
| Birch, R | 1 |
| McLendon, RE | 2 |
| Provenzale, JM | 2 |
| Dancey, JE | 1 |
| Maxwell, J | 1 |
| Tourt-Uhlig, S | 2 |
| Bigner, DD | 1 |
| Ready, N | 1 |
| Aronson, F | 1 |
| Wanebo, H | 1 |
| Kennedy, T | 1 |
| Cohen, MH | 1 |
| Johnson, JR | 1 |
| Pazdur, R | 1 |
| Leimgruber, A | 1 |
| Ostermann, S | 1 |
| Yeon, EJ | 1 |
| Buff, E | 1 |
| Maeder, PP | 1 |
| Meuli, RA | 1 |
| Weber, RW | 1 |
| O'Day, S | 1 |
| Rose, M | 1 |
| Deck, R | 1 |
| Ames, P | 1 |
| Good, J | 1 |
| Meyer, J | 1 |
| Allen, R | 1 |
| Trautvetter, S | 1 |
| Timmerman, M | 1 |
| Cruickshank, S | 1 |
| Cook, M | 1 |
| Gonzalez, R | 1 |
| Spitler, LE | 1 |
| Parlato, C | 1 |
| Barbarisi, M | 1 |
| Moraci, M | 1 |
| Moraci, A | 1 |
| Chamoun, RB | 1 |
| Alaraj, AM | 1 |
| Al Kutoubi, AO | 1 |
| Abboud, MR | 1 |
| Haddad, GF | 1 |
| Lavon, I | 1 |
| Zelikovitsh, B | 1 |
| Fuchs, D | 1 |
| Bokstein, F | 1 |
| Fellig, Y | 1 |
| Trudeau, ME | 1 |
| Crump, M | 1 |
| Charpentier, D | 1 |
| Yelle, L | 1 |
| Bordeleau, L | 1 |
| Matthews, S | 1 |
| Heeger, S | 1 |
| Haselmann, R | 1 |
| Edler, L | 2 |
| Schulz-Ertner, D | 2 |
| Losa, R | 1 |
| Fra, J | 1 |
| López-Pousa, A | 1 |
| Sierra, M | 1 |
| Goitia, A | 1 |
| Uña, E | 1 |
| Nadal, R | 1 |
| Del Muro, JG | 1 |
| Gión, M | 1 |
| Maurel, J | 1 |
| Escudero, P | 1 |
| Esteban, E | 1 |
| Buesa, JM | 1 |
| Laber, DA | 2 |
| Okeke, RI | 1 |
| Arce-Lara, C | 1 |
| Taft, BS | 2 |
| Schonard, CL | 1 |
| McMasters, KM | 1 |
| Kloecker, GH | 2 |
| Miller, DM | 1 |
| Piccirilli, M | 1 |
| Landi, A | 1 |
| Salvati, M | 1 |
| Tosoni, A | 2 |
| Cavallo, G | 1 |
| Bertorelle, R | 2 |
| Gioia, V | 1 |
| Biscuola, M | 1 |
| Blatt, V | 2 |
| Crinò, L | 1 |
| Ermani, M | 3 |
| Everhard, S | 1 |
| Crinière, E | 1 |
| Benouaich-Amiel, A | 1 |
| Lejeune, J | 1 |
| Marie, Y | 1 |
| Kujas, M | 1 |
| Thillet, J | 1 |
| Levine, KK | 1 |
| Betensky, RA | 1 |
| Romany, CA | 1 |
| Reavie, LB | 1 |
| Futreal, PA | 1 |
| Stratton, MR | 1 |
| Iafrate, AJ | 1 |
| Thompson, D | 1 |
| McArthur, GA | 1 |
| Kefford, RF | 1 |
| Harris, PA | 1 |
| Baka, S | 1 |
| Seebaran, A | 1 |
| Khan, MI | 1 |
| Schonard, C | 1 |
| Salvador, C | 1 |
| Blaschke, B | 1 |
| Gaviani, P | 1 |
| Fiumani, A | 1 |
| Botturi, A | 1 |
| Falcone, C | 1 |
| Solari, A | 1 |
| Filippini, G | 1 |
| Di Meco, F | 1 |
| da Fonseca, CO | 1 |
| Schwartsmann, G | 1 |
| Fischer, J | 1 |
| Nagel, J | 1 |
| Futuro, D | 1 |
| Quirico-Santos, T | 1 |
| Gattass, CR | 1 |
| Nagy, M | 1 |
| Rausch, R | 1 |
| Bischof, M | 1 |
| Welzel, T | 1 |
| Pession, A | 1 |
| Tallini, G | 1 |
| Bartolini, S | 1 |
| Calbucci, F | 1 |
| Andreoli, A | 1 |
| Frezza, G | 1 |
| Leonardi, M | 1 |
| Spagnolli, F | 1 |
| Stalpers, L | 1 |
| Sminia, P | 1 |
| Khan, OA | 1 |
| Michael, M | 1 |
| Olver, I | 1 |
| Levitt, NC | 1 |
| Midgley, R | 1 |
| Bromberg, JE | 1 |
| Swaak-Kragten, AT | 1 |
| Smitt, PA | 1 |
| van Es, CA | 1 |
| Paulsen, F | 1 |
| Hoffmann, W | 1 |
| Becker, G | 1 |
| Belka, C | 1 |
| Weinmann, M | 1 |
| Classen, J | 1 |
| van Brussel, JP | 1 |
| Busstra, MB | 1 |
| Lang, MS | 1 |
| Catsburg, T | 1 |
| Schröder, FH | 1 |
| Mickisch, GH | 1 |
| Basso, U | 1 |
| Amistà, P | 1 |
| Berti, F | 1 |
| Scienza, R | 1 |
| Rotilio, A | 1 |
| Pinna, G | 1 |
| Gardiman, M | 1 |
| Monfardini, S | 1 |
| Cokgor, L | 1 |
| Edwards, S | 1 |
| Affronti, ML | 1 |
| Stafford-Fox, V | 1 |
| Zaknoen, S | 1 |
| Early, M | 1 |
| Olson, JD | 1 |
| Raizer, JJ | 1 |
| Mack, M | 1 |
| Rodavitch, A | 1 |
| Boutros, DY | 1 |
| Malkin, MG | 1 |
| Croteau, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Evaluation of 18F-Fluciclovine PET-MRI to Differentiate Tumor Progression From Post-treatment Changes in Pediatric High-grade Glioma (HGG)[NCT05553041] | Early Phase 1 | 30 participants (Anticipated) | Interventional | 2023-08-07 | Recruiting | ||
| 11C-methionine in Diagnostics and Management of Glioblastoma Multiforme With Rapid Early Progression Patients Prior to Adjuvant Oncological Therapy (GlioMET)[NCT05608395] | Phase 2 | 71 participants (Anticipated) | Interventional | 2020-12-04 | Recruiting | ||
| A Phase Ib/II Study of AZD2171 in Combination With Daily Temozolomide and Radiation in Patients With Newly Diagnosed Glioblastoma Not Taking Enzyme-Inducing Anti-epileptic Drugs[NCT00662506] | Phase 1/Phase 2 | 46 participants (Actual) | Interventional | 2008-04-30 | Completed | ||
| Quantitative Assessment of the Early and Late Effects of Radiation and Chemotherapy on Glioblastoma Using Multiple MRI Techniques[NCT00756106] | 15 participants (Actual) | Interventional | 2008-07-31 | Terminated (stopped due to Funding ended) | |||
| Randomized Phase II Trial of Temozolomide Versus Hyd-Sulfate AZD6244 [NSC 748727] in Patients With Metastatic Uveal Melanoma[NCT01143402] | Phase 2 | 120 participants (Actual) | Interventional | 2010-06-30 | Completed | ||
| Phase III Trial Comparing Conventional Adjuvant Temozolomide With Dose-Intensive Temozolomide in Patients With Newly Diagnosed Glioblastoma[NCT00304031] | Phase 3 | 1,173 participants (Actual) | Interventional | 2006-01-31 | Completed | ||
| A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Trial of Bevacizumab, Temozolomide and Radiotherapy, Followed by Bevacizumab and Temozolomide Versus Placebo, Temozolomide and Radiotherapy Followed by Placebo and Temozolomide in Patie[NCT00943826] | Phase 3 | 921 participants (Actual) | Interventional | 2009-06-29 | Completed | ||
| Improvement of Functional Outcome for Patients With Newly Diagnosed Grade II or III Glioma With Co-deletion of 1p/19q - IMPROVE CODEL: the NOA-18 Trial[NCT05331521] | Phase 3 | 406 participants (Anticipated) | Interventional | 2021-04-07 | Recruiting | ||
| An Open-label, Single-arm, Phase II Study to Evaluate Safety and Efficacy of Doxorubicin in Combination With Radiotherapy, Temozolomide and Valproic Acid in Patients With Glioblastoma Multiforme (GBM) and Diffuse Intrinsic Pontine Glioma (DIPG)[NCT02758366] | Phase 2 | 21 participants (Actual) | Interventional | 2016-02-29 | Terminated (stopped due to Study was terminated due to high heterogeneity of enrolled patients) | ||
| The Use of TTFields for Newly Diagnosed GBM Patients in Germany in Routine Clinical Care - TIGER Study[NCT03258021] | 710 participants (Actual) | Observational | 2017-08-31 | Active, not recruiting | |||
| ENGOT-ov50 / GOG-3029 / INNOVATE-3: Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 200kHz) Concomitant With Weekly Paclitaxel for the Treatment of Recurrent Ovarian Cancer[NCT03940196] | Phase 3 | 540 participants (Actual) | Interventional | 2019-03-22 | Active, not recruiting | ||
| Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150kHz) Concomitant With Gemcitabine and Nab-paclitaxel for Front-line Treatment of Locally-advanced Pancreatic Adenocarcinoma[NCT03377491] | Phase 3 | 556 participants (Anticipated) | Interventional | 2018-02-10 | Active, not recruiting | ||
| HUMC 1612: A Phase I Trial of the Optune NovoTTF-200A System With Concomitant Temozolomide and Bevacizumab in Pediatric Patients With High-grade Glioma[NCT03128047] | Phase 1 | 6 participants (Actual) | Interventional | 2017-04-06 | Active, not recruiting | ||
| A Prospective, Multi-center Trial of NovoTTF-100A Together With Temozolomide Compared to Temozolomide Alone in Patients With Newly Diagnosed GBM.[NCT00916409] | Phase 3 | 700 participants (Anticipated) | Interventional | 2009-06-30 | Completed | ||
| HEPANOVA: A Phase II Trial of Tumor Treating Fields (TTFields, 150kHz) Concomitant With Sorafenib For Advanced Hepatocellular Carcinoma (HCC)[NCT03606590] | Phase 2 | 25 participants (Actual) | Interventional | 2019-02-15 | Active, not recruiting | ||
| Pivotal, Open-label, Randomized Study of Radiosurgery With or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases From Non-small Cell Lung Cancer (NSCLC).[NCT02831959] | Phase 3 | 270 participants (Anticipated) | Interventional | 2016-07-31 | Active, not recruiting | ||
| Use of TTFields in Germany in Routine Clinical Care Study PROgram - Daily Activity, Sleep and Neurocognitive Functioning in Newly Diagnosed Glioblastoma Patients Study[NCT04717739] | 500 participants (Anticipated) | Observational | 2021-12-30 | Recruiting | |||
| LUNAR: Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure[NCT02973789] | Phase 3 | 276 participants (Actual) | Interventional | 2016-12-31 | Active, not recruiting | ||
| A Phase 2, Single Arm, Multi-center, Open-Label Trial to Evaluate the Safety and Efficacy of Treatment With Tumor Treating Fields (TTFields) and Chemotherapy as First-Line Treatment for Subjects With Unresectable Gastroesophageal Junction (GEJ) Adenocarci[NCT04281576] | 28 participants (Anticipated) | Interventional | 2019-12-19 | Recruiting | |||
| A Randomized Phase III Study of Temozolomide and Short-Course Radiation Versus Short-Course Radiation Alone In The Treatment of Newly Diagnosed Glioblastoma Multiforme in Elderly Patients[NCT00482677] | Phase 3 | 562 participants (Actual) | Interventional | 2007-11-14 | Completed | ||
| Simultaneous Integrated Boost FDOPA PET Guided in Patients With Partially- or Non-operated Glioblastoma[NCT05653622] | Phase 2 | 75 participants (Anticipated) | Interventional | 2023-03-01 | Not yet recruiting | ||
| A Pilot and Phase II Study of OSI-774 and Temozolomide in Combination With Radiation Therapy in Glioblastoma Multiforme[NCT00039494] | Phase 2 | 171 participants (Anticipated) | Interventional | 2002-12-31 | Completed | ||
| Concomitant and Adjuvant Temozolomide and Radiotherapy for Newly Diagnosed Glioblastoma Multiforme - A Randomized Phase III Study[NCT00006353] | Phase 3 | 575 participants (Actual) | Interventional | 2000-07-31 | Completed | ||
| A Prospective Study of Concurrent Chemoradiotherapy With Temozolomide Versus Radiation Therapy Alone in Patients With IDH Wild-type/TERT Promoter Mutation Grade II/III Gliomas[NCT02766270] | Early Phase 1 | 30 participants (Anticipated) | Interventional | 2016-09-26 | Recruiting | ||
| Spatial Analysis and Validation of Glioblastoma on 7 T MRI[NCT02062372] | 5 participants (Actual) | Interventional | 2014-12-10 | Terminated (stopped due to Expectation that within the set time period insufficient patients will be included, so endpoints will not be achieved) | |||
| Pilot Study of Concomitant NovoTTF-200A and Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma[NCT03232424] | Phase 1 | 12 participants (Actual) | Interventional | 2017-07-26 | Completed | ||
| Metformin and Neo-adjuvant Temozolomide and Hypofractionated Accelerated Limited-margin Radiotherapy Followed by Adjuvant Temozolomide in Patients With Glioblastoma Multiforme (M-HARTT STUDY)[NCT02780024] | Phase 2 | 50 participants (Anticipated) | Interventional | 2015-03-31 | Active, not recruiting | ||
| Use of PET/CT Imaging With 18F-fluoroethylcholine (FEC) in the Evaluation of Patients Treated With Radiotherapy and Temozolomide Following a Diagnosis of Glioblastoma Multiforme[NCT00943462] | 0 participants (Actual) | Observational | 2009-06-30 | Withdrawn (stopped due to No eligible patients could be recruited.) | |||
| Demeclocycline Fluorescence for Intraoperative Delineation Brain Tumors[NCT02740933] | Phase 1 | 40 participants (Anticipated) | Interventional | 2016-04-30 | Not yet recruiting | ||
| Research on Precise Immune Prevention and Treatment of Glioma Based on Multi-omics Sequencing Data[NCT04792437] | 120 participants (Anticipated) | Observational | 2021-03-10 | Recruiting | |||
| Phase II Clinical Trial on the Combination of Avelumab and Axitinib for the Treatment of Patients With Recurrent Glioblastoma[NCT03291314] | Phase 2 | 52 participants (Actual) | Interventional | 2017-05-03 | Completed | ||
| Retrospective Evaluation of Prognostic and/or Predictive Profile of Melanocortin Receptor-4 Gene Polymorphisms in Patient With a Diagnosis of Glioblastoma Treated With Upfront Concomitant Radio-chemotherapy or Chemotherapy[NCT02458508] | 65 participants (Actual) | Observational | 2015-03-31 | Completed | |||
| Effect of stRess and exeRcize on the Outcome After Chemo-Radiation[NCT05431348] | 40 participants (Anticipated) | Observational | 2022-06-01 | Recruiting | |||
| Prospective Randomized Phase II Trial of Hypofractionated Stereotactic Radiotherapy in Recurrent Glioblastoma Multiforme[NCT01464177] | Phase 2 | 40 participants (Anticipated) | Interventional | 2011-10-31 | Active, not recruiting | ||
| Pre-operative Radiation Therapy (RT) and Temozolomide (TMZ) in Patients With Newly Diagnosed Glioblastoma. A Phase I Study. (PARADIGMA)[NCT03480867] | Phase 1 | 0 participants (Actual) | Interventional | 2017-03-31 | Withdrawn (stopped due to competing study was opened by the surgeon after this trial was opened) | ||
| A Modified Ketogenic, Anti-Inflammatory Diet for Patients With High-Grade Gliomas[NCT05373381] | 10 participants (Anticipated) | Interventional | 2022-05-18 | Recruiting | |||
| The Efficacy and Safety of Temozolomide in Patients With Relapsed or Advanced Anaplastic Oligodendroglioma and Oligoastrocytoma: a Multicenter, Single-arm, Phase II Trial[NCT01847235] | Phase 2 | 23 participants (Actual) | Interventional | 2013-05-31 | Completed | ||
| The Temozolomide RESCUE Study: A Phase II Trial of Continuous (28/28) Dose-intense Temozolomide (CDIT) Chemotherapy After Progression on Conventional 5/28 Day Temozolomide in Patients With Recurrent Malignant Glioma[NCT00392171] | Phase 2 | 120 participants (Actual) | Interventional | 2006-06-09 | Completed | ||
| Phase 2 Study of Temozolomide Plus Capecitabine in Patients With Grade 3 and Low Ki-67 Gastroenteropancreatic Neuroendocrine Tumors[NCT03079440] | Phase 2 | 31 participants (Actual) | Interventional | 2017-05-15 | Completed | ||
| Clinical Study of Radiopeptide 177Lu-DOTATOC in Combination With Capecitabine and Temozolomide in Advanced, Non-resectable and Progressive Neuroendocrine Tumors With Somatostatin Receptor Overexpression[NCT04194125] | Phase 2 | 25 participants (Anticipated) | Interventional | 2019-02-01 | Recruiting | ||
| Phase II Single Arm Trial of VEGF Trap in Patients With Recurrent Temozolomide-Resistant Malignant Gliomas[NCT00369590] | Phase 2 | 58 participants (Actual) | Interventional | 2006-08-31 | Completed | ||
| Second Line Chemotherapy With Temozolomide in Recurrent Oligodendroglial Tumors After PCV-Chemotherapy[NCT00003304] | Phase 2 | 29 participants (Anticipated) | Interventional | 1998-04-30 | Completed | ||
| First Line Chemotherapy With Temozolomide in Recurrent Oligodendroglial Tumors, a Phase II Trial[NCT00003731] | Phase 2 | 39 participants (Actual) | Interventional | 1998-12-31 | Completed | ||
| A Prospective Cohort to Study the Effect of Postoperative Upfront Temozolomide Chemotherapy on IDH Mutational Low Grade Gliomas in Eloquent Areas[NCT02209428] | Phase 2 | 54 participants (Actual) | Interventional | 2014-06-30 | Active, not recruiting | ||
| A Phase 2a Study of the Addition of Temozolomide to a Standard Conditioning Regimen for Autologous Stem Cell Transplantation in Relapsed and Refractory Central Nervous System (CNS) Lymphoma[NCT01235793] | Phase 2 | 11 participants (Actual) | Interventional | 2010-10-14 | Terminated (stopped due to The clinical trial was terminated due to poor enrollment) | ||
| A Phase II Trial of Temozolomide and BCNU for Anaplastic Gliomas[NCT00003176] | Phase 2 | 82 participants | Interventional | 1998-03-25 | Completed | ||
| Prospective Randomized Placebo-Controlled Trial of SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma (SURVIVE)[NCT05163080] | Phase 2 | 265 participants (Anticipated) | Interventional | 2021-11-18 | Recruiting | ||
| Phase I/II Study of the Combination of BKM120 and Bevacizumab in Patients With Refractory Solid Tumors (Phase I) and Relapsed/Refractory Glioblastoma Multiforme (Phase II)[NCT01349660] | Phase 1/Phase 2 | 88 participants (Actual) | Interventional | 2011-12-31 | Completed | ||
| Immunophenotype Characterization of Circulating and Tumor Infiltrating Immune Cells in Malignant Brain Tumors.[NCT05831631] | 200 participants (Anticipated) | Observational | 2022-08-01 | Recruiting | |||
| Phase I Trial of Zotiraciclib (TG02) Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of Zotiraciclib (TG02) Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma[NCT02942264] | Phase 1/Phase 2 | 53 participants (Actual) | Interventional | 2016-12-14 | Completed | ||
| Role of Repeat Resection in Recurrent Glioblastoma (4rGBM) Trial: a Randomized Care Trial for Patients With Recurrent GBM[NCT04838782] | 250 participants (Anticipated) | Interventional | 2021-08-26 | Recruiting | |||
| Role of Glutamate-mediate Excitotoxicity in Invasion and Progression Processes of Glioblastoma Multiforme[NCT05775458] | 50 participants (Anticipated) | Observational | 2020-06-01 | Recruiting | |||
| Evaluation of ex Vivo Drug Combination Optimization Platform in Recurrent High Grade Astrocytic Glioma[NCT05532397] | 10 participants (Anticipated) | Interventional | 2023-02-17 | Recruiting | |||
| Temozolomide Plus Bevacizumab Chemotherapy in Supratentorial Glioblastoma in 70 Years and Older Patients With an Impaired Functional Status (KPS<70)[NCT02898012] | Phase 2 | 70 participants (Actual) | Interventional | 2010-10-31 | Completed | ||
| Comparative Assessment of Methods to Analyze MGMT as a Predictive Factor of Response to Temozolomide in Glioblastomas.[NCT01345370] | 300 participants (Actual) | Observational | 2009-03-31 | Completed | |||
| The Combination of Hypofractionated Stereotactic Radiotherapy and Chemoradiotherapy Using Intensity-Modulated Radiotherapy for Newly Diagnosed Glioblastoma Multiforme: A Prospective, Single-Center, Single-Arm Phase II Clinical Trial[NCT04547621] | Phase 1/Phase 2 | 50 participants (Anticipated) | Interventional | 2020-09-01 | Active, not recruiting | ||
| A Pilot Study Investigating Neoadjuvant Temozolomide-based Proton Chemoradiotherapy for High-Risk Soft Tissue Sarcomas[NCT00881595] | Phase 2 | 0 participants (Actual) | Interventional | 2009-02-28 | Withdrawn (stopped due to No patients accrued since study opened) | ||
| Multicenter Phase II Study of Preoperative Chemoradiotherapy With CApecitabine Plus Temozolomide in Patients With MGMT Silenced and Microsatellite Stable Locally Advanced RecTal Cancer: the CATARTIC Trial[NCT05136326] | Phase 2 | 21 participants (Anticipated) | Interventional | 2021-12-01 | Recruiting | ||
| (Cost)Effectiveness of MR-guided LITT Therapy in Patients With Primary Irresectable Glioblastoma: a Prospective Multicenter Randomized Controlled Trial (EMITT)[NCT05318612] | Phase 3 | 238 participants (Anticipated) | Interventional | 2022-04-08 | Recruiting | ||
| Using Genomic Analysis to Guide Individual Treatment in Glioblastoma[NCT02725684] | 36 participants (Actual) | Observational | 2015-03-12 | Completed | |||
| Prospective, Phase II Clinical Trial to Evaluate Efficacy and Safety of Autologous Dendritic Cell Vaccination in Glioblastoma Multiforme Patients After Complete Surgical Resection With Fluorescence Microscope[NCT01006044] | Phase 2 | 26 participants (Actual) | Interventional | 2009-10-31 | Completed | ||
| A Phase I Study of Repeated Neural Stem Cell Based Virotherapy in Combination With N-Acetylcysteine Amid (NACA) and Standard Radiation and Chemotherapy for Newly Diagnosed High Grade Glioma[NCT06169280] | Phase 1 | 20 participants (Anticipated) | Interventional | 2024-01-02 | Not yet recruiting | ||
| Evaluating the Expression Levels of microRNA-10b in Patients With Gliomas[NCT01849952] | 200 participants (Anticipated) | Observational | 2020-02-28 | Recruiting | |||
| Phase I Study of Escalated Pharmacologic Dose, of Oral Folinic Acid in Combination With Temozolomide, According to Stupp R. Regimen, in Patients With Operated Grade-IV Astocytoma and a Non-methylated Gene Status of MGMT.[NCT01700569] | Phase 1 | 24 participants (Actual) | Interventional | 2013-01-31 | Terminated (stopped due to changing the standard of care) | ||
| Temozolomide and Irinotecan Consolidation in Patients With MGMT Silenced, Microsatellite Stable Colorectal Cancer With Persistence of Minimal Residual Disease in Liquid Biopsy After Standard Adjuvant Chemotherapy: the ERASE-TMZ Study[NCT05031975] | Phase 2 | 35 participants (Anticipated) | Interventional | 2022-05-02 | Recruiting | ||
| Prospective, Randomized Controlled Trial of Surgical Resection Prior to Bevacizumab Therapy for Recurrent Glioblastoma Multiforme[NCT01413438] | Phase 2 | 0 participants (Actual) | Interventional | 2011-07-15 | Withdrawn | ||
| A Phase I/II Study of the Safety and Feasibility of Administering T Cells Expressing Anti-EGFRvIII Chimeric Antigen Receptor to Patients With Malignant Gliomas Expressing EGFRvIII[NCT01454596] | Phase 1/Phase 2 | 18 participants (Actual) | Interventional | 2012-05-16 | Completed | ||
| Open-label Phase 1/2 (Safety Lead-in) Study of Trans Sodium Crocetinate (TSC) With Concomitant Treatment of Fractionated Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM) Patients to Evaluate Safety and Efficacy[NCT01465347] | Phase 1/Phase 2 | 59 participants (Actual) | Interventional | 2012-02-29 | Completed | ||
| Phase II Study of Neoadjuvant Chemoradiation for Resectable Glioblastoma (NeoGlio)[NCT04209790] | Phase 2 | 30 participants (Anticipated) | Interventional | 2020-04-01 | Recruiting | ||
| A Phase II, Randomized, Open-Label, Parallel-Group Study to Evaluate the Efficacy and Safety of Autologous Dendritic Cell Vaccination (ADCV01) as an Add-On Treatment for Primary Glioblastoma Multiforme (GBM) Patients[NCT04115761] | Phase 2 | 24 participants (Anticipated) | Interventional | 2019-06-06 | Recruiting | ||
| Re-irradiation of High Grade Gliomas: a Quality of Life Study[NCT01711580] | 0 participants (Actual) | Observational | 2013-03-31 | Withdrawn (stopped due to Another study was commenced for this patient group) | |||
| Phase I Trial of Temodar Plus O6-Benzylguanine (O6-BG) (NSC 637037) in the Treatment of Patients With Newly Diagnosed (Part 1) or Recurrent/Progressive (Parts 1 and 2) Cerebral Anaplastic Gliomas[NCT00006474] | Phase 1 | 0 participants | Interventional | 2001-03-31 | Completed | ||
| Treatment of Patients With Metastatic Malignant Melanoma With Chemobiotherapy With Temozolomide, GM-CSF, IL2, and Interferon Alfa-2b Phase II Trial[NCT00014092] | Phase 2 | 0 participants | Interventional | 1999-12-31 | Completed | ||
| Phase 1b Trial of 5-fluorouracil, Leucovorin, Irinotecan in Combination With Temozolomide (FLIRT) and Bevacizumab for the First-line Treatment of Patients With MGMT Silenced, Microsatellite Stable Metastatic Colorectal Cancer.[NCT04689347] | Phase 1 | 18 participants (Anticipated) | Interventional | 2021-01-01 | Recruiting | ||
| A Phase II, Open Label, Single Arm Study of Nivolumab for Recurrent or Progressive IDH Mutant Gliomas With Prior Exposure to Alkylating Agents[NCT03557359] | Phase 2 | 20 participants (Actual) | Interventional | 2018-06-12 | Active, not recruiting | ||
| Imaging After Stereotactic Radiosurgery for Brain Metastases or Primary Tumor Can Hybrid PET-MRI Differentiate Between Radiation Effects and Disease ?[NCT03068520] | 140 participants (Anticipated) | Interventional | 2017-03-01 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Apparent diffusion coefficient (ADC) is a measure of the magnitude of diffusion (of water molecules) within tissue. ADC was assessed using post-contrast T1-weighted images. Multiple images were used to assess each participant at every time-point and the median value for each participant was calculated by time-point. The data presented represent the average of those median values at each time-point.~CRT: Chemoradiotherapy Cx: The cycle number TMZ: temozolomide" (NCT00756106)
Timeframe: Baseline, weekly during treatment, monthly following treatment for up to six months
| Intervention | mm2/s (Mean) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline 1 | Baseline 2 | Week 1 CRT | Week 2 CRT | Week 3 CRT | Week 4 CRT | Week 5 CRT | Week 6 CRT | Pre-C1 TMZ | Pre-C2 TMZ | Pre-C3 TMZ | Pre-C4 TMZ | Pre-C5 TMZ | Pre-C6 TMZ | Post-TMZ | |
| Temozolomide and Radiation Therapy | 0.00110 | 0.00113 | 0.00106 | 0.00110 | 0.00118 | 0.00122 | 0.00125 | 0.00125 | 0.00132 | 0.00127 | 0.00108 | 0.00133 | 0.00148 | 0.00179 | 0.00140 |
"Permeability-surface Area Product (Ktrans). Ktrans reflects the efflux rate of contrast from blood plasma into the tissue extravascular extracellular space (EES). Ktrans was assessed using post-contrast T1-weighted images. Multiple images were used to assess each participant at every time-point and the median value for each participant was calculated by time-point. The data presented represent the average of those median values at each time-point.~CRT: Chemoradiotherapy Cx: The cycle number TMZ: temozolomide" (NCT00756106)
Timeframe: Baseline, weekly during treatment, monthly following treatment for up to six months
| Intervention | min ^-1 (Mean) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline 1 | Baseline 2 | Week 1 CRT | Week 2 CRT | Week 3 CRT | Week 4 CRT | Week 5 CRT | Week 6 CRT | Pre-C1 TMZ | Pre-C2 TMZ | Pre-C3 TMZ | Pre-C4 TMZ | Pre-C5 TMZ | Pre-C6 TMZ | Post-TMZ | |
| Temozolomide and Radiation Therapy | 0.053 | 0.039 | 0.055 | 0.048 | 0.055 | 0.053 | 0.058 | 0.059 | 0.063 | 0.042 | 0.050 | 0.058 | 0.056 | 0.060 | 0.032 |
"Relative cerebral blood flow (rCBF) is the blood flow rate (the volume of blood passing through the specified are over a specified period of time) in the region of interest (ROI) divided by the blood flow rate in the symmetrical region on the other side of the normal brain (control region). CBF was assessed using spin-echo post-contrast T1-weighted images. CBF was assessed using spin-echo post-contrast T1-weighted images. Multiple images were used to assess each participant at every time-point and the median value for each participant was calculated by time-point. The data presented represent the average of those median values at each time-point. The baseline value was measured twice (representing baseline 1 and 2) to make sure that the value was reproducible and to account for any variation attributable to measurement variation.~CRT: Chemoradiotherapy Cx: The cycle number TMZ: temozolomide" (NCT00756106)
Timeframe: Baseline, weekly during treatment, monthly following treatment for up to six months
| Intervention | ratio (Mean) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline 1 | Baseline 2 | Week 1 CRT | Week 2 CRT | Week 3 CRT | Week 4 CRT | Week 5 CRT | Week 6 CRT | Pre-C1 TMZ | Pre-C2 TMZ | Pre-C3 TMZ | Pre-C4 TMZ | Pre-C5 TMZ | Pre-C6 TMZ | Post-TMZ | |
| Temozolomide and Radiation Therapy | 0.83 | 0.86 | 0.92 | 0.94 | 0.80 | 0.79 | 0.83 | 0.73 | 0.63 | 0.59 | 0.60 | 0.60 | 0.52 | 0.47 | 0.37 |
"Relative cerebral blood volume (rCBV) is the blood volume in the region of interest (ROI) divided by the blood volume in the symmetrical region on the other side of the normal brain (control region). CBV was assessed using spin-echo post-contrast T1-weighted images. Multiple images were used to assess each participant at every time-point and the median value for each participant was calculated by time-point. The data presented represent the average of those median values at each time-point. The baseline value was measured twice (representing baseline 1 and 2) to make sure that the value was reproducible and to account for any variation attributable to measurement variation.~CRT: Chemoradiotherapy Cx: The cycle number TMZ: temozolomide" (NCT00756106)
Timeframe: Baseline, weekly during treatment, monthly following treatment for up to six months
| Intervention | ratio (Mean) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline 1 | Baseline 2 | Week 1 CRT | Week 2 CRT | Week 3 CRT | Week 4 CRT | Week 5 CRT | Week 6 CRT | Pre-C1 TMZ | Pre-C2 TMZ | Pre-C3 TMZ | Pre-C4 TMZ | Pre-C5 TMZ | Pre-C6 TMZ | Post-TMZ | |
| Temozolomide and Radiation Therapy | 0.88 | 0.90 | 0.95 | 1.0 | 0.88 | 0.83 | 0.86 | 0.76 | 0.68 | 0.61 | 0.59 | 0.65 | 0.61 | 0.64 | 0.32 |
The primary analysis will be performed among the Gnaq/Gna11 mutant patients. A stratified logrank test will be performed stratified by mutation status, M stage, and number of prior systemic therapies for metastatic disease. Due to the potential for a large number of strata and small strata sizes, the standard asymptotic stratified logrank test will be verified for robustness utilizing a permutation reference distribution. (NCT01143402)
Timeframe: The time from randomization to death due to any cause, assessed up to 5 years
| Intervention | Months (Median) |
|---|---|
| Arm I (Temozolomide) | 9.1 |
| Arm II (Selumetinib) | 11.8 |
The primary analysis will be performed among the Gnaq/Gna11 mutant patients. A stratified logrank test will be performed stratified by mutation status, M stage, and number of prior systemic therapies for metastatic disease. Due to the potential for a large number of strata and small strata sizes, the standard asymptotic stratified logrank test will be verified for robustness utilizing a permutation reference distribution. (NCT01143402)
Timeframe: The time from randomization to the earlier date of objective disease progression per Response Evaluation Criteria In Solid Tumors (RECIST) criteria or death due to any cause in the absence of progression, assessed up to 5 years
| Intervention | weeks (Median) |
|---|---|
| Arm I (Temozolomide) | 7 |
| Arm II (Selumetinib) | 15.9 |
Overall survival time is defined as time from registration/randomization to the date of death from any cause or last known follow-up (censored). Overall survival rates are estimated by the Kaplan-Meier method. The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire [EORTC QLQ]-C30 subscales are calculated as the mean of component items, then standardized such that subscale scores range from 0 to 100. A high score for a functional scale represents a healthy level of functioning. Controlled Oral Word Association (COWA) score is the sum of correct responses with a range of 0 to infinity. A higher score indicates better functioning. Hopkins Verbal Learning Test - Revised (HVLT-R) score ranges from 0 to 36 for total recall is 0 to 36, 0 to 12 for delayed recall, and -12 to 12 for recognition. A higher score indicates better functioning. (NCT00304031)
Timeframe: From randomization to last follow-up. Maximum follow-up at time of analysis was 4.4 years.
| Intervention | months (Median) |
|---|---|
| Both Arms Combined | 17.5 |
"Global Health Status is calculated from two questions on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire [EORTC QLQ]-C30. The question responses range from 1 very poor to 7 excellent such that a higher response indicates better quality of life (QOL). The mean of these responses is linearly transformed to a range of 0 (worst) to 100 (best). Change is calculated as time point - baseline such that a positive change value indicates worse symptoms compared to baseline." (NCT00304031)
Timeframe: Baseline and mid-cycle 1 (approximately 12 weeks)
| Intervention | score on a scale (Mean) |
|---|---|
| Conventional Adjuvant TMZ | -4.58 |
| Dose-dense Adjuvant TMZ | -2.63 |
"Global Health Status is calculated from two questions on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire [EORTC QLQ]-C30. The question responses range from 1 very poor to 7 excellent such that a higher response indicates better quality of life (QOL). The mean of these responses is linearly transformed to a range of 0 (worst) to 100 (best). Change is calculated as time point - baseline such that a positive change value indicates worse symptoms compared to baseline." (NCT00304031)
Timeframe: Baseline and mid-cycle 4 (approximately 24 weeks)
| Intervention | score on a scale (Mean) |
|---|---|
| Conventional Adjuvant TMZ | -2.78 |
| Dose-dense Adjuvant TMZ | -0.72 |
The MDASI-BT is a 28-item patient-reported outcome measure assessing symptom severity and resulting interference with daily living in brain cancer patients. All items range from 0 (not present) to 10 (as bad as you can imagine). The symptom severity score is the average of the symptom severity items, given a specified minimum numbers were completed. A score worse than baseline by at least one is considered deterioration. Change is calculated as time point - baseline such that a positive change value indicates worse symptoms compared to baseline. (NCT00304031)
Timeframe: Baseline and mid-cycle 1 (approximately 12 weeks)
| Intervention | score on a scale (Mean) |
|---|---|
| Conventional Adjuvant TMZ | 0.48 |
| Dose-dense Adjuvant TMZ | 0.39 |
The MDASI-BT is a 28-item patient-reported outcome measure assessing symptom severity and resulting interference with daily living in brain cancer patients. All items range from 0 (not present) to 10 (as bad as you can imagine). The symptom severity score is the average of the symptom severity items, given a specified minimum numbers were completed. A score worse than baseline by at least one is considered deterioration. Change is calculated as time point - baseline such that a positive change value indicates worse symptoms compared to baseline. (NCT00304031)
Timeframe: Baseline and mid-cycle 4 (approximately 24 weeks)
| Intervention | score on a scale (Mean) |
|---|---|
| Conventional Adjuvant TMZ | -0.23 |
| Dose-dense Adjuvant TMZ | 0.19 |
"Global Health Status is calculated from two questions on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire [EORTC QLQ]-C30. The question responses range from 1 very poor to 7 excellent such that a higher response indicates better quality of life (QOL). The mean of these responses is linearly transformed to a range of 0 (worst) to 100 (best)." (NCT00304031)
Timeframe: Baseline and cycle 10 (approximately 46 weeks)
| Intervention | score on a scale (Mean) |
|---|---|
| Conventional Adjuvant TMZ | 73.3 |
| Dose-dense Adjuvant TMZ | 69.7 |
The MDASI-BT is a 28-item patient-reported outcome measure assessing symptom severity and resulting interference with daily living in brain cancer patients. All items range from 0 (not present) to 10 (as bad as you can imagine). The symptom severity score is the average of the symptom severity items, given a specified minimum numbers were completed. (NCT00304031)
Timeframe: Baseline and cycle 10 (approximately 46 weeks)
| Intervention | score on a scale (Mean) |
|---|---|
| Conventional Adjuvant TMZ | 1.17 |
| Dose-dense Adjuvant TMZ | 1.18 |
The NCF Composite score is the arithmetic mean of the Hopkins Verbal Learning Test - Revised (HVLT-R) (Free Recall, Delayed Recall, Delayed Recognition), Trail Making Test Part A (TMTA), Trail Making Test Part B (TMTB), and Controlled Oral Word Association (COWA) test scores, all of which are standardized, adjusting for age, education, and gender as necessary, such that mean is 0 and standard deviation is 1. A participant must have at least 5 of the 6 scores. A higher composite score indicates better neurocognitive function. (NCT00304031)
Timeframe: Baseline and cycle 10 (approximately 46 weeks)
| Intervention | score on a scale (Mean) |
|---|---|
| Conventional Adjuvant TMZ | -0.95 |
| Dose-dense Adjuvant TMZ | -1.19 |
Overall survival time is defined as time from registration/randomization to the date of death from any cause. Overall survival rates are estimated by the Kaplan-Meier method. Patients last known to be alive are censored at the date of last contact. Analysis occurred after 647 deaths were reported. (NCT00304031)
Timeframe: From randomization to last follow-up. Maximum follow-up at time of analysis was 4.4 years.
| Intervention | months (Median) |
|---|---|
| Conventional Adjuvant TMZ | 16.6 |
| Dose-dense Adjuvant TMZ | 14.9 |
Progression is defined as greater than 25% increase in tumor area (two diameters) provided that the patient has not had his/her dose of steroids decreased since the last evaluation period. Progression-free survival time is defined as time from registration to the date of first progression, death, or last known follow-up (censored). Progression-free survival rates are estimated using the Kaplan-Meier method. A concomitant decrease in steroid dose will rule out a progression designation during the first 2 months after completion of radiation therapy. Analysis occurred after 647 deaths were reported. (NCT00304031)
Timeframe: From randomization to last follow-up. Maximum follow-up at time of analysis was 4.4 years.
| Intervention | months (Median) |
|---|---|
| Conventional Adjuvant TMZ | 5.5 |
| Dose-dense Adjuvant TMZ | 6.7 |
The MDASI-BT is a 28-item patient-reported outcome measure assessing symptom severity and resulting interference with daily living in brain cancer patients. All items range from 0 (did not interfere) to 10 (interfered completely). The symptom interference score is the average of the symptom interference items, given a specified minimum numbers were completed. A score worse than baseline by at least one is considered deterioration. (NCT00304031)
Timeframe: baseline and cycle 4 (approximately 22 weeks)
| Intervention | Participants (Count of Participants) |
|---|---|
| Conventional Adjuvant TMZ | 7 |
| Dose-dense Adjuvant TMZ | 13 |
The MDASI-BT is a 28-item patient-reported outcome measure assessing symptom severity and resulting interference with daily living in brain cancer patients. All items range from 0 (not present) to 10 (as bad as you can imagine). The symptom severity score is the average of the symptom severity items, given a specified minimum numbers were completed. A score worse than baseline by at least one is considered deterioration. (NCT00304031)
Timeframe: baseline and cycle 4 (approximately 22 weeks)
| Intervention | Participants (Count of Participants) |
|---|---|
| Conventional Adjuvant TMZ | 5 |
| Dose-dense Adjuvant TMZ | 11 |
Overall survival time is defined as time from registration to the date of death from any cause or last known follow-up (censored). Overall survival rates are estimated by the Kaplan-Meier method. Progression is defined as greater than 25% increase in tumor area (two diameters) provided that the patient has not had his/her dose of steroids decreased since the last evaluation period. (NCT00304031)
Timeframe: From randomization to last follow-up. Maximum follow-up at time of analysis was 4.4 years.
| Intervention | months (Median) |
|---|---|
| No Progression at 6 Months | 20.7 |
| Progression at 6 Months | 10.1 |
"Global Health Status is calculated from two questions on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire [EORTC QLQ]-C30. The question responses range from 1 very poor to 7 excellent such that a higher response indicates better quality of life (QOL). The mean of these responses is linearly transformed to a range of 0 (worst) to 100 (best). Change from baseline was calculated as time point value - baseline value with a positive change value indicating improved QOL from baseline." (NCT00304031)
Timeframe: Baseline, 10,12, 22, 24, and 46 weeks
| Intervention | score on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Week 10 (Cycle 1) | Week 12 (Cycle 1.5) | Week 22 (Cycle 4) | Week 24 (Cycle 4.5) | Week 46 (Cycle 10) | |
| Conventional Adjuvant TMZ | 0.0 | -4.6 | 3.9 | -2.8 | 5.4 |
| Dose-dense Adjuvant TMZ | -2.9 | -2.7 | -4.4 | -0.7 | -1.9 |
The MDASI-BT is a 28-item patient-reported outcome measure assessing symptom severity and resulting interference with daily living in brain cancer patients. All items range from 0 (not present) to 10 (as bad as you can imagine). The symptom severity score is the average of the symptom severity items, given a specified minimum numbers were completed. (NCT00304031)
Timeframe: Baseline, 10, 12, 22, 24, and 46 weeks
| Intervention | score on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Baseline | Week 10 (Cycle 1) | Week 12 (Cycle 1.5) | Week 22 (Cycle 4) | Week 24 (Cycle 4.5) | Week 46 (Cycle 10) | |
| Conventional Adjuvant TMZ | 1.3 | 1.4 | 1.6 | 1.0 | 1.0 | 1.2 |
| Dose-dense Adjuvant TMZ | 1.1 | 1.4 | 1.5 | 1.2 | 1.1 | 1.1 |
The NCF Composite score is the arithmetic mean of the HVLT-R (Free Recall, Delayed Recall, Delayed Recognition), TMTA, TMTB, and COWA scores, all of which are standardized, adjusting for age, education, and gender as necessary, such that mean is 0 and standard deviation is 1. A participant must have at least 5 of the 6 scores. A higher composite score indicates better neurocognitive function. (NCT00304031)
Timeframe: Baseline, 10, 22, and 46 weeks
| Intervention | score on a scale (Mean) | |||
|---|---|---|---|---|
| Baseline | Week 10 (Cycle 1) | Week 22 (Cycle 4) | Week 46 (Cycle 10) | |
| Conventional Adjuvant TMZ | -1.2 | -1.3 | -1.1 | -1.0 |
| Dose-dense Adjuvant TMZ | -1.5 | -1.45 | -1.3 | -1.2 |
Overall survival time is defined as time from randomization to the date of death from any cause. Overall survival rates are estimated by the Kaplan-Meier method. Patients last known to be alive are censored at the date of last contact. Tumor tissue submitted at baseline was analyzed to determine MGMT (O[6]-methylguanine-DNA methyltransferase) promoter methylation status (methylated / unmethylated). Analysis occurred after 647 deaths were reported. (NCT00304031)
Timeframe: From randomization to last follow-up. Maximum follow-up at time of analysis was 4.4 years.
| Intervention | months (Median) | |
|---|---|---|
| Unmethylated MGMT | Methylated MGMT | |
| Conventional Adjuvant TMZ | 14.6 | 21.4 |
| Dose-dense Adjuvant TMZ | 13.3 | 20.2 |
Progression is defined as greater than 25% increase in tumor area (two diameters) provided that the patient has not had his/her dose of steroids decreased since the last evaluation period. Progression-free survival time is defined as time from registration to the date of first progression, death, or last known follow-up (censored). Progression-free survival rates are estimated using the Kaplan-Meier method. A concomitant decrease in steroid dose will rule out a progression designation during the first 2 months after completion of radiation therapy. Tumor tissue submitted at baseline was analyzed to determine MGMT (O[6]-methylguanine-DNA methyltransferase) promoter methylation status (methylated / unmethylated). Analysis occurred after 647 deaths were reported. (NCT00304031)
Timeframe: From randomization to last follow-up. Maximum follow-up at time of analysis was 4.4 years.
| Intervention | months (Median) | |
|---|---|---|
| Unmethylated MGMT | Methylated MGMT | |
| Conventional Adjuvant TMZ | 5.1 | 6.5 |
| Dose-dense Adjuvant TMZ | 6.0 | 10.1 |
Overall Survival was defined as the time from randomization to death due to any cause. (NCT00943826)
Timeframe: Randomization until OS Event (Until data cutoff= 28 February 2013 [up to 42.2 months])
| Intervention | Months (Median) |
|---|---|
| Bevacizumab + RT + Temozolomide | 16.8 |
| Placebo + RT + Temozolomide | 16.7 |
PFS is defined as time from randomization to disease progression (PD) or death. PD was assessed using adapted Macdonald response criteria (modified World Health Organization [WHO] criteria) based on 3 components: radiological tumor assessments using Magnetic Resonance Imaging [MRI] scans,neurological assessment and changes in corticosteroid use. PD is assessed as greater than or equal to(>=) 25% increase in sum of products of the longest diameters of all index lesions (enhancing,measurable) compared with the smallest recorded sum (nadir); or unequivocal PD of existing non-index lesions (non-enhancing and enhancing,non-measurable); or unequivocal appearance of new lesions); or neurological worsening (if corticosteroid dose is stable or increased) compared to neurological evaluation at previous disease assessment with no need for a confirmatory scan. Participants without a PFS event were censored at last disease assessment. (NCT00943826)
Timeframe: Randomization until PFS Event [Until data cutoff= 31 March 2012 (up to 31.4 months)
| Intervention | Months (Median) |
|---|---|
| Bevacizumab + RT + Temozolomide | 10.6 |
| Placebo + RT + Temozolomide | 6.2 |
KM estimate of one year overall survival (probability to survive for at least 1 year) was reported. Corresponding 95% confidence interval (CI) was calculated using Greenwood's formula. (NCT00943826)
Timeframe: Randomization until Overall Survival Event (Until data cutoff= 28 February 2013 [up to 42.2 months])
| Intervention | probability of being alive (Number) |
|---|---|
| Bevacizumab + RT + Temozolomide | 0.72 |
| Placebo + RT + Temozolomide | 0.66 |
KM estimate of two year overall survival was reported (probability to survive for at least 2 years). Corresponding 95% CI was calculated using Greenwood's formula. (NCT00943826)
Timeframe: Randomization until Overall Survival Event (Until data cutoff= 28 February 2013 [up to 42.2 months])
| Intervention | probability of being alive (Number) |
|---|---|
| Bevacizumab + RT + Temozolomide | 0.34 |
| Placebo + RT + Temozolomide | 0.30 |
An Independent Review Facility reviewed the MRI scans used by investigator to evaluate radiological tumor response. PFS is defined as time from randomization to PD or death. PD was assessed using adapted Macdonald response (modified WHO) criteria based on 3 components: radiological tumor assessments using MRI scans, neurological assessment and changes in corticosteroid use. PD is assessed as >=25% increase in sum of products of the longest diameters of all index lesions (enhancing, measurable) compared with the smallest recorded sum (nadir); or unequivocal PD of existing non-index lesions (non-enhancing and enhancing, non-measurable); or unequivocal appearance of new lesions); or neurological worsening (if corticosteroid dose is stable or increased) compared to neurological evaluation at previous disease assessment with no need for a confirmatory scan. Participants without a PFS event were censored at last disease assessment. (NCT00943826)
Timeframe: Randomization until PFS Event (Until data cutoff= 31 March 2012 [up to 29.5 months])
| Intervention | Months (Median) |
|---|---|
| Bevacizumab + RT +Temozolomide | 8.4 |
| Placebo + RT + Temozolomide | 4.3 |
An adverse event (AE) was considered any unfavorable and unintended sign, symptom, or disease associated with the use of the study drug, whether or not considered related to the study drug. Preexisting conditions that worsened during the study were reported as AE.A serious adverse event (SAE) is any experience that suggests a significant hazard,contraindication, side effect or precaution that: results in death, is life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically significant. Non-serious adverse events (Non-SAEs) included all AEs except SAEs (non-SAEs = all AEs - SAEs). Nine participants randomized to the Placebo+RT+Temozolomide arm incorrectly received at least 1 dose of bevacizumab and were added to the Bevacizumab+RT+Temozolomide arm for Safety. (NCT00943826)
Timeframe: Randomization until study completion (Until data cutoff= 09 Sep 2015 [up to 64 months])
| Intervention | Participants (Number) | ||
|---|---|---|---|
| Non-SAEs | SAEs | Death | |
| Bevacizumab + RT + Temozolomide | 437 | 179 | 335 |
| Placebo + RT + Temozolomide | 412 | 115 | 337 |
EORTC QLQ-C30: 30 items; 5 functional scales; 9 symptom scales; & global health status. Most questions used 4-point scale (1:Not at all, 4:Very much), 2 questions used 7-point scale (1:very poor, 7:Excellent). EORTC QLQ-BN20: 20 items rated on a 4 point scale (1:not at all, 4:very much). EORTC QLQ-C30 and BN20 scores were transformed to a 0-100 scale, higher score=better functioning/global health (C30) or more severe symptoms (BN20). Stable HRQoL: change from baseline (BL) within 10 points. Improved HRQoL: an increase from BL >/=10 points for functioning/global health status, & decrease of >/=10 points for symptoms. PFS is reported for participants with Stable/Improved global health; physical, social functioning (C30); motor dysfunction & communication deficit (BN20). PFS: randomization to PD or death. PD: >=25% increase in sum of products of longest diameters of index lesions; or progression of existing non-index lesions; or appearance of new lesions; or neurological worsening. (NCT00943826)
Timeframe: Randomization until PFS Event [Until data cutoff= 31 March 2012 (up to 31.4 months)
| Intervention | Months (Median) | ||||
|---|---|---|---|---|---|
| Global health status (n=354, 309) | Physical functioning (n=353, 318) | Social functioning (n=352, 327) | Motor dysfunction (n=361, 314) | Communication deficit (n=365, 329) | |
| Bevacizumab + RT + Temozolomide | 8 | 7 | 8 | 7 | 8 |
| Placebo + RT + Temozolomide | 4 | 5 | 4 | 4 | 4 |
Overall survival for patients by Methylation status of the O6-methylguanine-DNA methyltransferase promoter (NCT00482677)
Timeframe: 7 years
| Intervention | Months (Median) |
|---|---|
| Temozolomide | 13.47 |
| Radiation | 7.69 |
Time from date of randomization to the date of death of any causes, or censored at last known alive date. (NCT00482677)
Timeframe: 7 years
| Intervention | Months (Median) |
|---|---|
| Temozolomide | 9.33 |
| Radiation | 7.62 |
Time from date of randomization to the date of disease progression or death whichever came first, or censored at last disease assessment date. (NCT00482677)
Timeframe: 7 years
| Intervention | Months (Median) |
|---|---|
| Temozolomide | 5.29 |
| Radiation | 3.94 |
Progression-free survival as determined by Kaplan-Meier method. (NCT00392171)
Timeframe: 6 months
| Intervention | Percentage of Participants (Number) | |||
|---|---|---|---|---|
| Anaplastic Glioma (n=28) | Early Glioblastoma Multiforme (GBM) (n=33) | Extended Glioblastoma Multiforme (GBM) (n=27) | Rechallenge Glioblastoma Multiforme (GBM) (n=28) | |
| Temozolomide | 35.7 | 27.3 | 7.4 | 35.7 |
all patients alive as of the last contact were censored for survival on the basis of that contact date (NCT00369590)
Timeframe: 3 years
| Intervention | weeks (Median) |
|---|---|
| Arm I - Anaplastic Glioma | 55 |
| Arm 2 - Glioblastoma | 39 |
"pts with confirmed radiographic response and their rate of progression (PFS).~Response determined by modified MacDonald Criteria Complete Response (CR): Complete disappearance of all measurable and evaluable disease, no new lesions. no steroids Partial Response (PR): Greater than or equal to 50% decrease under baseline in the sum of products of perpendicular diameters of all measurable lesions. No progression of evaluable lesions. no new lesions. steroid dose no > than maximum dose used in first 8 weeks of treatment.~Stable: Does not qualify for CR, PR, or progression steroid dose no > than maximum dose used in first 8 weeks of treatment.~Progression: 25% increase in the sum of products of all measurable lesions over smallest sum observed (over baseline if no increase) Clear clinical worsening." (NCT00369590)
Timeframe: up to 3 years
| Intervention | weeks (Median) |
|---|---|
| Arm I - Anaplastic Glioma | 45 |
| Arm 2 - Glioblastoma | 23 |
"This design yields 85% power to detect a true 30% 6-month PFS rate, while maintaining .91 probability of rejecting for a true 15% 6-month PFS rate.~pts had MRIs at screening and at the 3rd and 5th cycles then every 8 weeks until progression.~Response determined by modified MacDonald Criteria Complete Response (CR): Complete disappearance of all measurable and evaluable disease, no new lesions. no steroids Partial Response (PR): Greater than or equal to 50% decrease under baseline in the sum of products of perpendicular diameters of all measurable lesions. No progression of evaluable lesions. no new lesions. steroid dose no > than maximum dose used in first 8 weeks of treatment.~Stable: Does not qualify for CR, PR, or progression steroid dose no > than maximum dose used in first 8 weeks of treatment.~Progression: 25% increase in the sum of products of all measurable lesions over smallest sum observed (over baseline if no increase) Clear clinical worsening." (NCT00369590)
Timeframe: 6 months
| Intervention | percentage of participants (Number) |
|---|---|
| Arm I - Anaplastic Glioma | 25 |
| Arm 2 - Glioblastoma | 7.7 |
number of patients who experienced toxicity that led to being taken off treatment (NCT00369590)
Timeframe: Approximately 1 year (start of treatment - end of treatment)
| Intervention | participants (Number) |
|---|---|
| Arm I - Anaplastic Glioma | 8 |
| Arm 2 - Glioblastoma | 6 |
number of cycles patient was able to have before developing a toxicity that required removing the patient from treatment. Treatment: Aflibercept 4mg/kg intravenously on day 1 of every 14-day cycle - 2 week cycle. (NCT00369590)
Timeframe: Start to End of treatment 39 cycles or 1yr 7.5months (78 weeks)
| Intervention | cycles (Median) |
|---|---|
| Arm I - Anaplastic Glioma | 5 |
| Arm 2 - Glioblastoma | 3.5 |
"pts had MRIs at screening and at the 3rd and 5th cycles then every 8 weeks until progression. All responders were centrally reviewed for confirmation~Response determined by modified MacDonald Criteria Complete Response (CR): Complete disappearance of all measurable and evaluable disease, no new lesions. no steroids Partial Response (PR): Greater than or equal to 50% decrease under baseline in the sum of products of perpendicular diameters of all measurable lesions. No progression of evaluable lesions. no new lesions. steroid dose no > than maximum dose used in first 8 weeks of treatment.~Stable: Does not qualify for CR, PR, or progression steroid dose no > than maximum dose used in first 8 weeks of treatment.~Progression: 25% increase in the sum of products of all measurable lesions over smallest sum observed (over baseline if no increase) Clear clinical worsening." (NCT00369590)
Timeframe: Up to 2 years
| Intervention | participants (Number) | |
|---|---|---|
| Complete Response | Partial Response | |
| Arm 2 - Glioblastoma | 0 | 7 |
| Arm I - Anaplastic Glioma | 1 | 6 |
Safety will be assessed using a dose escalation design for temozolomide's use to determine the target dose and also to evaluate any and all acute treatment related toxicities. During the course of patient follow up and therapy, toxicities will be evaluated, particularly as the investigators will be determining the target dose of temozolomide. One of the major criteria for dose limiting toxicity for the study will be any Grade 3 or 4 nonhematologic toxicity from a list of commonly expected toxicities associated with autologous transplantation and temozolomide. (NCT01235793)
Timeframe: One Year
| Intervention | dose in mg/m^2 (Number) |
|---|---|
| DRBEAT Regimen | 773.25 |
"Efficacy of the DRBEAT Regimen will be assessed by analysis of~one-year progression-free survival (PFS), defined as the time interval from maximal response from therapy to tumor regrowth, progression*, or death, (*Progression is defined as meeting the response criteria listed in Table 4: Response Criteria for Primary Central Nervous System Lymphoma according to Abrey LE, Batchelor TT, Ferreri AJM et al.)~and~Overall survival, defined as the time interval between the date of transplant and the date of death from any cause." (NCT01235793)
Timeframe: (1) One Year (2) Until date of death from any cause, assessed up to 2 years
| Intervention | Days (Median) | |
|---|---|---|
| Progression Free Survival | Overall Survival | |
| DRBEAT Regimen | 132 | 564 |
Two groups of patients in the Phase II trial will be considered separately, 1) participants who have not received previous bevacizumab and 2) participants who have received bevacizumab as part of first-line treatment. Overall survival is measured as the interval from first study treatment until date of death, or date last known alive. (NCT01349660)
Timeframe: every 12 weeks for up to 60 months
| Intervention | months (Median) |
|---|---|
| Phase II Participants - Prior Bevacizumab | 6.6 |
| Phase II Participants - Bevacizumab Naive | 10.8 |
Two groups of patients in the Phase II trial will be considered separately, 1) participants who have not received previous bevacizumab and 2) participants who have received bevacizumab as part of first-line treatment. PFS is measured from the date of first protocol treatment until date of disease progression or death occurs, or date of last adequate tumor assessment using RANO or McDonald criteria. McDonald disease progression criteria: a 25% or greater increase in sum of the diameters of lesions, new lesions, or clinical deterioration (McDonald et al, 1990). RANO disease progression criteria: a 25% or greater increase in the enhancing lesions sum compared with smallest tumor measurement, significant increase in T2/FLAIR nonenhancing lesion on stable or increasing corticosteroids, new lesions, or clinical deterioration (Wen et al 2010) (NCT01349660)
Timeframe: every 8 weeks for up to 33 months
| Intervention | months (Median) |
|---|---|
| Phase II Patients With Prior Bevacizumab Treatment. | 2.8 |
| Phase II Patients Without Prior Bevacizumab Treatment | 5.3 |
The optimal dose of BKM120 to administer in combination with standard dose bevacizumab determined as the dose at which ≤1 of 6 patients experiences a DLT assessed using NCI CTCAE v4.03 during Cycle 1 (28 days). The optimal dose of BKM120 was determined to be 60 mg by mouth (PO), once a day for each 28 day cycle along with bevacizumab, administered 10 mg/kg intravenously (IV) on Day 1 and Day 15 of each 28 day cycle. (NCT01349660)
Timeframe: Collected from day of first dose to the end of the first treatment cycle, up to 28 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Phase I Dose Level 1 (60 mg BKM120, 10mg/kg Bevacizumab) | 0 |
| Phase I Dose Level 2 (80 mg BKM120, 10mg/kg Bevacizumab) | 3 |
Two groups of participants in the Phase II trial will be considered separately, 1) those who have not received previous bevacizumab and 2) those who have received bevacizumab as part of first-line treatment. Overall Response (OR) = number of patients with complete or partial responses (CR or PR) per McDonald or RANO criteria. McDonald: CR as disappearance of all disease for at least four weeks, no new lesions, no steroids; PR as 50% or greater decrease in the sum of all lesions compared with baseline for at least four weeks, no new lesions, stable or reduced steroids (McDonald 1990). RANO: CR as disappearance of all disease for at least 4 weeks, no new lesions, stable or improved nonenhancing lesions, and no steroid usage; and PR as a 50% or greater decrease in the sum of all lesions compared with baseline measurement for at least four weeks, no new lesions, stable or improved nonenhancing lesions on same or lower steroid dose compared to baseline (Wen 2010). (NCT01349660)
Timeframe: every 8 weeks, projected 24 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Phase II Participants - Prior Bevacizumab. | 1 |
| Phase II Participants - Bevacizumab Naive | 18 |
Defined as the number of participants with treatment-emergent grade 3/4/5 adverse events/serious adverse events utilizing the National Cancer Institute Common Technology Criteria for Adverse Events (NCI CTCAE) v4.03 (NCT01349660)
Timeframe: every 4 weeks for up to 5.2 years
| Intervention | Participants (Count of Participants) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Fatigue | Confusion | Hyperglycemia | Diarrhea | Alanine aminotransferase increased | Hypertension | Seizure | Asthenia | Aspartate Aminotransferase Increased | Hypertriglyceridemia | Abdominal pain | Altered Mental Status | Gait Disturbance | Ataxia | Lipase Increased | Muscle Weakness | Pneumonia | Sepsis | Respiratory Failure | Thrombocytopenia | Hypercholesterolemia | Mucositis | Anorexia | Memory Impairment | Pruritis | Vomiting | Mood Alteration | Weight Loss | Neutropenia | Dehydration | Dyspnea | Hemorrhage | Somnolence | Taste Alteration | Agitation | Dysarthria | Fall | Hypermagnesemia | Ejection Fraction Decreased | Elevated Liver Enzymes | Hypoalbuminemia | Hypophosphatemia | Psychosis | Suicidal Ideation | Thromboembolic Event | Akathisia | Cellulitis | Chronic Obstructive Pulmonary Disease | Delirium | Diabetic Ketoacidosis | Enteritis | Female Genital Tract Fistula | Gastrointestinal Infection | Hyperlipidemia | Intracranial Hemorrhage | Left Ventricular Systolic Dysfunction | Necrotizing Fasciitis | Palsy | Paralysis | Personality Change | Syncope | Transaminitis | Urine Output Decreased | Vaginal Fistula | Volume Depletion | Headache | Hypokalemia | Hyponatremia | Nausea | Proteinuria | Rash | Urinary Tract Infection | |
| Phase I - Dose Level 1 (60 mg BKM, 10mg/kg Bevacizumab) | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Phase I - Dose Level 2 (80 mg BKM120, 10mg/kg Bevacizumab) | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 2 | 0 | 1 | 2 |
| Phase II - (60 mg BKM120, 10mg/kg Bevacizumab) | 8 | 8 | 5 | 5 | 5 | 6 | 6 | 4 | 5 | 2 | 1 | 1 | 1 | 0 | 2 | 2 | 1 | 2 | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 2 | 4 | 3 | 1 | 3 | 2 | 2 |
We first determined the MTDs in each ARM and we then performed the cohort expansion at the MTD in both ARMs separately, until we treated a total of 18 participants at this dose in each ARM. PFS is defined as the duration of time from start of registration to time of progression or death, whichever comes first. Progression was assessed by the Response Assessment in Neuro-Oncology Criteria (RANO). Progression is ≥25% increase in tumor volume compared to baseline in the sum of the products of perpendicular diameters of enhancing lesions compared with the smallest measurement obtained either at baseline or best response with the participant on stable or increasing doses of steroids. Significant increase in T2-weighted-Fluid-Attenuated Inversion Recovery (T2/FLAIR) non-enhancing lesions with the participant on stable or increasing doses of steroids (not caused by comorbid events). Any new lesions. (NCT02942264)
Timeframe: 4 months
| Intervention | percentage of participants (Number) |
|---|---|
| All Participants | 25 |
We first determined the maximum tolerated dose (MTDs) in each ARM and we then performed the cohort expansion at the MTD in both ARMs separately, until we treated a total of 18 participants at this dose in each ARM. PFS is defined as the duration of time from start of registration to time of progression or death, whichever comes first. Progression was assessed by the Response Assessment in Neuro-Oncology Criteria (RANO). Progression is ≥25% increase in tumor volume compared to baseline in the sum of the products of perpendicular diameters of enhancing lesions compared with the smallest measurement obtained either at baseline or best response with the participant on stable or increasing doses of steroids. Significant increase in T2-weighted-Fluid-Attenuated Inversion Recovery (T2/FLAIR) non-enhancing lesions with the participant on stable or increasing doses of steroids (not caused by comorbid events). Any new lesions. (NCT02942264)
Timeframe: 4 months
| Intervention | percentage of participants (Number) |
|---|---|
| All Participants | 40 |
Here is the number of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. (NCT02942264)
Timeframe: Date treatment consent signed to date off study, approximately 15mo(m)/8days(d), 26m, 7m/26d, 13m/17d, 11m/30d, 12m/6d, 19m/11d, 9m/28d and 18m/21d for Group 1-9 respectively.
| Intervention | Participants (Count of Participants) |
|---|---|
| ARM 1 Dose Level 0 - (Starting Dose) | 6 |
| ARM 1 Dose Level 1 - (Dose Escalation) | 13 |
| ARM 2 Dose Level 0 (Starting Dose) | 3 |
| ARM 2 Dose 1 - (Dose Escalation) | 6 |
| ARM 2 Dose 0 - (Dose De-escalation) | 3 |
| ARM 2 Dose Level II - (Dose Escalation) | 2 |
| ARM 2 Dose Level I - (Dose De-escalation) | 7 |
| ARM 1 Dose Level 1 (MTD Level in ARM1) | 6 |
| ARM 2 Dose Level 1 (MTD Level in ARM2) | 7 |
Maximum tolerated dose of metronomic (mn) Zotiraciclib (TG02) was assessed using the Bayesian Optimal Interval (BOIN) design. The MTD is defined as the dose for which the isotonic estimate of the toxicity rate is closest to the target toxicity rate of 0.35. If there are ties, we select the higher dose level when the isotonic estimate is lower than the target toxicity rate; and we select the lower dose level when the isotonic estimate is greater than the target toxicity rate of 0.35. (NCT02942264)
Timeframe: 4 weeks after initiation of treatment
| Intervention | mg/day (Number) |
|---|---|
| All Participants | 250 |
Maximum tolerated dose of Zotiraciclib (TG02) in combination with dose dense Temozolomide (TMZ) was assessed using the Bayesian Optimal Interval (BOIN) design. The MTD is defined as the dose for which the isotonic estimate of the toxicity rate is closest to the target toxicity rate of 0.35. If there are ties, we select the higher dose level when the isotonic estimate is lower than the target toxicity rate; and we select the lower dose level when the isotonic estimate is greater than the target toxicity rate of 0.35. (NCT02942264)
Timeframe: 4 weeks after initiation of treatment
| Intervention | mg/day (Number) |
|---|---|
| All Participants | 250 |
DLT is defined as any adverse events attributed to the study drug. For example, Grade 4 neutropenia lasting 5 days or more. Febrile neutropenia defined as grade 3-4 neutropenia with fever ≥38.5ºC and/or infection requiring antibiotic or antifungal treatment. Nausea or vomiting that responds to symptomatic therapy and lasts ≤7 days. Fatigue that responds to symptomatic therapy and lasts ≤7 days. And weight gain (in patients on steroids). (NCT02942264)
Timeframe: 4 weeks after initiation of treatment
| Intervention | Participants (Count of Participants) |
|---|---|
| ARM 1 Dose Level 0 - (Starting Dose) | 1 |
| ARM 1 Dose Level 1 - (Dose Escalation) | 3 |
| ARM 2 Dose Level 0 (Starting Dose) | 0 |
| ARM 2 Dose 1 - (Dose Escalation) | 3 |
| ARM 2 Dose 0 - (Dose De-escalation) | 1 |
| ARM 2 Dose Level II - (Dose Escalation) | 1 |
| ARM 2 Dose Level I - (Dose De-escalation) | 4 |
CAR and vector presence were quantitated in peripheral blood mononuclear cell (PBMC) samples using established polymerase chain reaction (PCR) techniques (NCT01454596)
Timeframe: 1 month post transplant
| Intervention | K/µL (Median) |
|---|---|
| Group A (Steroids) - Cohort 1: 1x10(7) | 23 |
| Group A (Steroids) - Cohort 2: 3x10(7) | 70 |
| Group A (Steroids) - Cohort 3: 1x10(8) | 36 |
| Group B (No Steroids) - Cohort 1: 1x10(7) | 67 |
| Group B (No Steroids) - Cohort 2: 3x10(7) | 7 |
| Group B (No Steroids) - Cohort 3: 1x10(8) | 43 |
| Group B (No Steroids) - Cohort 4: 3x10(8) | 28 |
| Group B (No Steroids) - Cohort 5: 1x10(9) | 25 |
| Combined Steroids/no Steroids) - Cohort 6: 3x10(9) | 12 |
| Combined Steroids/no Steroids) - Cohort 7: 1x10(10) | 67.5 |
| Combined Steroids/no Steroids) - Cohort 8: 3-6x10(10) | NA |
| Combined Steroids/no Steroids) - Cohort 9: 3x10(10) | 8 |
Here is the count of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. (NCT01454596)
Timeframe: 51 dys Grp A, Cohort 1; Cohort 2:68 dys; Cohort 3:40 dys; Grp B, Cohort 1:67 dys; Cohort 2:48 dys; Cohort 3:55 dys; Cohort 4: 46 dys; Cohort 5:147 dys; C. Ster/No Ster Grp, Cohort 6:12 mos, 26 dys; Cohort 7:11 mos, 18 dys; Cohort 8:7 dys; Cohort 9:70 dys.
| Intervention | Participants (Count of Participants) |
|---|---|
| Group A (Steroids) - Cohort 1: 1x10(7) | 1 |
| Group A (Steroids) - Cohort 2: 3x10(7) | 1 |
| Group A (Steroids) - Cohort 3: 1x10(8) | 1 |
| Group B (No Steroids) - Cohort 1: 1x10(7) | 1 |
| Group B (No Steroids) - Cohort 2: 3x10(7) | 1 |
| Group B (No Steroids) - Cohort 3: 1x10(8) | 1 |
| Group B (No Steroids) - Cohort 4: 3x10(8) | 1 |
| Group B (No Steroids) - Cohort 5: 1x10(9) | 3 |
| Combined Steroids/no Steroids) - Cohort 6: 3x10(9) | 3 |
| Combined Steroids/no Steroids) - Cohort 7: 1x10(10) | 3 |
| Combined Steroids/no Steroids) - Cohort 8: 3-6x10(10) | 1 |
| Combined Steroids/no Steroids) - Cohort 9: 3x10(10) | 1 |
Objective response was assessed by comparison with baseline dynamic contrast enhanced magnetic resonance imaging with perfusion using Neuro-oncology Working Group proposed guidelines. Complete Response is disappearance of all measurable and non-measurable disease for at least 4 weeks. Partial Response is >/= 50% decrease in lesions for at least 4 weeks. Stable Disease does not meet the criteria for complete response, partial response or progression and requires stable lesions compared with baseline. Progression is >/= 25% increase in lesions. (NCT01454596)
Timeframe: 4 weeks after cell infusion and monthly as feasible up to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Group A (Steroids) - Cohort 1: 1x10(7) | 0 |
| Group A (Steroids) - Cohort 2: 3x10(7) | 0 |
| Group A (Steroids) - Cohort 3: 1x10(8) | 0 |
| Group B (No Steroids) - Cohort 1: 1x10(7) | 0 |
| Group B (No Steroids) - Cohort 2: 3x10(7) | 0 |
| Group B (No Steroids) - Cohort 3: 1x10(8) | 0 |
| Group B (No Steroids) - Cohort 4: 3x10(8) | 0 |
| Group B (No Steroids) - Cohort 5: 1x10(9) | 0 |
| Combined Steroids/no Steroids) - Cohort 6: 3x10(9) | 0 |
| Combined Steroids/no Steroids) - Cohort 7: 1x10(10) | 0 |
| Combined Steroids/no Steroids) - Cohort 8: 3-6x10(10) | 0 |
| Combined Steroids/no Steroids) - Cohort 9: 3x10(10) | 0 |
Aggregate of all adverse events ≥Grade 3 that are possibly, probably, and definitely related to treatment. Adverse events were assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0). Per CTCAE, Grade 3 adverse events are severe, Grade 4 is life threatening, and Grade 5 is death. (NCT01454596)
Timeframe: From 4 weeks after cell infusion up to 77 days
| Intervention | adverse events (Number) |
|---|---|
| Group A (Steroids) - Cohort 1: 1x10(7) | 0 |
| Group A (Steroids) - Cohort 2: 3x10(7) | 0 |
| Group A (Steroids) - Cohort 3: 1x10(8) | 0 |
| Group B (No Steroids) - Cohort 1: 1x10(7) | 0 |
| Group B (No Steroids) - Cohort 2: 3x10(7) | 0 |
| Group B (No Steroids) - Cohort 3: 1x10(8) | 0 |
| Group B (No Steroids) - Cohort 4: 3x10(8) | 0 |
| Group B (No Steroids) - Cohort 5: 1x10(9) | 0 |
| Combined Steroids/no Steroids) - Cohort 6: 3x10(9) | 0 |
| Combined Steroids/no Steroids) - Cohort 7: 1x10(10) | 0 |
| Combined Steroids/no Steroids) - Cohort 8: 3-6x10(10) | 1 |
| Combined Steroids/no Steroids) - Cohort 9: 3x10(10) | 1 |
Progression was assessed by the Response Assessment in Neuro-Oncology (RANO) criteria and is defined as the circumstance when the magnetic resonance imaging (MRI) scan is ranked -2 (definitely worse) or -3 (development of a new lesion). (NCT01454596)
Timeframe: Time from the date of registration to the date of first observation of progressive disease up to 6 months after end of treatment
| Intervention | months (Median) |
|---|---|
| Group A (Steroids) - Cohort 1: 1x10(7) | 1.1 |
| Group A (Steroids) - Cohort 2: 3x10(7) | 1.1 |
| Group A (Steroids) - Cohort 3: 1x10(8) | 1.3 |
| Group B (No Steroids) - Cohort 1: 1x10(7) | 1.9 |
| Group B (No Steroids) - Cohort 2: 3x10(7) | 2.0 |
| Group B (No Steroids) - Cohort 3: 1x10(8) | 1.5 |
| Group B (No Steroids) - Cohort 4: 3x10(8) | 1.2 |
| Group B (No Steroids) - Cohort 5: 1x10(9) | 1.1 |
| Combined Steroids/no Steroids) - Cohort 6: 3x10(9) | 2.7 |
| Combined Steroids/no Steroids) - Cohort 7: 1x10(10) | 1.1 |
| Combined Steroids/no Steroids) - Cohort 8: 3-6x10(10) | 0 |
| Combined Steroids/no Steroids) - Cohort 9: 3x10(10) | 2.0 |
Number of Participants in Phase 1 with Dose Limiting Toxicities (DLTs) (NCT01465347)
Timeframe: During phase 1
| Intervention | Participants (Count of Participants) |
|---|---|
| TSC 0.25 mg/kg - 9 Dose Group | 0 |
The sum of the product of the diameters of the tumor (using recorded tumor diameter measurements made from brain MRI images) was used to express tumor size. Results were summarized for actual and percentage change from baseline. Individual subjects results were listed, including tumor volume and tumor response from independent reviewers. Investigator data were listed but not used in the analysis. Percent response (according to independent reviewer assessments) by percentage tumor reduction from tumor resection or definitive biopsy to the last MRI were summarized. (NCT01465347)
Timeframe: From Baseline to Week 110
| Intervention | Participants (Count of Participants) | |||||
|---|---|---|---|---|---|---|
| tumor not reduced | 0 to 39% tumor reduction | 40 to 63% tumor reduction | 64 to 93% tumor reduction | 94 to 99% tumor reduction | 100% tumor reduction | |
| TSC 0.25 mg/kg - 18 Dose Group - Phase 2 | 10 | 6 | 2 | 6 | 2 | 11 |
| TSC 0.25mg/kg - 9 Dose Group - Phase 1 | 1 | 0 | 0 | 0 | 0 | 2 |
Participants in phase 2 (18 dose group, 6 weeks treatment with TSC) were monitored for up to 3 years (last follow-up - February 16, 2016). Overall Survival (OS) was defined as the length of time from the date of tumor resection surgery or definitive biopsy to the date of death. The OS analyses were performed using the Kaplan-Meier estimate method. The OS rates at 6, 12, 18 and 24 months were estimated. Median OS values were calculated; a corresponding 95% confidence interval for each median value was determined using a log rank analysis. The length of OS (in months) was calculated as follows: date of death or censored - date of surgery or definitive biopsy / 30.4375. (NCT01465347)
Timeframe: 6, 12, 18, 24 months
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| 6 month OS | 12 month OS | 18 month OS | 24 month OS | |
| TSC 0.25 mg/kg - 18 Dose Group - Phase 2 | 89.3 | 71.2 | 43.8 | 36.3 |
The PFS analyses were performed using the Kaplan-Meier estimate method. The PFS rates at 6, 12, 18 and 24 months were estimated. Median PFS values were calculated; a corresponding 95% confidence interval for each median value was determined using a log rank analysis. Time to disease progression (in months) was calculated as follows: date of event* or censoring - date of surgery or definitive biopsy / 30.4375; *event = first tumor progression or death. (NCT01465347)
Timeframe: 6,12,18, 24 months
| Intervention | percentage of participants (Number) | |||
|---|---|---|---|---|
| 6 months | 12 months | 18 months | 24 months | |
| TSC 0.25 mg/kg - 18 Dose Group - Phase 2 | 30.9 | 9.9 | 4.0 | 0.0 |
26 reviews available for temozolomide and Disease Exacerbation
| Article | Year |
|---|---|
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Neoadjuvant Therapy for Neuroendocrine Neoplasms: Recent Progresses and Future Approaches.
Topics: Capecitabine; Chemoradiotherapy; Disease Progression; Disease-Free Survival; Everolimus; Humans; Neo | 2021 |
Procarbazine, lomustine and vincristine for recurrent high-grade glioma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cytarabine; Dacarbazine; Dis | 2017 |
Temozolomide-associated hypermutation in gliomas.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Disease Progression; DNA Methylation; DNA Repair | 2018 |
Treatment-induced brain tissue necrosis: a clinical challenge in neuro-oncology.
Topics: Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Chemoradiotherapy; Diagnosis, Differentia | 2019 |
Pseudoprogression after glioma therapy: a comprehensive review.
Topics: Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease Progression; | 2013 |
Efficacy and side effects of dacarbazine in comparison with temozolomide in the treatment of malignant melanoma: a meta-analysis consisting of 1314 patients.
Topics: Administration, Intravenous; Administration, Oral; Antineoplastic Agents, Alkylating; Dacarbazine; D | 2013 |
The role of cytotoxic chemotherapy in the management of progressive glioblastoma : a systematic review and evidence-based clinical practice guideline.
Topics: Absorbable Implants; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; B | 2014 |
Supratentorial low-grade diffuse astrocytoma: medical management.
Topics: Antineoplastic Agents; Astrocytoma; Dacarbazine; Disease Progression; Humans; Neoplasm Grading; Nitr | 2014 |
Treatment of pituitary carcinomas and atypical pituitary adenomas: a review.
Topics: Adenoma; Administration, Oral; Antineoplastic Agents, Alkylating; Cell Transformation, Neoplastic; C | 2014 |
Dose-dense temozolomide: is it still promising?
Topics: Antineoplastic Agents, Alkylating; Clinical Trials as Topic; Dacarbazine; Disease Progression; Dose- | 2015 |
The role of temozolomide in the treatment of aggressive pituitary tumors.
Topics: Adenoma; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Dacarbazine; Disease Progression; DN | 2015 |
Low-grade gliomas.
Topics: Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease Progression; | 2015 |
Economic Evaluation of Bevacizumab for the First-Line Treatment of Newly Diagnosed Glioblastoma Multiforme.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro | 2015 |
MGMT testing allows for personalised therapy in the temozolomide era.
Topics: Aged; Dacarbazine; Disease Progression; Disease-Free Survival; DNA Methylation; Gene Silencing; Huma | 2016 |
Pseudoprogression and pseudoresponse in the treatment of gliomas.
Topics: Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Diagnostic Imaging; Disease Progression; Glioma | 2009 |
[Pseudoprogression or pseudoresponse: a challenge for the diagnostic imaging in Glioblastoma multiforme].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A | 2011 |
[Use of angioneogenesis inhibitor monoclonal antibody following standard therapy in recurrent or progressive glioblastoma multiforme].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Antin | 2012 |
[Therapy of malignant melanoma at the stage of distant metastasis].
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineo | 2004 |
Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression.
Topics: Antineoplastic Combined Chemotherapy Protocols; Artifacts; Astrocytoma; Brain Edema; Brain Neoplasms | 2004 |
Benefit of temozolomide compared to procarbazine in treatment of glioblastoma multiforme at first relapse: effect on neurological functioning, performance status, and health related quality of life.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials as Topic; | 2005 |
[New place of the chemotherapy in gliomas].
Topics: Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Chemotherapy, Adjuvant; Clinical Tr | 2005 |
Advances in the treatment of primary brain tumors: dawn of a new era?
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials, Phase III as Topic; Combined Mo | 2006 |
Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas.
Topics: Acute Disease; Antineoplastic Agents, Alkylating; Apoptosis; Brain Edema; Brain Neoplasms; Chemother | 2008 |
Temozolomide in malignant gliomas.
Topics: Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Clinical Trials as Topic; Dacarbazi | 2000 |
Adults with newly diagnosed high-grade gliomas.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Antioxidan | 2001 |
91 trials available for temozolomide and Disease Exacerbation
| Article | Year |
|---|---|
Advanced ADC Histogram, Perfusion, and Permeability Metrics Show an Association with Survival and Pseudoprogression in Newly Diagnosed Diffuse Intrinsic Pontine Glioma: A Report from the Pediatric Brain Tumor Consortium.
Topics: Adolescent; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Benchmarking; Benzimidazoles | 2020 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli | 2021 |
Phase 1/2 Trial of 5-Fraction Stereotactic Radiosurgery With 5-mm Margins With Concurrent and Adjuvant Temozolomide in Newly Diagnosed Supratentorial Glioblastoma: Health-Related Quality of Life Results.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Chem | 2017 |
Phase II study of bi-weekly temozolomide plus bevacizumab for adult patients with recurrent glioblastoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizu | 2017 |
Radiologic progression of glioblastoma under therapy-an exploratory analysis of AVAglio.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomark | 2018 |
Investigating the Effect of Reirradiation or Systemic Therapy in Patients With Glioblastoma After Tumor Progression: A Secondary Analysis of NRG Oncology/Radiation Therapy Oncology Group Trial 0525.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Cranial Irradiation; Dacarbaz | 2018 |
Interim Results of a Phase II Study of Hypofractionated Radiotherapy with Concurrent Temozolomide Followed by Adjuvant Temozolomide in Patients over 70 Years Old with Newly Diagnosed Glioblastoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Pr | 2018 |
Health-related quality of life in elderly patients with newly diagnosed glioblastoma treated with short-course radiation therapy plus concomitant and adjuvant temozolomide.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cognition; Combined Mod | 2013 |
Continuous tamoxifen and dose-dense temozolomide in recurrent glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Disease Progression; Dose-Response | 2013 |
Sorafenib plus daily low-dose temozolomide for relapsed glioblastoma: a phase II study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2013 |
Low incidence of pseudoprogression by imaging in newly diagnosed glioblastoma patients treated with cediranib in combination with chemoradiation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Dac | 2014 |
Low incidence of pseudoprogression by imaging in newly diagnosed glioblastoma patients treated with cediranib in combination with chemoradiation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Dac | 2014 |
Low incidence of pseudoprogression by imaging in newly diagnosed glioblastoma patients treated with cediranib in combination with chemoradiation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Dac | 2014 |
Low incidence of pseudoprogression by imaging in newly diagnosed glioblastoma patients treated with cediranib in combination with chemoradiation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Dac | 2014 |
Cilengitide treatment of newly diagnosed glioblastoma patients does not alter patterns of progression.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradio | 2014 |
Whole brain reirradiation and concurrent temozolomide in patients with brain metastases.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Breast Neoplasms; Carcinoma; Carcin | 2014 |
Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Benzimidazoles; Dacarbazine; Dise | 2014 |
Variation over time and interdependence between disease progression and death among patients with glioblastoma on RTOG 0525.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Progression; DNA Methylatio | 2015 |
Wilms tumor 1 peptide vaccination combined with temozolomide against newly diagnosed glioblastoma: safety and impact on immunological response.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cancer Vaccines; Cohort Stud | 2015 |
Health-Related Quality of Life in a Randomized Phase III Study of Bevacizumab, Temozolomide, and Radiotherapy in Newly Diagnosed Glioblastoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humaniz | 2015 |
Health-Related Quality of Life in a Randomized Phase III Study of Bevacizumab, Temozolomide, and Radiotherapy in Newly Diagnosed Glioblastoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humaniz | 2015 |
Health-Related Quality of Life in a Randomized Phase III Study of Bevacizumab, Temozolomide, and Radiotherapy in Newly Diagnosed Glioblastoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humaniz | 2015 |
Health-Related Quality of Life in a Randomized Phase III Study of Bevacizumab, Temozolomide, and Radiotherapy in Newly Diagnosed Glioblastoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humaniz | 2015 |
A Phase 2 Study of Concurrent Radiation Therapy, Temozolomide, and the Histone Deacetylase Inhibitor Valproic Acid for Patients With Glioblastoma.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents, Alkylating; Bone Marrow; Brain Neoplasms; Chemoradi | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Carmusti | 2015 |
[Randomized controlled study of limited margins IMRT and temozolomide chemotherapy in patients with malignant glioma].
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Chemotherapy, Adjuvant; Dacar | 2015 |
Bevacizumab, temozolomide, and radiotherapy for newly diagnosed glioblastoma: comprehensive safety results during and after first-line therapy.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Che | 2016 |
Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) Trial.
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Aurora Kina | 2016 |
Cilengitide with metronomic temozolomide, procarbazine, and standard radiotherapy in patients with glioblastoma and unmethylated MGMT gene promoter in ExCentric, an open-label phase II trial.
Topics: Adult; Aged; Antineoplastic Agents; Central Nervous System Neoplasms; Chemoradiotherapy; Dacarbazine | 2016 |
Evaluation of pseudoprogression rates and tumor progression patterns in a phase III trial of bevacizumab plus radiotherapy/temozolomide for newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Chemoradi | 2016 |
Chemotherapy for adult low-grade gliomas: clinical outcomes by molecular subtype in a phase II study of adjuvant temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine | 2017 |
Continuous dose-intense temozolomide and cisplatin in recurrent glioblastoma patients.
Topics: Adult; Aged; Antineoplastic Agents; China; Cisplatin; Dacarbazine; Disease Progression; Female; Glio | 2017 |
Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma.
Topics: Aged; Aged, 80 and over; Central Nervous System Neoplasms; Chemoradiotherapy; Dacarbazine; Disease P | 2017 |
Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma.
Topics: Aged; Aged, 80 and over; Central Nervous System Neoplasms; Chemoradiotherapy; Dacarbazine; Disease P | 2017 |
Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma.
Topics: Aged; Aged, 80 and over; Central Nervous System Neoplasms; Chemoradiotherapy; Dacarbazine; Disease P | 2017 |
Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma.
Topics: Aged; Aged, 80 and over; Central Nervous System Neoplasms; Chemoradiotherapy; Dacarbazine; Disease P | 2017 |
Association of 11C-methionine PET uptake with site of failure after concurrent temozolomide and radiation for primary glioblastoma multiforme.
Topics: Adult; Aged; Algorithms; Antineoplastic Agents, Alkylating; Biopsy; Brain; Brain Neoplasms; Combined | 2009 |
Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Comb | 2008 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2009 |
O(6)-methylguanine-DNA methyltransferase depletion and DNA damage in patients with melanoma treated with temozolomide alone or with lomeguatrib.
Topics: Antineoplastic Agents; Biopsy; Dacarbazine; Disease Progression; DNA Damage; DNA Repair; DNA Replica | 2009 |
Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine | 2009 |
Prospective evaluation of radiotherapy with concurrent and adjuvant temozolomide in children with newly diagnosed diffuse intrinsic pontine glioma.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Child, Preschool; Combined Mo | 2010 |
Radiotherapy and concomitant temozolomide during the first and last weeks in high grade gliomas: long-term analysis of a phase II study.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbaz | 2010 |
Population-based study of pseudoprogression after chemoradiotherapy in GBM.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brai | 2009 |
NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brai | 2009 |
A phase 1 trial of ABT-510 concurrent with standard chemoradiation for patients with newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brai | 2010 |
Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Chemotherapy, Adjuvant; Dacarbazi | 2010 |
Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Chemotherapy, Adjuvant; Dacarbazi | 2010 |
Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Chemotherapy, Adjuvant; Dacarbazi | 2010 |
Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Canada; Chemotherapy, Adjuvant; Dacarbazi | 2010 |
Radiotherapy followed by adjuvant temozolomide with or without neoadjuvant ACNU-CDDP chemotherapy in newly diagnosed glioblastomas: a prospective randomized controlled multicenter phase III trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Chemotherapy, Adjuvant; Combined Modalit | 2011 |
Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium study.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Chemotherapy, Adjuvant; Cohort Studies; Dacarba | 2011 |
Phase II study of Gleevec plus hydroxyurea in adults with progressive or recurrent low-grade glioma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemother | 2012 |
The addition of temozolomide does not change the pattern of progression of glioblastoma multiforme post-radiotherapy.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine | 2012 |
Human umbilical vein endothelial cell vaccine therapy in patients with recurrent glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cancer Vaccines; Chemotherapy, Adjuvant; Dacarba | 2013 |
"One week on-one week off": efficacy and side effects of dose-intensified temozolomide chemotherapy: experiences of a single center.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Progression; Drug Ad | 2013 |
Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neop | 2003 |
Phase II evaluation of temozolomide and 13-cis-retinoic acid for the treatment of recurrent and progressive malignant glioma: a North American Brain Tumor Consortium study.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Dacarbazin | 2003 |
Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Progression; Drug Ad | 2003 |
Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Progression; Drug Ad | 2003 |
Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Progression; Drug Ad | 2003 |
Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Progression; Drug Ad | 2003 |
Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dacarbaz | 2003 |
A first feasibility study of temozolomide for Japanese patients with recurrent anaplastic astrocytoma and glioblastoma multiforme.
Topics: Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Disease Progres | 2003 |
Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas.
Topics: Administration, Oral; Adult; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Disease Progressio | 2003 |
Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and radiological response.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Disease Prog | 2003 |
Dose-dense regimen of temozolomide given every other week in patients with primary central nervous system tumors.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazin | 2004 |
Phase II trial of cisplatin plus temozolomide, in recurrent and progressive malignant glioma patients.
Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherap | 2004 |
Phase II study of neoadjuvant 1, 3-bis (2-chloroethyl)-1-nitrosourea and temozolomide for newly diagnosed anaplastic glioma: a North American Brain Tumor Consortium Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Pro | 2004 |
Temozolomide for treatment-resistant recurrent meningioma.
Topics: Administration, Oral; Aged; Antineoplastic Agents, Alkylating; Dacarbazine; Dexamethasone; Disease P | 2004 |
BCNU as second line therapy for recurrent high-grade glioma previously treated with Temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Dacarbazine; Disease Pr | 2004 |
One week on/one week off: a novel active regimen of temozolomide for recurrent glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Combined Modality Therapy; Dacarbazine; Disease Prog | 2004 |
Temozolomide in paediatric high-grade glioma: a key for combination therapy?
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined | 2004 |
Initial chemotherapy in gliomatosis cerebri.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combin | 2004 |
Chemotherapy as initial treatment in gliomatosis cerebri: results with temozolomide.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Combined Modalit | 2004 |
Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression.
Topics: Antineoplastic Combined Chemotherapy Protocols; Artifacts; Astrocytoma; Brain Edema; Brain Neoplasms | 2004 |
The effect of temozolomide-based chemotherapy in patients with cerebral metastases from melanoma.
Topics: Adult; Aged; Brain Neoplasms; Dacarbazine; Disease Progression; Drug Therapy, Combination; Female; H | 2004 |
Temozolomide chemotherapy of patients with recurrent anaplastic astrocytomas and glioblastomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Disease P | 2004 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemothera | 2005 |
Randomized phase II study of temozolomide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; D | 2005 |
Temozolomide with or without radiotherapy in melanoma with unresectable brain metastases.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2006 |
Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Disease P | 2005 |
A low rate of central nervous system progression in a phase II trial of outpatient chemobiologic therapy with cisplatin, temozolomide, interleukin-2, and interferon alfa 2-B for metastatic malignant melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Disease Progres | 2005 |
Food and Drug Administration Drug approval summary: temozolomide plus radiation therapy for the treatment of newly diagnosed glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Mo | 2005 |
Perfusion and diffusion MRI of glioblastoma progression in a four-year prospective temozolomide clinical trial.
Topics: Analysis of Variance; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Diffusion Mag | 2006 |
Low-dose outpatient chemobiotherapy with temozolomide, granulocyte-macrophage colony stimulating factor, interferon-alpha2b, and recombinant interleukin-2 for the treatment of metastatic melanoma.
Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Dac | 2005 |
Surgery, radiotherapy and temozolomide in treating high-grade gliomas.
Topics: Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Clinical Trials as Topic; Co | 2006 |
Role of temozolomide in spinal cord low grade astrocytomas: results in two paediatric patients.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Astrocytoma; Child; Dacarbazine; Disease Progression; | 2006 |
Temozolomide in metastatic breast cancer (MBC): a phase II trial of the National Cancer Institute of Canada - Clinical Trials Group (NCIC-CTG).
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Alkylating; Breast Neoplasms; Dacarbazine; | 2006 |
Treatment of primary glioblastoma multiforme with cetuximab, radiotherapy and temozolomide (GERT)--phase I/II trial: study protocol.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C | 2006 |
Phase II study with the combination of gemcitabine and DTIC in patients with advanced soft tissue sarcomas.
Topics: Adult; Aged; Alanine Transaminase; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; | 2007 |
A phase II study of extended dose temozolomide and thalidomide in previously treated patients with metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease Progression; Dose- | 2006 |
Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO).
Topics: Adult; Aged; Anemia; Antineoplastic Agents, Alkylating; Brain Neoplasms; Constipation; Dacarbazine; | 2006 |
MGMT methylation: a marker of response to temozolomide in low-grade gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Dacarbazine; Dis | 2006 |
Randomized trial of the combination of lomeguatrib and temozolomide compared with temozolomide alone in chemotherapy naive patients with metastatic cutaneous melanoma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2007 |
A phase I study of thalidomide, capecitabine and temozolomide in advanced cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Combined Modality Therapy | 2007 |
Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Progression; DNA Met | 2007 |
Preliminary results from a phase I/II study of perillyl alcohol intranasal administration in adults with recurrent malignant gliomas.
Topics: Administration, Intranasal; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Blood-Brain Ba | 2008 |
A phase II trial of lomeguatrib and temozolomide in metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 2008 |
Chemotherapy in the treatment of recurrent glioblastoma multiforme: ifosfamide versus temozolomide.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Dacarbazin | 1999 |
Health-related quality of life in patients treated with temozolomide versus procarbazine for recurrent glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; | 2000 |
A phase II study of temozolomide in hormone-refractory prostate cancer.
Topics: Adult; Antineoplastic Agents, Alkylating; Dacarbazine; Disease Progression; Humans; Male; Prostate-S | 2000 |
Health-related quality of life in patients with anaplastic astrocytoma during treatment with temozolomide.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Disease P | 2000 |
Temozolomide as a second-line systemic regimen in recurrent high-grade glioma: a phase II study.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Progression; D | 2001 |
Phase I study of Gliadel wafers plus temozolomide in adults with recurrent supratentorial high-grade gliomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Carmustine; Cohort Studies | 2001 |
A phase II trial of temozolomide for patients with recurrent or progressive brain metastases.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Dac | 2001 |
171 other studies available for temozolomide and Disease Exacerbation
| Article | Year |
|---|---|
A positive feedback loop of lncRNA-RMRP/ZNRF3 axis and Wnt/β-catenin signaling regulates the progression and temozolomide resistance in glioma.
Topics: Adult; Animals; Apoptosis; beta Catenin; Brain; Cell Line, Tumor; Disease Progression; Down-Regulati | 2021 |
Inhibition of FABP6 Reduces Tumor Cell Invasion and Angiogenesis through the Decrease in MMP-2 and VEGF in Human Glioblastoma Cells.
Topics: Animals; Cell Line, Tumor; Cell Movement; Clone Cells; Disease Progression; Extracellular Matrix; Fa | 2021 |
PET With 11C-Methyl-l-Methionine as a Predictor of Consequential Outcomes at the Time of Discontinuing Temozolomide-Adjuvant Chemotherapy in Patients With Residual IDH-Mutant Lower-Grade Glioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Carbon Radioisotopes; Chemotherapy, Adjuvant; Di | 2022 |
Continuing maintenance temozolomide therapy beyond 12 cycles confers no clinical benefit over discontinuation at 12 cycles in patients with IDH1/2-wildtype glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Progression; Disease-Free S | 2022 |
Plasma IL13Rα2 as a novel liquid biopsy biomarker for glioblastoma.
Topics: Biomarkers; Brain Neoplasms; Disease Progression; Glioblastoma; Humans; Interleukin-13 Receptor alph | 2022 |
Plasma IL13Rα2 as a novel liquid biopsy biomarker for glioblastoma.
Topics: Biomarkers; Brain Neoplasms; Disease Progression; Glioblastoma; Humans; Interleukin-13 Receptor alph | 2022 |
Plasma IL13Rα2 as a novel liquid biopsy biomarker for glioblastoma.
Topics: Biomarkers; Brain Neoplasms; Disease Progression; Glioblastoma; Humans; Interleukin-13 Receptor alph | 2022 |
Plasma IL13Rα2 as a novel liquid biopsy biomarker for glioblastoma.
Topics: Biomarkers; Brain Neoplasms; Disease Progression; Glioblastoma; Humans; Interleukin-13 Receptor alph | 2022 |
Plasma IL13Rα2 as a novel liquid biopsy biomarker for glioblastoma.
Topics: Biomarkers; Brain Neoplasms; Disease Progression; Glioblastoma; Humans; Interleukin-13 Receptor alph | 2022 |
Plasma IL13Rα2 as a novel liquid biopsy biomarker for glioblastoma.
Topics: Biomarkers; Brain Neoplasms; Disease Progression; Glioblastoma; Humans; Interleukin-13 Receptor alph | 2022 |
Plasma IL13Rα2 as a novel liquid biopsy biomarker for glioblastoma.
Topics: Biomarkers; Brain Neoplasms; Disease Progression; Glioblastoma; Humans; Interleukin-13 Receptor alph | 2022 |
Plasma IL13Rα2 as a novel liquid biopsy biomarker for glioblastoma.
Topics: Biomarkers; Brain Neoplasms; Disease Progression; Glioblastoma; Humans; Interleukin-13 Receptor alph | 2022 |
Plasma IL13Rα2 as a novel liquid biopsy biomarker for glioblastoma.
Topics: Biomarkers; Brain Neoplasms; Disease Progression; Glioblastoma; Humans; Interleukin-13 Receptor alph | 2022 |
LncRNA-PVT1 was identified as a key regulator for TMZ resistance and STAT-related pathway in glioma.
Topics: Datasets as Topic; Disease Progression; Drug Resistance, Neoplasm; Genome, Human; Genomics; Glioma; | 2023 |
Extracellular Vesicles Shedding Promotes Melanoma Growth in Response to Chemotherapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Cell Communication; Cell Line, Tumor; Cell-Derived Micro | 2019 |
BMP signaling mediates glioma stem cell quiescence and confers treatment resistance in glioblastoma.
Topics: Animals; Antineoplastic Agents; Bone Morphogenetic Protein 4; Bone Morphogenetic Proteins; Brain Neo | 2019 |
Chemotherapy Following PD-1 Inhibitor Blockade in Patients with Unresectable Stage III/Stage IV Metastatic Melanoma: A Single Academic Institution Experience.
Topics: Academic Medical Centers; Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Imm | 2020 |
Whole brain apparent diffusion coefficient measurements correlate with survival in glioblastoma patients.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Di | 2020 |
Identification of Subtypes of Barrett's Esophagus and Esophageal Adenocarcinoma Based on DNA Methylation Profiles and Integration of Transcriptome and Genome Data.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Barrett Esophagus; Cyclin E; Disease Progression; DNA M | 2020 |
miR-152-5p suppresses glioma progression and tumorigenesis and potentiates temozolomide sensitivity by targeting FBXL7.
Topics: Animals; Apoptosis; Carcinogenesis; Cell Line, Tumor; Cell Proliferation; Disease Progression; Drug | 2020 |
MicroRNA-155-3p promotes glioma progression and temozolomide resistance by targeting Six1.
Topics: Animals; Base Sequence; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Disease Progression; | 2020 |
Nearing the Summit: Associating Liver Partitioning and Portal Ligation for Staged Hepatectomy (ALPPS) in Progressive Carcinoid Disease.
Topics: Antineoplastic Agents; Capecitabine; Disease Progression; Female; Hepatectomy; Humans; Liver; Liver | 2020 |
Multidimensional hydrogel models reveal endothelial network angiocrine signals increase glioblastoma cell number, invasion, and temozolomide resistance.
Topics: Biocompatible Materials; Brain Neoplasms; Cell Count; Cell Line, Tumor; Cell Movement; Cell Prolifer | 2020 |
Conventional Treatment of Glioblastoma Reveals Persistent CD44
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Disease Progression; Glioblastoma; Humans; Hyaluronan Re | 2020 |
Irinotecan and temozolomide chemotherapy in paediatric and adult populations with relapsed Ewing Sarcoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Diarrhea; Disease Prog | 2021 |
Gradient hydrogels for screening stiffness effects on patient-derived glioblastoma xenograft cellfates in 3D.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Disease Pr | 2021 |
Diagnosis of Pseudoprogression Following Lomustine-Temozolomide Chemoradiation in Newly Diagnosed Glioblastoma Patients Using FET-PET.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brai | 2021 |
Long noncoding RNA just proximal to X-inactive specific transcript facilitates aerobic glycolysis and temozolomide chemoresistance by promoting stability of PDK1 mRNA in an m6A-dependent manner in glioblastoma multiforme cells.
Topics: Adenosine; Aerobiosis; Alpha-Ketoglutarate-Dependent Dioxygenase FTO; Antineoplastic Agents, Alkylat | 2021 |
Short article: Evaluation of O6-methylguanine-DNA methyltransferase as a predicting factor of response to temozolomide-based chemotherapy in well-differentiated metastatic pancreatic neuroendocrine tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C | 2017 |
Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma: a secondary analysis of EORTC and NRG Oncology/RTOG.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modalit | 2017 |
SNORD47, a box C/D snoRNA, suppresses tumorigenesis in glioblastoma.
Topics: Adult; Aged; Animals; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Transfor | 2017 |
Downregulation of β-arrestin 1 suppresses glioblastoma cell malignant progression vis inhibition of Src signaling.
Topics: Animals; beta-Arrestin 1; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Diseas | 2017 |
TREATMENT OF PROGRESSION OF DIFFUSE ASTROCYTOMA BY HERBAL MEDICINE: CASE REPORT.
Topics: Adult; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; | 2016 |
Impact of interim progression during the surgery-to-radiotherapy interval and its predictors in glioblastoma treated with temozolomide-based radiochemotherapy.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Dis | 2017 |
High Expression of Glypican-1 Predicts Dissemination and Poor Prognosis in Glioblastomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Dacarbazine; Disease Progres | 2017 |
O6-Methylguanine DNA Methyltransferase Status Does Not Predict Response or Resistance to Alkylating Agents in Well-Differentiated Pancreatic Neuroendocrine Tumors.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Cell Differentiation; | 2017 |
Perfusion of surgical cavity wall enhancement in early post-treatment MR imaging may stratify the time-to-progression in glioblastoma.
Topics: Aged; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Contrast Media; Dacarbazine; Di | 2017 |
[Contribution of temozolomide chemotherapy for intramedullary grade II spinal cord astrocytomas in adults: Our experience].
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Chemotherapy, Adjuvant; Dacarbazine; Di | 2017 |
Significance of perivascular tumour cells defined by CD109 expression in progression of glioma.
Topics: Animals; Antigens, CD; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Proliferation; Dacar | 2017 |
Sequential proton boost after standard chemoradiation for high-grade glioma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Dacarb | 2017 |
Comparison between the Prebolus T1 Measurement and the Fixed T1 Value in Dynamic Contrast-Enhanced MR Imaging for the Differentiation of True Progression from Pseudoprogression in Glioblastoma Treated with Concurrent Radiation Therapy and Temozolomide Che
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Contrast Media; | 2017 |
Increased signal intensity within glioblastoma resection cavities on fluid-attenuated inversion recovery imaging to detect early progressive disease in patients receiving radiotherapy with concomitant temozolomide therapy.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2018 |
Temozolomide post pazopanib treatment failure in patients with advanced sarcoma: A case series.
Topics: Adult; Aged; Antineoplastic Agents; Dacarbazine; Disease Progression; Female; High-Throughput Nucleo | 2017 |
Long-term impact of temozolomide on 1p/19q-codeleted low-grade glioma growth kinetics.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Chromosome Deletion; Chromos | 2018 |
Injectable Hydrogels for Localized Chemotherapy and Radiotherapy in Brain Tumors.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Combined Modality Therapy; Dacarb | 2018 |
The JAK2/STAT3 inhibitor pacritinib effectively inhibits patient-derived GBM brain tumor initiating cells in vitro and when used in combination with temozolomide increases survival in an orthotopic xenograft model.
Topics: Animals; Apoptosis; Blood-Brain Barrier; Brain Neoplasms; Bridged-Ring Compounds; Cell Proliferation | 2017 |
Quantitative Magnetization Transfer in Monitoring Glioblastoma (GBM) Response to Therapy.
Topics: Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Disease Progression; Female; Gamma Rays; | 2018 |
Incorporating diffusion- and perfusion-weighted MRI into a radiomics model improves diagnostic performance for pseudoprogression in glioblastoma patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherap | 2019 |
CD73 Downregulation Decreases In Vitro and In Vivo Glioblastoma Growth.
Topics: 5'-Nucleotidase; Adenosine; Animals; Biomarkers, Tumor; Brain Neoplasms; Cell Line, Tumor; Cell Move | 2019 |
FoxG1 facilitates proliferation and inhibits differentiation by downregulating FoxO/Smad signaling in glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Differentiation; Cell Line, Tumor; Cell Pro | 2018 |
Podoplanin expression is a prognostic biomarker but may be dispensable for the malignancy of glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain; Brain Neoplasms; Cell Line, Tumor; Cel | 2019 |
Increase of pseudoprogression and other treatment related effects in low-grade glioma patients treated with proton radiation and temozolomide.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Thera | 2019 |
PLK4 is a determinant of temozolomide sensitivity through phosphorylation of IKBKE in glioblastoma.
Topics: Adolescent; Adult; Aged; Animals; Brain Neoplasms; Cell Line, Tumor; Child; Disease Progression; Dru | 2019 |
The clinical conundrum of managing relapsed small cell lung cancer.
Topics: Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplas | 2019 |
MicroRNA-34a-5p suppresses tumorigenesis and progression of glioma and potentiates Temozolomide-induced cytotoxicity for glioma cells by targeting HMGA2.
Topics: Animals; Base Sequence; Carcinogenesis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Disease | 2019 |
Susceptibility and Tumor Size Changes During the Time Course of Standard Treatment in Recurrent Glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Disease Progression; Female; Gliobl | 2019 |
Aggressive Progression in Glioblastoma Cells through Potentiated Activation of Integrin α5β1 by the Tenascin-C-Derived Peptide TNIIIA2.
Topics: Animals; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cel | 2019 |
Exosomes derived from microRNA-199a-overexpressing mesenchymal stem cells inhibit glioma progression by down-regulating AGAP2.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell | 2019 |
Morphologic MRI features, diffusion tensor imaging and radiation dosimetric analysis to differentiate pseudo-progression from early tumor progression.
Topics: Antineoplastic Agents; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Diffusion Magnetic Resonance | 2013 |
Relapse in medulloblastoma: what can be done after abandoning high-dose chemotherapy? A mono-institutional experience.
Topics: Administration, Intravenous; Administration, Oral; Adolescent; Adult; Antineoplastic Combined Chemot | 2013 |
Glioma initiating cells form a differentiation niche via the induction of extracellular matrices and integrin αV.
Topics: Animals; Brain Neoplasms; Carcinogenesis; Cell Adhesion; Cell Differentiation; Cell Movement; Cell S | 2013 |
Differentiation of true progression from pseudoprogression in glioblastoma treated with radiation therapy and concomitant temozolomide: comparison study of standard and high-b-value diffusion-weighted imaging.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Dif | 2013 |
Factors associated with a higher rate of distant failure after primary treatment for glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Progression; DNA Modificati | 2014 |
Is there pseudoprogression in secondary glioblastomas?
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Chromo | 2013 |
Treatment patterns and outcomes among patients with metastatic melanoma treated in community practice.
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Community Health Services; Dacarbazi | 2014 |
Liver toxicity during temozolomide chemotherapy caused by Chinese herbs.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Bevac | 2014 |
3-Dimensional magnetic resonance spectroscopic imaging at 3 Tesla for early response assessment of glioblastoma patients during external beam radiation therapy.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Aspartic Acid; Biomarkers, Tumor; Brain Neoplasms; C | 2014 |
Significant anti-tumor effect of bevacizumab in treatment of pineal gland glioblastoma multiforme.
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab | 2014 |
Survival outcomes of giant cell glioblastoma: institutional experience in the management of 20 patients.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Pr | 2014 |
Clinicopathological and molecular features of malignant optic pathway glioma in an adult.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2015 |
ADC texture--an imaging biomarker for high-grade glioma?
Topics: Adult; Age Factors; Aged; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Chemoradiothera | 2014 |
Glioblastoma treated with concurrent radiation therapy and temozolomide chemotherapy: differentiation of true progression from pseudoprogression with quantitative dynamic contrast-enhanced MR imaging.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modalit | 2015 |
Glutathione depletion sensitizes cisplatin- and temozolomide-resistant glioma cells in vitro and in vivo.
Topics: Animals; Apoptosis; Brain Neoplasms; Buthionine Sulfoximine; Cell Line, Tumor; Cell Survival; Cispla | 2014 |
Suppressor of fused (Sufu) represses Gli1 transcription and nuclear accumulation, inhibits glioma cell proliferation, invasion and vasculogenic mimicry, improving glioma chemo-sensitivity and prognosis.
Topics: Adult; Animals; Brain Neoplasms; Cell Line, Tumor; Cell Nucleus; Cell Proliferation; Dacarbazine; Di | 2014 |
Primary glioblastoma of the trigeminal nerve root entry zone: case report.
Topics: Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Combined Modality Therapy; Cranial Nerve | 2015 |
Temozolomide in the treatment of newly diagnosed diffuse brainstem glioma in children: a broken promise?
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Stem; Brain Stem Neoplasms; Chemotherapy, Adjuv | 2015 |
Diffusion and perfusion MRI to differentiate treatment-related changes including pseudoprogression from recurrent tumors in high-grade gliomas with histopathologic evidence.
Topics: Aged; Antineoplastic Agents; Brain Diseases; Brain Neoplasms; Dacarbazine; Disease Progression; Fema | 2015 |
Outcome of salvage treatment for recurrent glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherap | 2015 |
Evolution of DNA repair defects during malignant progression of low-grade gliomas after temozolomide treatment.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cohort Studies; Dacarbazine; Disease Progression | 2015 |
Glioblastoma adaptation traced through decline of an IDH1 clonal driver and macro-evolution of a double-minute chromosome.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Chromosomes, Huma | 2015 |
Genomically amplified Akt3 activates DNA repair pathway and promotes glioma progression.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Dacarbazine; Disease Progression; DNA Damage; DNA Repair | 2015 |
[Radiation and temozolomide therapy].
Topics: Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Disease Progression; Glioblastoma | 2015 |
Volumetric modulated arc therapy for hippocampal-sparing radiotherapy in transformed low-grade glioma: A treatment planning case report.
Topics: Antineoplastic Agents, Alkylating; Astrocytoma; Brain Damage, Chronic; Cell Dedifferentiation; Combi | 2015 |
Recurrence of glioblastoma after radio-chemotherapy is associated with an angiogenic switch to the CXCL12-CXCR4 pathway.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Benzylamines; Brain Neoplasms; Chemokine | 2015 |
An image guided small animal radiation therapy platform (SmART) to monitor glioblastoma progression and therapy response.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Line, Tumor; Chemoradiotherapy; Co | 2015 |
Dual Anti-angiogenic Chemotherapy with Temozolomide and Celecoxib in Selected Patients with Malignant Glioma Not Eligible for Standard Treatment.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Che | 2015 |
Dynamic contrast enhanced T1 MRI perfusion differentiates pseudoprogression from recurrent glioblastoma.
Topics: Adult; Aged; Aged, 80 and over; Alkaloids; Antineoplastic Agents, Alkylating; Brain Neoplasms; Contr | 2015 |
Independent Poor Prognostic Factors for True Progression after Radiation Therapy and Concomitant Temozolomide in Patients with Glioblastoma: Subependymal Enhancement and Low ADC Value.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Cranial Irradiation; Dacarbazine | 2015 |
Metformin influences progression in diabetic glioblastoma patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Blood Glucose; Brain; | 2015 |
Temozolomide for aggressive ACTH pituitary tumors: failure of a second course of treatment.
Topics: ACTH-Secreting Pituitary Adenoma; Adenoma; Adult; Antineoplastic Agents, Alkylating; Chemotherapy, A | 2016 |
Monoamine oxidase A (MAO A) inhibitors decrease glioma progression.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Proliferation; Dacarbaz | 2016 |
Comparative Analysis of Matrix Metalloproteinase Family Members Reveals That MMP9 Predicts Survival and Response to Temozolomide in Patients with Primary Glioblastoma.
Topics: Biomarkers, Tumor; Dacarbazine; Disease Progression; DNA Methylation; Gene Expression Regulation, Ne | 2016 |
Pseudoprogression in children, adolescents and young adults with non-brainstem high grade glioma and diffuse intrinsic pontine glioma.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Brain Stem Neoplasms; Child; | 2016 |
Temozolomide induces radiologic pseudoprogression and tumor cell vanishing in oligodendroglioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Diffusion Magnetic Resonance Imagin | 2016 |
Concurrent Chemoradiotherapy with Temozolomide Followed by Adjuvant Temozolomide for Newly Diagnosed Glioblastoma Patients: A Retrospective Multicenter Observation Study in Korea.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biopsy; Brain Neoplasms; Chemorad | 2017 |
Impact of tapering and discontinuation of bevacizumab in patients with progressive glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Immunological; Bevacizumab; Brain Neoplasms; Dacarbazine; Diseas | 2016 |
Recurrent Glioblastoma: Combination of High Cerebral Blood Flow with MGMT Promoter Methylation Is Associated with Benefit from Low-Dose Temozolomide Rechallenge at First Recurrence.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Blood Volume; Brain Neoplasms; Cerebrova | 2017 |
Slowing down glioblastoma progression in mice by running or the anti-malarial drug dihydroartemisinin? Induction of oxidative stress in murine glioblastoma therapy.
Topics: Animals; Antimalarials; Artemisinins; Brain Neoplasms; Cell Line, Tumor; Combined Modality Therapy; | 2016 |
Stem cell markers in glioma progression and recurrence.
Topics: Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Cell Differentiation; Dacarbazine; Disease Pro | 2016 |
IDH mutation and MGMT promoter methylation are associated with the pseudoprogression and improved prognosis of glioblastoma multiforme patients who have undergone concurrent and adjuvant temozolomide-based chemoradiotherapy.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy, Adjuvant; Dacarbazine; | 2016 |
MR Imaging Analysis of Non-Measurable Enhancing Lesions Newly Appearing after Concomitant Chemoradiotherapy in Glioblastoma Patients for Prognosis Prediction.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Dis | 2016 |
Exosomal miR-221 targets DNM3 to induce tumor progression and temozolomide resistance in glioma.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; | 2017 |
Refractory pituitary adenoma: a novel classification for pituitary tumors.
Topics: Adenoma; Adult; Aged; Antineoplastic Agents, Alkylating; Biopsy; Cell Proliferation; Dacarbazine; Di | 2016 |
Analysis of temozolomide resistance in low-grade gliomas using a mechanistic mathematical model.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Dise | 2017 |
Impact of Including Peritumoral Edema in Radiotherapy Target Volume on Patterns of Failure in Glioblastoma following Temozolomide-based Chemoradiotherapy.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Edema; Brain Neoplasms; Chemoradiotherapy; Coh | 2017 |
A mathematical model of low grade gliomas treated with temozolomide and its therapeutical implications.
Topics: Brain Neoplasms; Cell Proliferation; Dacarbazine; Disease Progression; Female; Glioma; Humans; Male; | 2017 |
DNA repair enzyme expression and differential response to temozolomide in a patient with both glioblastoma and metastatic pancreatic neuroendocrine tumor.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2008 |
Pseudoprogression after radiotherapy with concurrent temozolomide for high-grade glioma: clinical observations and working recommendations.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; D | 2009 |
Effect of adding temozolomide to radiation therapy on the incidence of pseudo-progression.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Di | 2009 |
Rechallenge with temozolomide in patients with recurrent gliomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Cohort Studies; Dacarbazine; | 2009 |
The sodium pump alpha1 sub-unit: a disease progression-related target for metastatic melanoma treatment.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Cardenolides; Cell Line, Tumor; Dacarbazine; | 2009 |
MSH6 inactivation and emergent temozolomide resistance in human glioblastomas.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease Pro | 2008 |
Temozolomide: a safe and effective treatment for malignant digestive endocrine tumors.
Topics: Aged; Analysis of Variance; Antineoplastic Agents, Alkylating; Carcinoid Tumor; Dacarbazine; Digesti | 2009 |
Pseudoprogression and MGMT status in glioblastoma patients: implications in clinical practice.
Topics: Aged; Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease Progre | 2009 |
First experiences with low-dose anti-angiogenic treatment in gliomatosis cerebri with signs of angiogenic activity.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Cell Proliferation; Cyclooxy | 2009 |
Inter- and intrapatients comparison of WHO grade II glioma kinetics before and after surgical resection.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Child; Dacarbazi | 2010 |
Therapy-related myelodysplastic syndrome/acute myeloid leukemia after treatment with temozolomide in a patient with glioblastoma multiforme.
Topics: Adult; Aged; Biopsy; Bone Marrow Cells; Brain Neoplasms; Dacarbazine; Disease Progression; Female; G | 2009 |
The clinical efficacy of combination of docetaxel and temozolomide in previously treated patients with stage IV melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease Progression; Docetaxel; Humans; | 2010 |
Bevacizumab and dose-intense temozolomide in recurrent high-grade glioma.
Topics: Adolescent; Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize | 2010 |
Temozolomide in advanced and recurrent uterine leiomyosarcoma and correlation with o6-methylguanine DNA methyltransferase expression: a case series.
Topics: Adult; Antineoplastic Agents, Alkylating; Biomarkers, Pharmacological; Biomarkers, Tumor; Dacarbazin | 2010 |
Pseudoprogression following chemoradiotherapy for glioblastoma multiforme.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease | 2010 |
Long-term adjuvant administration of temozolomide in patients with glioblastoma multiforme: experience of a single institution.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biopsy; Combined Modality Therapy | 2010 |
Therapy for recurrent high-grade gliomas: does continuous dose-intense temozolomide have a role?
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease Pro | 2010 |
Pattern of failure after limited margin radiotherapy and temozolomide for glioblastoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Brain Neoplasms; Combi | 2011 |
Evaluation of diffusion parameters as early biomarkers of disease progression in glioblastoma multiforme.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; D | 2010 |
Pseudoprogression in patients with malignant gliomas treated with concurrent temozolomide and radiotherapy: potential role of p53.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modalit | 2011 |
A pilot study of hypofractionated radiation therapy with temozolomide for adults with glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbaz | 2011 |
Feasibility study of 21-day-on/7-day-off temozolomide in children with brain tumors.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Child, Preschool; Dacarbazine | 2011 |
Prolonged survival of a patient with cervical intramedullary glioblastoma multiforme treated with total resection, radiation therapy, and temozolomide.
Topics: Adult; Antineoplastic Agents, Alkylating; Biopsy; Cervical Vertebrae; Chemotherapy, Adjuvant; Combin | 2010 |
Correlation of MRI sequences to assess progressive glioblastoma multiforme treated with bevacizumab.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antin | 2011 |
Unsuccessful high dose IL-2 therapy followed immediately by near continuous low dose temozolomide can result in rapid durable complete and near-complete remissions in metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Dacarbazine; Disease Progression; Dose-Response Rela | 2010 |
Assessment of perfusion MRI-derived parameters in evaluating and predicting response to antiangiogenic therapy in patients with newly diagnosed glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therap | 2011 |
Usefulness of MS-MLPA for detection of MGMT promoter methylation in the evaluation of pseudoprogression in glioblastoma patients.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Progression; D | 2011 |
[Efficiency of radiation or chemoradiation therapy for diffusely growing brainstem tumors in children].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Brain Stem Neoplas | 2008 |
Clinical effect of temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Antineoplastic Co | 2011 |
Clinical effect of temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Antineoplastic Co | 2011 |
Clinical effect of temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Antineoplastic Co | 2011 |
Clinical effect of temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Antineoplastic Co | 2011 |
Pseudoprogression following concurrent temozolomide and radiotherapy in a patient with glioblastoma: findings on functional imaging techniques.
Topics: Antineoplastic Agents, Alkylating; Combined Modality Therapy; Dacarbazine; Disease Progression; Fema | 2010 |
Safety and efficacy of stereotactic radiosurgery and adjuvant bevacizumab in patients with recurrent malignant gliomas.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alky | 2012 |
Response to temozolomide in supratentorial multifocal recurrence of malignant ependymoma.
Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Disease Progression; Ependymoma; Female; | 2011 |
Response to nimotuzumab in a child with a progressive diffuse intrinsic pontine glioma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Antine | 2011 |
International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chr | 2011 |
Glioblastoma: patterns of recurrence and efficacy of salvage treatments.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Progression; F | 2011 |
Prolonged temozolomide for treatment of glioblastoma: preliminary clinical results and prognostic value of p53 overexpression.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Proliferation; Chemotherapy, A | 2012 |
In regard McDonald et al., to Pattern of failure after limited margin radiotherapy and temozolomide for glioblastoma (Int J Radiat Oncol Biol Phys 2011;79:130-136).
Topics: Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease Progression; | 2011 |
Conditional probability of survival in patients with newly diagnosed glioblastoma.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents; Brain Neoplasms; Chemotherapy, Adjuvant; Clinical T | 2011 |
Toxicity after radiochemotherapy for glioblastoma using temozolomide--a retrospective evaluation.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Disease Pr | 2011 |
Prolonged administration of temozolomide in adult patients with anaplastic glioma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carcinoma; Dacarbazine; Disease Pro | 2011 |
Reoxygenation of glioblastoma multiforme treated with fractionated radiotherapy concomitant with temozolomide: changes defined by 18F-fluoromisonidazole positron emission tomography: two case reports.
Topics: Aged; Antineoplastic Agents, Alkylating; Cell Hypoxia; Chemoradiotherapy, Adjuvant; Dacarbazine; Dis | 2012 |
Extended adjuvant temozolomide for treatment of newly diagnosed glioblastoma multiforme.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Ad | 2012 |
Bevacizumab plus irinotecan in recurrent malignant glioma shows high overall survival in a multicenter retrospective pooled series of the Spanish Neuro-Oncology Research Group (GEINO).
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2012 |
Late and prolonged pseudoprogression in glioblastoma after treatment with lomustine and temozolomide.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2012 |
IDH1 mutation as a potential novel biomarker for distinguishing pseudoprogression from true progression in patients with glioblastoma treated with temozolomide and radiotherapy.
Topics: Adult; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Brain Neoplasms; Combined Modality Ther | 2013 |
A restricted cell population propagates glioblastoma growth after chemotherapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Proliferation; Cell Tracking; Daca | 2012 |
Targeting neuroendocrine tumor: mixing standard options with novel therapies.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Combined Modality Therapy; Dacarbazine; Di | 2012 |
Temozolomide as second or third line treatment of patients with neuroendocrine carcinomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; Dacarbazine; D | 2012 |
Abbreviated course of radiation therapy with concurrent temozolomide for high-grade glioma in patients of advanced age or poor functional status.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherap | 2012 |
Radiation-induced spinal cord anaplastic astrocytoma subsequent to radiotherapy for testicular seminoma.
Topics: Antineoplastic Agents; Astrocytoma; Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; | 2012 |
Sarcomatous evolution of oligodendroglioma ("oligosarcoma"): confirmatory report of an uncommon pattern of malignant progression in oligodendroglial tumors.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromosome Deletion; Chromosomes, Human, | 2012 |
Serum soluble MICB (sMICB) correlates with disease progression and survival in melanoma patients.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Cisplatin; Dacarbazine; Disease Progression; Disease-Free | 2013 |
Multimodal magnetic resonance imaging and 18F-L-dihydroxyphenylalanine positron emission tomography in early characterization of pseudoresponse and nonenhancing tumor progression in a pediatric patient with malignant transformation of ganglioglioma treate
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brai | 2013 |
Combined temozolomide and radiation as an initial treatment for anaplastic glioma.
Topics: Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Disease Progression; Diseas | 2013 |
The value of temozolomide in combination with radiotherapy during standard treatment for newly diagnosed glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Chemotherapy, Ad | 2013 |
Breast metastasis of anaplastic oligodendroglioma: a case report.
Topics: Antineoplastic Agents, Alkylating; Aphasia; Brain Neoplasms; Breast Neoplasms, Male; Chemoradiothera | 2012 |
O6-methyl-guanine-DNA methyltransferase methylation in serum and tumor DNA predicts response to 1,3-bis(2-chloroethyl)-1-nitrosourea but not to temozolamide plus cisplatin in glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemo | 2003 |
Temozolomide: too early for definitive conclusions.
Topics: Adult; Age Factors; Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Clinical Trials as To | 2003 |
Response of recurrent anaplastic ependymoma to a combination of tamoxifen and isotretinoin.
Topics: Adrenal Cortex Hormones; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Neoplas | 2003 |
Promises and controversies in the management of low-grade glioma.
Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Clinical Trials, Phase II as Topic; Combined Mod | 2003 |
Gliomatosis cerebri: better definition, better treatment.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Astrocyt | 2004 |
Cerebral metastases of malignant melanoma: contemporary treatment modalities and survival outcome.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Di | 2005 |
Response to temozolomide in second-line treatment of recurrent nonsmall cell lung carcinoma: case report.
Topics: Administration, Oral; Antineoplastic Agents, Alkylating; Carcinoma, Non-Small-Cell Lung; Dacarbazine | 2005 |
Temozolomide in combination with BCNU before and after radiotherapy in patients with inoperable newly diagnosed glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Combined M | 2005 |
[Favourable result for temozolomide in recurrent high-grade glioma].
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Disease Progression; F | 2005 |
[Spinal and cerebral leptomeningeal seeding from a melanocytoma of the cerebello-pontine angle].
Topics: Administration, Oral; Adult; Antineoplastic Agents, Alkylating; Arachnoid; Cerebellar Diseases; Cere | 2005 |
Progressive low-grade oligodendrogliomas: response to temozolomide and correlation between genetic profile and O6-methylguanine DNA methyltransferase protein expression.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chromosomes, Human, Pai | 2006 |
Gliomatosis cerebri treatment in 11 elderly patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Combined M | 2006 |
Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Proliferation; Dacarbazine; Di | 2007 |
Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Proliferation; Dacarbazine; Di | 2007 |
Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Proliferation; Dacarbazine; Di | 2007 |
Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Proliferation; Dacarbazine; Di | 2007 |
Treatment of recurrent glioblastoma: can local delivery of mitoxantrone improve survival?
Topics: Adult; Aged; Aging; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combi | 2008 |
Comparative evaluation of radiochemotherapy with temozolomide versus standard-of-care postoperative radiation alone in patients with WHO grade III astrocytic tumors.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Child; Com | 2008 |
MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Diseases; Brain Neoplasms; Chemotherapy, Adjuv | 2008 |
Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide.
Topics: Adolescent; Adult; Aged; Cohort Studies; Combined Modality Therapy; Dacarbazine; Disease Progression | 2008 |